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Abstract

VITAMIN C: A POTENTIAL REGULATOR OF INFLAMMATORY RESPONSE
By: Bassem M. Mohammed, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Major Director: Donald F. Brophy, PharmD, MS, FCCP, FASN, BCPS, Professor and
Chairman, Department of Pharmacotherapy and Outcomes Science

Introduction: Neutrophils (PMNs) and Macrophages are the first responders recruited
consecutively to the site of injury/inflammation. PMNs’ response/fate as well as
macrophage reprogramming ultimately determine the course of resolution of
inflammation. Physiologic wound healing has a significant inflammatory component. An
exaggerated inflammation however is self-defeating leading to delayed healing.
Parenteral vitamin C (VitC) attenuated inflammation in murine sepsis models and in
patients with sepsis. However information about the mechanisms by which VitC
regulates these events is limited.
Methods: Humanized mice lacking VitC synthesis capability (Gulo-/-) were used. VitC

sufficient and deficient mice were challenged with sterile inflammation, or septic insults.
Some VitC deficient mice received parenteral VitC (200mg/kg) following the challenge
to give deficient + AscA mice up to 14 days. Using a murine model of excisional wound,
two full thickness excisional wounds were created on the back of the different Gulo-/-

mice groups. Wound tissues were excised at day 7 and 14 post-wounding for analysis.
Cell counts, immunohistochemistry, circulating free DNA, the expression of pro- and
anti-inflammatory proteins were investigated. Additional in vitro experiments were
carried out using human PMN (huPMNs), THP-1 monocyte/macrophage, and neonatal
human dermal fibroblasts (HnDF).
Results: VitC deficiency delayed resolution of lung inflammation and led to exaggerated
pro-inflammatory responses. PMNs from VitC deficient mice demonstrated increased
autophagy, histone citrullination, and NFκB activation, while inhibiting apoptosis. VitC
sufficiency/supplementation restored macrophage phenotype, as well as attenuated
neutrophil extracellular trap (NET) formation. VitC attenuated pro-inflammatory
responses in THP-1 macrophages. In wound healing model, wounds from VitC
sufficient/AscA infused mice had lower gene expression of the pro-inflammatory
mediators; higher expression of genes promoting wound healing and resolution.
Exposure of HnDF to AscA increased their intracellular VitC levels; promoted fibroblast
proliferation and induced expression of fibroblast self-renewal genes.
Conclusion: Our findings identify VitC as a novel regulator of PMN and macrophage
responses. In wound healing, VitC favorably impacted the spatiotemporal expression of
transcripts associated with early resolution of inflammation and tissue remodeling.
Collectively, these results substantiate the protective notion of parenteral VitC and
support its clinical use.

CHAPTER 1. BACKGROUND
1.1 Ascorbic Acid
1.1.1 History and Discovery
Ascorbic acid (AA or AscA) or Vitamin C (VitC) was first isolated in 1928 by the
Hungarian scientist Albert Szent Györgyi from the adrenal cortex of animals. Györgyi
was interested in the strong reducing properties of AscA but could not prove its
antiscorbutic effects. The isolated molecule was first called hexuronic acid owing to its
structure which had 6 carbon atoms and due to its acidic nature. Several years later
(1932), a team led by Charles Gllen King at the University of Pittsburg was able to
isolate AA. King’s team was trying to isolate the common molecule responsible for
treating Scurvy across a number of anti-scorbutics and confirmed that the isolated
molecule was in fact Györgyi hexuronic acid. The structure of the vitamin was then
resolved in 1933 at the University of Brimingham, UK by Norman Haworth research
team.(1) In 1937, Györgyi was awarded the Nobel Prize in Physiology or Medicine. In
the same year, Haworth was also awarded the Nobel Prize in chemistry for determining
the structure of AA.
1.1.2 Overview
Ascorbic acid (AA) is the reduced and most
predominant form of vitamin C (VitC). It is a small
organic (Carbohydrate), water soluble molecule,
with strong anti-oxidant properties.(2, 3) Its water

Figure 1: Ascorbic Acid

solubility enables the vitamin to contribute to the body total anti-oxidant capacity both at
1

the plasma level, as well as at the cellular level. Thus protecting host proteins/lipids
against oxidative modification via scavenging reactive oxygen species (ROS).
The biological activity of VitC is limited to the more active and naturally occurring
(L)-isomer of the vitamin (L-Ascorbic acid). Although, D-isomer has the same antioxidant properties, it does not occur in nature. It (the D-isomer) can only be synthesized
in a lab setting and does not possess the same biological activity as the L-isomer.(4)
When involved in a redox reaction, AA is easily oxidized to the unstable
dehydroascorbic acid (DHA).i However, DHA is not normally detected in the plasma (but
may appear temporarily at times of stress). Data
comparing the concentrations of “AA” and “AA +
DHA” as total AA, showed no difference.(5)
Along with its anti-oxidant properties, VitC is an
essential co-factor involved in the enzymatic and
non-enzymatic synthesis of several important bodily
molecules. This includes: collagen (The most
abundant protein in the human body used to make
skin, cartilage, tendons, ligaments, and blood
vessels), carnitine (an important metabolite needed
for fatty acid transfer into the mitochondria for energy
production),

and

neurotransmitters

(such

as

Figure 2: Synthesis Pathway of
L-Ascorbic acid

catecholamines).(6)

i

AA, AscA, and VitC abbreviations will be used interchangeably in the text to refer to L-Ascorbic acid

2

As to the vitamin sources, the vast majority of animals are able to synthesize their
own requirement of VitC using the pathway shown in Figure 2 above. However, humans
and few animal species (e.g. guinea pigs, bats, and other primates) have lost this
capability. A genetic mutation developed overtime led to the loss of the enzyme Lgulono-γ-lactone oxidase. This enzyme executes the final step of VitC biosynthetic
pathway. Therefore, Humans and those few animal species are dependent upon
external supply in diet to maintain their daily requirement of VitC.(2, 3) This genetic flaw
was referred to as Hypoascorbemia and was first described by Dr. Irwin Stone late in
the 20th century.(7)
A severe prolonged VitC deficiency results in a pathological condition known as
Scurvy. Scurvy is characterized by alteration of extracellular matrix leading to fatigue,
gingivitis, bleeding gums, nose bleeds, ease of bruising, dry/splitted hair, dry/scaly and
rough skin, and higher susceptibility to infection. Vision problems, bone fragility, and
neurological disorder are also encountered in severe cases of scurvy. Most of the
symptoms are due to inactivation of 2-oxoglutarate dependent dioxygenases enzymes
as well as other AA dependent enzymes. These enzymes catalyze hydroxylation,
desaturation, and oxidative ring-closure or expansion in various major biochemical
pathways.(6)
1.1.3 Pharmacokinetics (Absorption/Distribution/Metabolism/Elimination)
As mentioned earlier, AA is the predominant form of VItC. AA is readily absorbed
from the intestine and widely distributed into the different body tissues. The body pool of
AA is reported to be nearly 20 mg/kg (1400 mg for 70 kg person).(8, 9) Symptoms of
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Scurvy are evident with a body pool less than 4.3 mg/kg (< 300 mg for a 70 kg
person).(10) Figure 3 shows AA content of plasma and several body organs.(11)
AA is present free in the plasma; data from centrifugal ultrafilteration experiments
showed that AA exhibits no protein binding.(5) Its oral absorption is a saturable process;
higher doses yield lower Foral (Fraction of drug absorbed). AA administration with food or
as a divided dose (versus single dose) improves AA Foral within a dose range of AA.
AA absorption is an active process
requiring transporters that are located
primarily at the proximal part of the
intestine. This was first pointed out with
food studies where delaying GI emptying
resulted in an increased Foral. Transport of
vitamin C into tissues is achieved by two
sodium dependent vitamin C transporters
(SVCT1 and SVCT2). SVCT1 is the
predominant transporter in the intestine. In
Figure 3: Various organs and plasma AA content.
Adapted from reference 11

addition to SVCT transporters which are

involved in AA active transport, the glucose transporters GLUT1 and GLUT3 are
involved in the transportation of the oxidized form DHA via a facilitated diffusion
mechanism. GLUT transporters thus provide entry of DHA to cells lacking SVCT(s) such
as RBCs.(12, 13) Older studies have reported SVCTs transporters Vmax to be
approximately 70 uM with transporter Km of 5 -30 uM.(14) In a more recent review, Km
values for SVCTs were reported to range 65 – 237 uM for SVCT1; and 8 – 113 uM for
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SVCT2 in human models with SVCT1 having higher Vmax as compared to SVCT2.(13)
SVCTs are specific for L-AA transport with very low or no affinity to other forms of the
vitamin (eg. D-AA and DHA). SVCT 1 and 2 expressions vary across organs and
tissues signifying no redundancy in function.(13)
In addition to saturable absorption, AA renal clearance (CLr) is shown to follow
nonlinear pattern with a saturable re-absorption mechanism. At lower doses (producing
plasma AA levels below 70uM), CLr is low and the reabsorption is not saturated and
half-life is reported to be between 8 to 40 days.(15, 16) As the doses increase beyond
renal threshold for reabsorption, most of the AA dose is eliminated renally and the nonrenal pathways contribution diminishes (CLnr becomes negligible).(17)
As to AA metabolism, the only detectable metabolites of ascorbic acid are
dehydroascorbic acid (result of reversible oxidation), 2,3-diketogulonic acid, oxalate
(inactive), saccharo-ascorbic acid and ascorbate-2-sulfate (inactive). Carbon dioxide
was also reported as a metabolite of AA at doses > 180mg.(18) All of these compounds
have been isolated and identified in urine. Ascorbic acid is also excreted in the bile but
there is no evidence for enterohepatic circulation.(9) The average fecal excretion of
ascorbic acid or its metabolites was found to be approximately 3% of the oral dose
when given in physiological amounts. A negligible amount of labeled material (less than
1% during 10 days) was found in the feces after intravenous injection of (l -14C) ascorbic
acid. Thus, in humans the principal route for elimination of AA metabolic products is the
urine via the kidneys. Daily urinary excretion consists of about 20 - 25% as unchanged
ascorbic acid and dehydro-ascorbic acid, about 20% as diketogulonic acid and about 40
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- 45% as oxalate. Ascorbic acid 2-sulphate and saccharo-ascorbic acid contribute only
very small percentages.(9, 18)
AA Plasma levels: Clinical
pharmacokinetics showed that AA
levels in plasma and tissues are
tightly controlled. At an oral dose of
>

100mg/day,

concentration

the

plasma

plateau

between

70uM and 80uM. Ingestion of larger
doses has been associated with
minimal change in these values
(Figure 4). It is also reported that
supplementation near the maximum

Figure 4: Ascorbic acid dose – plasma concentration curve
adopted from reference 19

tolerated dose (2-4gm per oral) yields a plasma level of <250 uM and more frequently
<150uM. This ceiling effect is brought about by saturable absorption in the intestine and
saturable renal re-absorption as mentioned earlier.(16, 19)
The recommended daily allowance (RDA) for AAii is calculated based on the
average daily intake needed to meet the requirement of all healthy individual. However,
RDA is not sufficient when individuals are under the stress of a disease or injury. AA
Pharmacokinetics studies showed that when vitamin C is taken orally, plasma and
tissue concentrations in healthy individuals are tightly controlled by at least 3

ii

Acceptable serum levels in mg/dl units are 0.4 to 1.5 mg/dl. In the United States, the recommended
adult dietary allowance is 60 mg/day. This amount reportedly maintains the body pool and serum levels of
0.75 mg/dl in normal adults.(8)

6

mechanisms: absorption, tissue accumulation, and renal reabsorption. A more recently
emphasized 4th mechanism is the rate of utilization which comes into play under stress
states (e.g. disease, trauma, surgery…etc.)(19) In such cases, increased oral supply or
parenteral administration of higher doses are deemed necessary.
Recommended Dietary Allowances (RDAs) for Vitamin C (20)
Age
Male
Female
Pregnancy
Lactation
0–6 months
40 mg*
40 mg*
7–12 months
50 mg*
50 mg*
1–3 years
15 mg
15 mg
4–8 years
25 mg
25 mg
9–13 years
45 mg
45 mg
14–18 years
75 mg
65 mg
80 mg
115 mg
19+ years
90 mg
75 mg
85 mg
120 mg
Individuals who smoke require 35 mg/day
Smokers
more vitamin C than nonsmokers.
*Adequate intake
Last, to provide perspective on AA requirements, animals that can synthesize AA
have larger AA body pool. For examples, rats were reported to synthesize ~26
mg/Kg/day; Dogs ~81 mg/Kg/day; Goat ~190 mg/Kg/day. The synthesized amounts are
also significantly increased when under states of stress due to a disease or injury. A
simple extrapolation to a 70 kg body mass showed that between 1.8 gm/day and 13.3
gm/day will be synthesized/needed. Human RDA on the other hand is around
100mg/day and the maximum plasma AA levels that can be reached with the oral route
is below 240 uM which is enough to maintain a body pool of 1.4 gm/70kg.(21) Changing
RDA will lead to minimal plasma AA changes, since as described before oral route and
the renal elimination threshold limit further plasma AA increment beyond that achieved
with RDA. Comparing human and animal data clearly point out what could be a
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limitation in the human AA homeostasis preventing optimal therapeutic dosing through
the oral route especially under conditions of stress.
1.2 Ascorbic acid and clinical disease states

Under stress, the affected organs/tissues concentrate AA leading to decrease
vitamin levels in the circulation. Low/Undetectable AA levels signify a set of dynamic
processes involving AA utilization and re-distribution. Re-distribution of AA body pool
and high consumption occur as early as the stressful state occur and is sustained as
long as it continues. Re-distribution takes place in a way that favors replenishing of the
affected tissues, thus increasing their anti-oxidant capacity and preventing the
uncoupling of the normal catabolic oxidative processes. Uncoupling of these normal
processes is a major contributor of oxidative stress. Therefore, following the major event
AA starts to reach a new but lower steady state in the plasma.(8, 22, 23) Dilutional
effects associated with massive transfusion protocols used in major injuries also need to
be considered.(24) As well, It has been found that the degree of stress and the patient’s
initial conditions (e.g. Age, dietary intake, comorbidities) play a major role in determining
how much of AA is needed.
AA concentration decreases significantly within few hours in critically ill patients
during trauma, shock, sepsis, burns, surgery, postoperatively and with postoperative
complications.(24, 25) These conditions are known to increase the turnover of ascorbic
acid. Reduction in AA level was not corrected by the oral route because of limited
absorption. Moreover, the use of low dose parenteral doses (100 – 1000 mg/day) had
failed to restore normal vitamin levels for several days in this patient population.(8)
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Concentrations achieved orally, in such cases, may approaches that required for
enzyme modulation, but are not enough to scavenge superoxide anion which signifies
the importance and advantage of the parenteral route.(26) All of these observations in
the last century had led investigators to call for increasing AA supplementation for
patient undergoing surgery as early as 1946.(8) Not only acute injuries but also chronic
disease states such as diabetes and gastritis has also been associated with reduced
plasma AA levels.(8)
Timely achievement of AA homeostasis and the added benefits of AA
supplementation have been reported in randomized controlled trials involving trauma
patients, major burns, critically ill cardiac patients as well as patients with subarachnoid
hemorrhage that employed intravenous (IV) vitamin C supplementation. Doses used
were between 1gm every 8hours to 66mg/kg/hr (110gm/24hours for a 70kg patient). A
significant improvement in patient outcomes was observed in these studies. There was
a decrease in patients’ ICU length of stay, hospital length of stay, duration on
mechanical ventilation, the inflammation marker C-reactive protein (CRP), wound
edema, time to wound healing and an overall decrease in morbidity and mortality.(25) In
addition, recent research in cardiac surgery has suggested that the use of Vitamin C
decreases atrial fibrillation.(25) It is clear that an exaggerated inflammatory response
with an oxidative stress self-perpetuating element is central to all of these insults.
Indeed, reactive oxygen species (ROS) burst is dominant in critical illness - both acute
and chronic - and predispose to multi-organ dysfunction syndrome (MODS), worsening
of clinical outcomes, and death.(8)
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The sometimes controversial clinical trial results associated with the use of AA could
be in part due to the use of different routes of administration. Many of the studies
reporting lack of efficacy have employed AA orally in a relatively low dose, which is
thought to be less effective. In contrast, when administered intravenously higher plasma
concentrations (many folds higher-milliMolar concentrations) are achievable and
outcomes are more likely to be affected favorably. Evidence from the literature together
with previous work in our labs have shown that there are additional pharmacological
benefits that can be reaped when AA levels are in the low millimolar (mM) range (1-3
mM) during periods of stress due to injury or disease.
Lastly, a major fraction of plasma AA is redistributed to immune cells especially
neutrophils, macrophage, and lymphocytes. These cells concentrate AA many folds
significantly higher than plasma and are major effector cells in the inflammatory
response that is known their high utilization of the vitamin. (27, 28)
1.3 Ascorbic acid as a modulator of inflammation (Hands-on experience)
In the span of the last few years, collaborative work between Dr. Natarajan and
Fowler, and the Brophy laboratories (VCU advancement Coagulation Lab “VCAL”) have
resulted in several in-vitro preclinical studies and a Phase I clinical trial. These series of
studies were executed to examine the role of endogenous physiological levels of AA as
well as verify the beneficial effect of short term parenteral high dose AA
supplementation; explore possible mechanistic pathways regulating these effects; and
lastly advocate the clinical usage of this intervention as an add on therapy. Following, in
this section, is a discussion of the results of 3 in-vitro studies and the phase I clinical
trials conducted in our Laboratories at VCU and the VCU health systems hospital.
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Study #1: “Ascorbic acid attenuates lipopolysaccharide induced acute lung
injury”.(29)

In

this

lipopolysaccharide

study,

the

running

hypothesis

was

that

AA

attenuate

(LPS)-mediated

acute lung injury by inhibiting NFkB
activation. The research team was able
to show that parenteral AA and DHA
both at a dose of 200mg/kg were able to
prolong survival versus 100% mortality
in mice which were only exposed to
LPS (Figure 5). AA treatment was shown
to preserve the lung architecture as well.
Sequestered

neutrophil in

the

lung

Figure 5: Ascorbic acid (AscA) and dehydroascorbic
acid (DHA) prolong survival in septic mice after
lipopolysaccharide (LPS) administration. C57BL/6 mice
were injected intraperitoneally with LPS (10 µg/g). AscA
or DHA (200 mg/kg) was administered intraperitoneally
in saline 30 mins after treatment with LPS. LPS vs. LPS
+ AscA, p < .001, log-rank analysis; LPS vs. LPS +
DHA, p < .001, log-rank analysis (n = 7 for each group)

remained limited to the capillaries with
limited to no migration into the alveolar spaces in untreated mice. It also preserved the
lung microvascular barrier as evident by less protein content detected in the
bronchoalveolar lavage. AA also attenuated the exaggerated neutrophil response and
sequestration as evident by the reducedm RNA expression of myeloperoxidase.
Looking into the lung NFkB dependent pro-inflammatory cytokines mRNA expression,
AA was found to attenuate the augmented increase in KC (Neutrophil chemoattractant
factor), LIX (LPS-induced CXC chemokine), MCP-1 (Monocyte chemotactic protein-1),
and MCP-2 (Macrophage inflammatory protein-2) expression besides attenuating NFkB
signaling itself and diminishing its translocation into the nucleus in the lungs.
Hematoxylin and Eosin (H&E) staining of lung sections showed that AA treatment
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attenuate sepsis induced coagulopathy and microvascular thrombosis. Areas of
microthrombi formation (calculated as % of lung) were significantly reduced following
AA or DHA treatment vs untreated lungs in LPS-induced sepsis model. Moreover, AA or
DHA treated septic mice had prothrombin time (PT) and activated partial thromboplastin
time (APTT) values comparable to the controls. On the contrary, untreated septic mice
had significantly prolonged PT and APTT. These results collectively signify blood
coagulation factors consumption within the septic mice vasculature underlying an
ongoing disseminated intravascular coagulopathy which could be attenuated if the mice
were rescued with either AA or DHA i.p. injections following the LPS challenge. On a
more molecular level, tissue factor (TF) mRNA expression was also reduced following
LPS induced sepsis in the AA or DHA treated groups versus untreated mice. Tissue
factor expression is known to be in part regulated by NFkB activation status. Therefore,
attenuation of TF expression could either be due to NFkB inhibition or another
mechanistic pathway. In conclusion, AA and DHA attenuated LPS-induced lung injury
by attenuating the inflammatory response following injury and the associated
coagulopathies.
Study #2: “Mechanisms of attenuation of abdominal sepsis induced acute lung
injury by ascorbic acid”.(30) This study came as logical step after study #1. Study #1
explored VitC supplementation in a more controlled system i.e. endotoxin induced lung
injury. In this study, a live septic insult is employed using fecal stem solution (FIP)
prepared from mice fecal pellets and containing live micro-organisms and their
respective toxin products. The hypothesis was that VitC will protect lungs against
peritonitis induced acute lung injury (ALI). VitC supplementation, at 200mg/kg following
12

sepsis challenge, is expected to restore alveolar epithelial barrier integrity and prevent
sepsis induced coagulopathies. VitC deficient mice experiences 100% mortality within
26 hr from the septic insult. On the contrast, animals treated with VitC rescue dose
experienced negligible mortality. Also VitC treatment attenuated the exaggerated
expression of pro-inflammatory chemokines KC, LIX, MPO, HMGB1. VitC was shown to
maintain barrier function as hypothesized. In more details, VitC treated animals
exhibited significantly lower wet/dry lung weight tissue compared to VitC deficient
animals at 16 hour post insult. Bronchoalveolar lavage (BAL) from the treated mice
showed lower FITC-Dextran (FD4) content compared to untreated mice. From a
mechanistic standpoint, VitC was found to prevent sepsis mediated disassembly of the
Na+-K+ ATPase pump in vitro. VitC treatment also induced the expression of Aqp 5
(aquaporin 5), CFTR (cystic fibrosis transmembrane conductance regulator) and ENaC
(Epithelial sodium channel). Similar observations were made when A549 human
alveolar epithelial cells were treated with VitC post endotoxin challenge. Lastly in this
work,

the

authors

explored

the

coagulopathies

occuring

during

sepsis.

Thromoboelastography (TEG) was done to assess the blood viscoelastic properties.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were also
carried out. Lung tissue expression of tissue factor, tissue factor pathway inhibitor,
thrombomodulin, tissue plasminogen activator, and endothelial protein c receptor were
examined. Untreated deficient mice coagulation profile parameters demonstrated a
more procoagulant profile and showed marks of consumptive coagulopathies. On the
other hand, septic mice treated with VitC showed clot forming parameters that were not
different from controls on the TEG (with no indication of consumptive coagulopathies),
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and a protein expression profile favoring an anticoagulant environment (i.e favoring less
clot formation).
Study #3: “Attenuation Of Sepsis Induced Organ Injury By Vitamin C”.(31) Aside
from sepsis-induced lung injury (most frequent following sepsis), a more severe septic
insult results in multiple organ dysfunction syndrome. Lungs, liver, and kidneys are the
most frequent susceptible organs known to manifest sepsis-induced dysfunction. Acute
lung injury (ALI) is considered to be the most frequent complication of sepsis followed
by liver dysfunction. Patients with sepsis-induced acute kidney injury (AKI) also have
much higher mortality compared to either patients with sepsis or AKI alone. In this
study, the same animals grouping as study #2 (discussed earlier) were used. However,
the FIP dose used to render animals septic were reduced four folds (180mg/ml to
45mg/ml) to allow VitC deficient mice to live long enough through the experimental
period. This also demonstrated increased deficient mice susceptibility to FIP-induced
sepsis. Immunohistochemistry, molecular, and biochemical analyses used in the study
were able to demonstrate several important aspects. First, the FIP model of animal
sepsis was able to produce reproducible sepsis and sepsis-induced organ injury.
Second, Multiple organ dysfunction (MODS) was attenuated in VitC sufficient Gulo-/mice and in VitC deficient Gulo-/- mice infused with a single dose of parenteral AscA
compared to VitC deficient Gulo-/- mice. Also deficient Gulo-/- mice developed significant
abnormalities in the coagulation system and circulating blood cells which was again
attenuated in with either mice VitC sufficiency status or infusion with VitC as AscA. In
more details, septic lungs of VitC deficient Gulo-/- mice demonstrated an exaggerated
pro-inflammatory response and expressed significantly higher mobility group box-1
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(HMGB1),

cytokine-induced

neutrophil

chemoattractant

factor

(KC),

matrix

metalloproteinase 9 (MMP9) and myeloperoxidase compared to lungs from VitC
sufficient Gulo-/- mice subjected to FIP. Deficient septic mice also displayed pulmonary
edema, thickened alveolar walls infiltrated with intramural PMNs, and hemorrhage
compared to relatively normal histology with few sequestered PMNs, reduced
pulmonary edema and an attenuated pro-inflammatory response seen in sufficient mice.
FIP exposed VitC deficient Gulo-/- mice infused with intraperitoneal AscA also had
significantly attenuated lung inflammation and reduced lung water compared to
untreated deficient mice (p<0.05). With respect to sepsis-induced AKI, Kidney sections
from VitC deficient Gulo-/- mice subjected to FIP showed mild morphological damage,
including tubule vacuolation and occasional loss of brush border. These changes were
observed in all FIP exposed groups. In contrast to FIP exposed VitC sufficient Gulo -/mice or VitC deficient Gulo-/- mice infused with AscA, the kidneys of VitC deficient Gulo/- mice subjected to FIP were more pro-inflammatory (KC) and displayed increased
expression of biomarkers of AKI including kidney injury molecule 1 (KIM1), neutrophil
gelatinase associated lipocalin (NGAL), chitinase (ChiA), and chitinase 3-like 3 (Chi3L3)
(Figure 3B-H). Blood urea nitrogen (BUN) and creatinine levels were reduced in FIP
exposed VitC sufficient Gulo-/- mice and VitC deficient Gulo-/- mice infused with AscA.
However a statistically significant difference was achieved only with the BUN levels. As
to sepsis-induced liver injury, ALT and AST levels following FIP were elevated in the
VitC deficient Gulo-/- mice. These were normalized in both FIP exposed VitC sufficient
Gulo-/- mice and VitC deficient Gulo-/- mice infused with AscA In addition MMP9, a
critical mediator of tissue injury, was elevated in the FIP exposed VitC deficient Gulo-/-
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mice. In contrast MMP9 expression was attenuated in FIP exposed VitC sufficient Gulo /-

mice and VitC deficient Gulo-/- mice infused with AscA. Another important piece of this

study, was the effect of VitC sufficiency and/or infusion (in previously deficient mice) on
the septic mice coagulation profile. The viscoelastic properties, as measured with
thromboelastography using TEG machines, of blood from the different mice groups
were examined. Blood from septic VitC deficient Gulo-/- mice also displayed profound
changes in the rate and kinetics of clot formation (K and Angle). These changes were
not evident in FIP exposed VitC sufficient Gulo -/- mice. In addition, AscA infusion
restored hemostasis in VitC deficient Gulo-/- septic mice through the normalization of
these viscoelastic properties and their hematocrit. The favorable changes conferred by
VitC were also associated with a reduction in tissue factor (TF) expression and elevated
expression of tissue factor pathway inhibitor (TFPI) and thrombomodulin (TM) in the
lung tissues of FIP exposed VitC sufficient Gulo -/- mice and VitC deficient mice infused
with AscA.
Study #4: “Phase I safety trial of intravenous ascorbic acid in patients with
severe sepsis”.(32) This study is considered our first trial in patients with sepsis using
VitC. The study main purpose was to verify the safety of the intervention. Moreover,
important information collected during the study supported the protective notions of
using AscA treatment. Important to note that although the study was not powered to
assess efficacy, the promising results of the study together with previous in-vitro work
fueled a now ongoing multi-center NIH-funded study evaluating the efficacy of using
intravenous parenteral AscA as an add-on therapy for the treatment of sepsis-induced
ALI. This study was a randomized, double blind clinical trial. Patients were randomized
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to one of three groups: Placebo (receiving 5% dextrose), Low AscA group (receiving
50mg/kg/day), and a high AscA
group

(receiving

200mg/kg/day).

Daily treatments were divided into 4
doses and treatment was continued
for four days. AscA levels in patients
on admission were 17.9 ± 2.4uM
(compared to normal levels 50 – 70
uM). Levels were not significantly
different

across

admission.

VitC

the

groups
levels

on
rose

significantly in the low and high AscA
groups reaching 331 uM, and 3082
uM, respectively compared to the
placebo group which continued to
decline by day 4 of treatment.
Sequential organ failure assessment
(SOFA) score across groups were
initially the same (p>0.05, NS). Over
the 4 days of treatment, both AscA
groups showed significant steady

Figure 6: Serum C-reactive protein (CRP) and procalcitonin
levels in septic placebo controls and ascorbic acid infused
patients. (A) Both the Lo-AscA and the Hi-AscA dosages
produced rapid reductions in serum CRP levels, becoming
significantly lower than placebo (*p < 0.05 vs placebo) as
early as 24 hours. Ascorbic acid infusion reduced CRP
levels in both groups throughout the 4 study days (#p< 0.05
vs 0 hr). CRP levels in placebo patients slowly fell over the
course of the 4 day study period. (B) Patients in the Lo-AscA
and Hi-AscA groups exhibited reduced serum PCT levels
beginning at 12 hours. Patients in the Hi-VitC group
exhibited further significant reduction in serum PCT
between 36 to 48 hours (#p < 0.05 vs 0 hr). Placebo patients
exhibited a trend towards increased PCT levels which
declined starting at 72 hours post onset of sepsis. Placebo
(О), Lo-AscA (▼), Hi-AscA (▲)

decline in SOFA scores compared to the placebo group patients, whose score remained
around the baseline values. Additionally, three biomarkers were screened for during the
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study course. C-reactive protein (CRP) and procalcitonin (PCT) were used as surrogate
biomarkers (Figure 6) for inflammation, and thrombomodulin (TM) as a surrogate for
endothelial injury. Both AscA groups showed a significant rapid drop in CRP at 24 hours
and continued during the follow up
period. PCT levels were lower in the
AscA groups but not significant over the
first 24 hours. PCT levels started to
decrease in the AscA groups with the
high AscA group being significantly
lower than placebo past the 24 hr time
point and throughout the rest of the
follow up period. Low AscA group had
lower PCT levels at each timepoint

Figure 7: Plasma thrombomodulin (TM) levels measured in
septic placebo controls and ascorbic acid infused patients.
Plasma TM levels measured in the ascorbic acid infused
patients exhibited no rise throughout the 4 days of study.
Patients in the placebo group showed a trend towards
increased plasma TM levels beginning at 36 hours, though
it did not achieve statistical significance. Placebo (О), LoAscA (▼), Hi-AscA (▲).

compared to placebo but with no enough evidence to show significance due to sample
size and variability constrains. It is also important to note that in the placebo group PCT
levels started to increase post the 24 hr point and remained significantly elevated till the
72 hr time point. As to TM, it is initially expressd on endothelial cells where it binds and
neutralizes thrombin. Higher soluble TM found in plasma is a marker of endothelial
injury. TM levels in patients (Figure 7) randomized to placebo started to rise at
approximately 36 hrs and continue to rise throughout the follow up period. In contrast,
patients randomized to either doses of ascorbic acid exhibited no subsequent rise in
plasma TM. Data spread was considerable and the difference did not reach statistical
significance. In conclusion, using the previously described doses of AscA intravenously
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is safe; though the cohort size was small, the data suggested that AscA infusion could
significantly attenuate inflammation and endothelial injury inflicted by sepsis.
As mentioned earlier neutrophils, macrophages and lymphocytes and platelets
concentrate millimolar quantities of VitC underscoring its essential metabolic role for
normal functioning in these types of cells.
1.4 Safety
Short term, high dose, parenteral AA is not only successful at achieving the desired
high plasma AA concentration but it is also better tolerated than oral route and
associated with less discomfort.(21) In general, AA has a large safety margin and low
toxicity profile even at higher intakes.(20, 33)
Several online drug databases as well as the AA material safety data sheet report
that the most common side effects associated with AA use are: nausea, diarrhea,
gastrointestinal tract (GIT) discomfort and cramps.(21, 33, 34) These side effects are
associated with the oral route and are believed to be the result of high osmotic pressure
effects that is built up by unabsorbed AA in the GIT.(33, 34) Also side effects like
headache and fatigue have been reported. These are acute in nature and usually last
less than one day.(21) Diuretic effects have been observed with the use of IV AA and
patients should be observed for any signs of dehydration.(35)
AA acidifies the urine. This combined with increased oxalate and uric acid excretion,
products of AA and normal metabolism, has been reported to increase the probability of
kidney stones formation. Strong evidence to support kidney stones formation with AA
intake in the literature is lacking.(21) Intakes from as low as 30 mg and up to 10 gm/day
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have been studies with controversial results.(20) May be the two most scientifically
sound conclusions in this regard are: 1- AA may contribute to kidney stone formation in
patients with an already impaired renal function and/or with pre-esxisting oxalouria; and
2- Higher probability of kidney stones could be associated with continuous
intake/infusion over a long period of time (days to weeks) and is limited to oxalate renal
calculi.(36, 37)
AA is known to enhance iron absorption. This phenomenon does not adversely
affect healthy individuals. On the other hand, individuals with iron overload disorders
such as hereditary hemochromatosis, Thalassemia, Sideroblastic anemia, Glucose-6Phosphate dehydrogenase deficiency (G6PD) and sickle cell anemia need to exercise
caution and be screened. An exacerbated iron overload with AA intakes in such cases
may lead to tissue damage.(20, 38)
It is important that patients are checked for Glucose-6-phosphate dehydrogenase
(G6PD) deficiency before starting treatment with high dose AA. Intravenous high dose
of AA can result in hemolysis in such individuals.(39)
Another potential concern was the hypothesized pro-oxidant property of high dose
Vitamin C. However, evidence supporting this claim in literature is weak (except at very
high doses of.100g/day given IV) and the antioxidant property prevails at the low
millimolar range except with increased free iron load.(40)
It is fortunate that the safety of the dose, route, and targeted plasma levels in our
studies have been verified in the literature as well as in our preclinical and clinical work.
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The general safety profile of even much higher doses has been verified in studies
conducted in cancer patients.(41)
To conclude, overall AA is a very safe and low risk intervention over a wide range of
doses orally and parentrally. The parenteral route is considered most effective for
delivery of high AA levels that bypass the GIT absorption boundaries, thus serves
making Vitamin C a “new (emerging) drug” to be used in conjunction with current
therapies for patients.
1.5 Setting the stage
This thesis work is formulated into an introduction plus five chapters. All the
chapters collectively elaborate on the uses of AA as a modulator of inflammation in
varying contexts while providing a mechanistic approach to such findings. Chapters
two, three and four are already published work, and are incorporated into the thesis
as published. Only difference between the work as presented here and the
published version are the figures numbers and citation order. Figures’ number and
citation throughout the thesis are flowing as a continuum throughout. Chapter five
refers to an in-progress clinical trial [the study has been approved by the
institutional review board (IRB), and we are currently in the process of applying for
an indication-specific investigational new drug application (IND)]. Each of the
chapter/papers/research protocols is divided into subcomponents (introduction,
methods, results, and conclusion) and hence complete. Enjoy!
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CHAPTER 2: VITAMIN C: A NOVEL REGULATOR OF NEUTROPHIL
EXTRACELLULAR TRAP FORMATION

2.1 Introduction
Polymorphonuclear neutrophils (PMN) play key roles in the host response to
pathogens by regulating innate host defenses and modulating inflammation. PMN
combat pathogens by multiple mechanisms including phagocytosis, followed by
exposure

to

reactive

oxygen

intermediates

(short-lived

and

long-lived)

in

phagolysosomes (42), degranulation, which involves release of anti-bacterial peptides
and proteases to kill pathogens (43), as well as production of cytokines and other
inflammatory mediators. Aside from these traditional mechanisms, another mechanism
for pathogen killing, the formation of neutrophil extracellular traps (NETs) by NETosis, a
novel cell death pathway different from apoptosis and necrosis, was recently
identified.(44, 45) Although NETosis plays a crucial role in host defense during local
infection by trapping and killing pathogens, excessive NET formation during systemic
infections becomes self-defeating by promoting tissue injury and organ damage.(46)
Sepsis, a leading cause of death with high mortality rates, is characterized by excessive
inflammation and exuberant immune responses that lead to increased circulating PMN
levels and extensive PMN sequestration in the lung. This massive influx of PMNs to the
lungs often leads to acute lung injury (ALI).(47) One postulated mechanism by which
PMNs cause ALI is NETosis.(48) In sepsis, NETs are formed in response to proinflammatory stimuli such as lipopolysaccharide (LPS) and interleukin-8 (IL-8) (49, 50)
by expulsion of genomic DNA into web-like extracellular structures that display
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antimicrobial proteins such as histones, neutrophil elastase, and myeloperoxidase.(51)
During NETosis, various signaling pathways lead to dissolution of nuclear envelope,
thus allowing the mixing of nuclear chromatin with granular antimicrobial proteins from
cytoplasmic granules, and then, by releasing the DNA into lattice-like structures, NETs
concentrate proteases and antimicrobial proteins in the vicinity of trapped pathogens.
However, in sepsis, exposure to NETs also produces organ injury. Indeed, Dwivedi et
al. recently showed that NETosis, as determined by the circulating cell free DNA (cfDNA) content, could predict ICU mortality in severe sepsis better than existing severity
of illness or organ dysfunction scoring systems and was also better than IL-6, thrombin,
and protein C.(52) While effective targeting or inhibition of NET structures has been
suggested as therapy to benefit sepsis,(49) identification of agents with the potential to
alter NET formation remains elusive.
Vitamin C (VitC) is an essential vitamin for humans. While its role as an endogenous
antioxidant is well recognized, our recent research suggests that VitC beneficially
impacts multiple pathways associated with sepsis.(29) Its pleiotropic mechanisms
including attenuation of the pro-inflammatory response, enhancement of epithelial
barrier function, increasing alveolar fluid clearance, and prevention of coagulation
abnormalities constitute a primary line of defense that is protective in sepsis
syndromes.(30) Intracellular levels of VitC in various tissues differ significantly from
circulating plasma levels with high cellular concentrations considered to be indicative of
essential metabolic function.(53) In particular, VitC accumulates in millimolar quantities
in PMNs where it regulates neutrophil apoptosis.(53, 54) We recently showed that VitC
attenuated neutrophiliccapillaritis and improved survival in murine sepsis models.(29,
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30) However, whether VitC alters NETosis in sepsis settings remains unknown.
Humans lack functional L-gulono-γ-lactone oxidase (Gulo), the final enzyme in the
biosynthesis of VitC.(55) In contrast, mice express functional Gulo, resulting in tissues
generally maintaining high levels of VitC. In order to translate data from VitC studies in
mice to humans we have examined NETosis in septic mice lacking Gulo (Gulo−/−). Our
studies show that VitC sufficiency attenuated NETosis in septic mice. Importantly, at a
cellular level, we show that VitC deficient PMN were more susceptible to undergo
NETosis through increased activation of endoplasmic reticulum (ER) stress and
autophagy, processes considered vital for NETosis.(56) VitC deficient PMNs displayed
increased expression of peptidylargininedeiminase 4 (PAD4), the key enzyme required
for hypercitrullination of histones and chromatin decondensation.(57) Moreover, our
studies show that the pro-survival transcription factor nuclear factor kappa B (NFκB)
was augmented in the VitC deficient PMNs while apoptosis was suppressed. The
inhibitory effect of VitC on NETosis was recapitulated in phorbolmyristate acetate (PMA)
activated human PMN.
2.2 Experimental Section
2.2.1 Animals
Gulo−/− mice were bred in-house from an established homozygous colony as
previously described.(31) Vitamin C sufficient mice were fed ad libitum with regular
chow and water supplemented with vitamin C (0.330 g/L) renewed twice per week.
Vitamin C deficient mice were generated by reducing vitamin C supplementation (0.033
g/L) for one week, followed by complete removal of dietary vitamin C for an additional
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two weeks. Others have shown that this reduced supplementation significantly
decreases the concentration of VitC in immune cells, plasma and organs.(58, 59)
2.2.2 Feces Induced Peritonitis
Polymicrobial sepsis (peritonitis) was induced by intraperitoneal (i.p.) introduction of
fecal stem solution into the peritoneum as described previously.(30, 31) Thirty minutes
after fecal challenge (45 mg/mL), some mice received i.p. injection of VitC as ascorbic
acid (200 mg/kg in saline). Untreated mice received i.p. saline instead of VitC. Blood
was collected 16 h later by cardiac puncture, and lungs harvested. Blood was allowed to
coagulate, spun to separate serum, and stored at −80 °C for batch analysis of cell-free
DNA (see below). All animal studies were performed in accordance to the Virginia
Commonwealth University Animal Care and Use Committee’s approved protocols
(Protocol # AM10100, approved 15 March, 2011).
2.2.3 Gulo−/− Mice Were Divided into Five Groups
(1) (+): vitamin C sufficient mice received saline alone (0.4 mL, i.p.)
(2) FIP(+): vitamin C sufficient mice received fecal stem solution (0.4 mL, i.p.) followed
30 min later by saline (0.1 mL, i.p.)
(3) (−): vitamin C deficient mice received saline alone (0.4 mL, i.p.)
(4) FIP(−): vitamin C deficient mice received fecal stem solution (0.4 mL, i.p.) followed
30 min later by saline (0.1 mL, i.p.)
(5) FIP(−) + AscA: vitamin C deficient mice received fecal stem solution (0.4 mL, i.p.)
followed 30 min later by ascorbic acid (0.1 mL, i.p.)
2.2.4 Isolation of Mouse Peritoneal Neutrophils
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Induction of an enriched exudate of leukocytes in the peritoneal cavity of mice was
performed by i.p. injection of 1 mL of aged, sterile 3% thioglycollate solution.(55) After
16 h, mice were euthanized, and the peritoneal cavity was flushed with 5 mL sterile
Hanks’ balanced salt solution containing 1% BSA (HBSS). The leukocyte pellet
containing ~80% neutrophils and ~20% macrophages was washed with HBSS and
resuspended in RPMI-1640 medium. Total cell counts were determined with a
hemacytometer. Leukocyte viability was assessed by trypan blue exclusion (>99%).
PMNs were then purified by adherence to a plastic dish as described by Tsurubuchi et
al..(60) Briefly, cells from peritoneal exudate were plated into a 35-mm plastic dish and
incubated at 37 °C in 5% CO2 in air for 10 min in HBSS. The cells were washed twice
with fresh HBSS to remove non-adherent cells. Although there was loss of some PMNs,
which did not adhere to the dish, this procedure eliminated most of the macrophages.
Cytochemical staining of adherent cells using HARLECO® Hemacolor® Solution (EMD
Millipore, EMD Millipore) revealed that >95% of the adherent cells were PMNs.
2.2.5 Immunofluorescence and Differential Interference Contrast Imaging of Lung
NETs
Formalin fixed paraffin embedded mouse lung sections (3 μm) were rehydrated and
heat induced antigen retrieval performed in 0.01 M citrate buffer pH 6.0 for 20 min.
Sections were blocked with 1% normal swine serum (NSS, DAKO, Carpinteria, CA,
USA) and incubated with primary antibody #1, rat anti-mouse CD41 (MWReg30,
ab33661, Abcam, Cambridge, MA, USA), 1:10 diluted in 1% NSS/PBS overnight at 4
°C. Sections were then incubated with goat anti-rat Alexa Fluor® 488 1:50 (Abcam) in
PBS for 4 h followed by incubation with primary antibody #2, rabbit anti-
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myeloperoxidase (ab45977, Abcam) 1:10 diluted in PBS overnight at 4 °C. Sections
were then incubated with chicken anti-rabbit Alexa Fluor® 647 (Invitrogen, Life
Technologies, Grand Island, NY, USA) 1:50 in PBS for 4 h followed by incubation with
primary antibody #3, mouse anti-histone H2A (L88A6, Cell Signaling, Danvers, MA,
USA) 1:200 in PBS overnight at 4 °C, and then finally incubated with goat anti-mouse
IgG1 Alexa Fluor® 594 (Invitrogen) 1:50 in PBS for 4 h. Nuclear counterstain was
performed with DAPI (Invitrogen) 1:500 for 5 min and sections mounted with Slow Fade
Gold (Invitrogen). Negative controls were run in parallel with nonspecific IgG or specific
isotype. Confocal microscopy was performed with a Leica TCS SP2 laser scanning
confocal microscopy system of the VCU Department of Anatomy and Neurobiology
Microscope Facility. Separate images of optical sections were acquired with filters for
Alexa Fluor® (AF) 488, 594, 647 and DAPI. Images were assembled with ImageJ
software.
2.2.6 RNA Isolation and Real-Time Quantitative PCR (QPCR) Analysis
Isolation of total RNA and real-time QPCR analyses were performed as described
previously.(29) Primers used for QPCR are listed in Table 1 below.
Table 1. Murine primers used for Quantitative PCR (QPCR).
Name

Sequence 5′ to 3′

ATF4 forward

CCTAGGTCTCTTAGATGACTATCTGGAGG

ATF4 reverse

CCAGGTCATCCATTCGAAACAGAGCATCG

BiP forward

GTGCAGCAGGACATCAAGTTCTTGCC

BiP reverse

TTCCCAAATACGCCTCAGCAGTCTCC

CHOP forward

CACCTATATCTCATCCCCAGGAAACG

CHOP reverse

TTCCTTGCTCTTCCTCCTCTTCCTCC
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EDEM forward

GCCCTTTGGTGACATGACAATTGAGG

EDEM reverse

TCATTATTGCTGTCAGGAGGAACACC

XBP-1s forward

TGAGTCCGCAGCAGGTGC

XBP-1s reverse

CAACTTGTCCAGAATGCCCAAAAGG

XBP-1un forward

AAGAACACGCTTGGGAATGGACACGC

XBP-1un reverse

ACCTGCTGCAGAGGTGCACATAGTC

PAD4 forward

ACAGGTGAAAGCAGCCAGC

PAD4 reverse

AGTGATGTAGATCAGGGCTTGG

ATG3 forward

CACCACTGTCCAACATGGC

ATG3 reverse

GTTTACACCGCTTGTAGCATGG

ATG5 forward

ACAAGCAGCTCTGGATGGG

ATG5 reverse

GGAGGATATTCCATGAGTTTCCG

ATG6 forward

CACGAGCTTCAAGATCCTGG

ATG6 reverse

TCCTGAGTTAGCCTCTTCCTCC

ATG7 forward

ACGATGACGACACTGTTCTGG

ATG7 reverse

AGGTTACAGGGATCGTACACACC

ATG8 forward

ACAAAGAGTGGAAGATGTCCG

ATG8 reverse

GGAACTTGGTCTTGTCCAGG

TNFα forward

GATGAGAAGTTCCCAAATGGC

TNFα reverse

TTGGTGGTTTGCTACGACG

IL-1β forward

CTGAACTCAACTGTGAAATGCC

IL-1β reverse

CAGGTCAAAGGTTTGGAAGC

18S forward

GATAGCTCTTTCTCGATTCCG

18S reverse

AGAGTCTCGTTCGTTATCGG

2.2.7 Western Blot Analysis
Neutrophil whole-cell and nuclear extracts were isolated for Western blot analysis as
described previously.(30) Nuclear extracts were isolated using the NE-PER kit (Pierce
Biotechnology, Rockford, IL, USA). Proteins were resolved by SDS polyacrylamide gel
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electrophoresis (4%–20%) and electrophoretically transferred to polyvinylidene fluoride
membranes

(0.2

μm

pore

size).

Immunodetection

was

performed

using

chemiluminescent detection with the Renaissance Western Blot Chemiluminescence
Reagent Plus (Perkin Elmer Life Sciences Inc., Boston, MA, USA). Blots were stripped
using the Restore™ Western Blot Stripping Buffer (Pierce Biotechnology Inc., Rockford,
IL, USA) as described by the manufacturer. Purified rabbit polyclonal antibodies to
LC3B (L7543, Sigma-Aldrich), cleaved caspase-3 (#9661, Cell Signaling), caspase-3
(#9662, Cell Signaling), p62/SQSTM1 (NBP1-48320, Novus Biologicals), NFκB p65 (sc109, Santa Cruz Biotechnology), Lamin B (sc-6216, Santa Cruz Biotechnology), and
actin (sc-1616, Santa Cruz Biotechnology) were used in this study. Optical densities of
antibody-specific bands were determined using Quantity One acquisition and analysis
software (Bio-Rad, Hercules, CA, USA).
2.2.8 Isolation of Human Neutrophils and NETs Release
Human neutrophils were isolated by density gradient centrifugation and hypotonic
lysis.(61) Cells were adjusted to 2 × 106/mL in RPMI-1640, seeded onto 8-well IbiTreat
μ-slides (Ibidi #80826), 0.3 mL per well, and allowed to adhere for 15 min. PMNs were
VitC loaded by incubating for 1 h with 0.3 mM or 3 mM buffered ascorbic acid (Mylan
Institutional LLC, Rockville, IL, USA). Neutrophils were stimulated with 50 nM PMA for
three hours at 37 °C. Neutrophil conditioned media were centrifuged at 400× g for 5 min
and the supernatants used for quantification of cf-DNA.(62)
2.2.9 Immunofluorescence Staining of Human NETs
PMNs were fixed with 4% paraformaldehyde, permeabilized with 0.15% Triton X-100 in
PBS, and blocked with 5% normal chicken serum (Sigma) in PBS. To stain NETs, slides
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were incubated with a mouse monoclonal anti-myeloperoxidase antibody (1:200; Santa
Cruz sc-52707) and a secondary Alexa Fluor® 488-conjugated chicken anti-mouse IgG
antibody (1:200; Molecular Probes A-21200). After staining of DNA with DAPI,
neutrophil-derived NET formation was visualized by immunofluorescence microscopy
performed on an Olympus model IX70 inverted microscope outfitted with an IX-FLA
fluorescence observation system equipped with a FITC and DAPI filter cubes (Chroma
Technology, Brattleboro, VT, USA) through Uplan FI objectives (20×, 60×). Images
were captured by an Olympus XM10 digital camera using CellSens imaging software
(Olympus America, Melville, NY, USA).
2.2.10 Quantification of Cell Free DNA
The levels of cf-DNA in human neutrophil supernatants and mouse serum were
quantified using the Invitrogen Quant-iTPicoGreendsDNA assay kit according to the
manufacturer’s instructions (Life Technologies, Grand Island, NY, USA). Fluorescence
intensity was measured on a SpectraMax Gemini XPS microplate reader with excitation
at 490 nm and emission at 525 nm, with a 515 nm emission cutoff filter (Molecular
Devices, Sunnyvale, CA, USA).
2.2.11 Statistical Analysis
Statistical analysis was performed using SAS 9.3 and GraphPad Prism 6.0 (GraphPad
Software, San Diego, CA, USA). Data are expressed as mean ± SE. Results were
compared using Student-Newman-Keuls test or one-way ANOVA and the post hoc
Tukey test to identify specific differences between groups. Statistical significance was
confirmed at a p value of <0.05.

30

2.3 Results
2.3.1 Vitamin C Sufficient Mice Demonstrate Reduced Lung NETs and Lower cf-DNA
Following Peritonitis-Induced Sepsis
We have previously shown that fecal peritonitis promotes PMN infiltration of the lungs in
VitC deficient mice.(31) Here we used immunofluorescence staining and DIC
microscopy to examine the extent of NETs in lungs of mice following FIP induced
sepsis. Immuno-positive staining for platelet CD-41 (green), nuclear histones (red), and
myeloperoxidase (grey) are visible in the lungs of saline exposed mice (Figure 8A). No
appreciable immuno-positive staining differences were seen in the lungs of saline
exposed VitC deficient mice (Figure 8C). FIP induced a mild increase in CD-41 immunopositivity as well as some cytosolic histone staining (Figure 8B). However, no significant
histological changes were evident in the VitC sufficient septic mice. In contrast, FIP
induced significant NETs in VitC deficient mice as evidenced by dramatically increased
co-staining for platelet CD-41 (green), histones (red), and myeloperoxidase (grey) in the
vascular and alveolar spaces of septic mice (arrowheads, Figure 8D). Moreover,
extensive extra-nuclear staining of histones (arrows) is also evident in this
representative section along with thickened alveolar walls. Importantly, FIP exposed
vitamin C deficient mice treated with ascorbic acid exhibited significant attenuation of
NETs (Figure 8E).
In order to quantify NETs we determined levels of cf-DNA in the serum of VitC sufficient
and deficient mice 16 h after sham treatment or FIP. Levels of serum cf-DNA were
significantly elevated in the FIP exposed VitC deficient mice (Figure 8F, 5-fold, p <
0.05). Treatment of septic VitC deficient mice with ascorbic acid significantly lowered
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the cf-DNA values to control levels (p < 0.05). In addition peritoneal neutrophils from
vitamin C deficient mice were more susceptible to NETosis than those from vitamin C
deficient mice (Supplementary Material section below).

Figure 8 Vitamin C sufficient Gulo−/− mice demonstrate reduced lung NETs and lower cf-DNA following
peritonitis-induced sepsis. Representative immunofluorescence and differential interference contrast
imaging of lung NETs (A–E): (A) VitC sufficient Gulo−/− mice (+) received saline alone (0.4 mL, i.p.); (B) FIP
exposed VitC sufficient Gulo−/− mice [FIP(+)] received fecal stem solution (45 mg/mL, i.p.) followed 30 min
later by saline (0.1 mL, i.p.); (C) VitC deficient Gulo−/− mice (−) received saline alone (0.4 mL, i.p.); (D) FIP
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exposed VitC deficient Gulo−/− mice [FIP(−)] mice received fecal stem solution (45 mg/mL, i.p.) followed 30
min later by saline (0.1 mL, i.p.). (E) AscA treated FIP exposed VitC deficient Gulo−/− mice [FIP(−) + AscA]
mice received fecal stem solution (45 mg/mL, i.p.) followed 30 min later by AscA (200 mg/kg, i.p.). Platelet
CD-41 (green), histones (red), and myeloperoxidase (grey) are seen in the merged images. Arrowheads
indicate NET formation shown by co-staining for platelet CD-41 (green), histones (red), myeloperoxidase
(grey), and DAPI (blue) in the vascular and alveolar spaces. Arrows indicate extensive extra-nuclear histones
(red); (10× magnification, N = 3 for each group). (F) Serum levels of cf-DNA were quantified using the QuantiTPicoGreen dsDNA assay kit (N = 5–11 for each group, p < 0.05).

2.3.2 Vitamin C Deficient Neutrophils Show Increased PAD4 mRNA
Unlike apoptosis, rapid intracellular decondensation of nuclear chromatin is a hallmark
of NETosis.(31, 63) Decondensation of nuclear chromatin requires the removal of
positively charged arginine residues on histones by deimination or citrullination, which is
carried out by a family of peptidylargininedeiminases (PAD). Of these, only PAD4 is
expressed by neutrophils (64) and possesses a classical nuclear localization signal.(65)
Importantly Wang et al. have shown that PAD4 is indispensable for NETosis.(57)
Therefore, we examined mRNA expression of PAD4 in PMNs from VitC sufficient and
deficient mice. As seen in Figure 9, PAD4 mRNA expression was significantly higher in
thioglycollate elicited peritoneal PMNs from VitC deficient mice (p < 0.05).

Figure 9 Vitamin C deficient neutrophils show increased PAD4 mRNA. Real time QPCR for PAD4 shows twofold increase in mRNA expression from peritoneal PMNs of VitC deficient Gulo−/− mice when compared to
PMNs from VitC sufficient Gulo−/− mice (N = 6 for each group, * p < 0.05).
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2.3.3 Autophagy Signaling Is Induced in Vitamin C Deficient Neutrophils
Autophagy is a vital process for the catabolism of cytosolic proteins and organelles, but
has also been shown to be required for NETosis.(56, 66) To examine whether VitC
regulates autophagy in PMNs we assessed the expression of several autophagy genes
in thioglycollate elicited PMNs from VitC sufficient and deficient mice. As seen in Figure
10A, the expression of autophagy related signaling molecules (except for ATG6) were
significantly elevated in the VitC deficient PMNs (p < 0.05).
Activation of the autophagic process causes lipidation of ATG8/LC3B (LC3B-I to LC3BII conversion) and the lipid-modified LC3B-II translocates to autophagosomes. This
LC3B-I to LC3B-II conversion is considered a critical marker of autophagy
activation.(67) We observed significantly enhanced LC3B-I to LC3B-II conversion in cell
lysates of VitC deficient PMNs by immunoblotting (Figure 3B, p < 0.05).
To further investigate the regulation of autophagy signaling by VitC in PMNs, we
examined the accumulation of p62/sequestosome I in these cell lysates. The loss of p62
in cells is typically indicative of increased autophagic activity.(68) Detection of p62 by
immunoblotting showed a trend towards decreases p62 levels in the VitC deficient
PMNs (Figure 10C). However this decline did not reach statistical significance (p = 0.3).
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Figure 10 Autophagy signaling is induced in Vitamin C deficient neutrophils. (A) Real time QPCR for ATG3,
ATG5, ATG6, ATG7, and ATG8 mRNA from peritoneal PMNs of VitC sufficient and deficient Gulo−/− mice, (N
= 6 for each group, * p < 0.05). (B) Representative Western blot for expression of LC3B-I and LC3B-II from
peritoneal PMNs of VitC sufficient and deficient Gulo−/− mice. Densitometry of LC3B-II/actin from peritoneal
PMNs of VitC sufficient and deficient Gulo−/− mice (N = 6 for each group, * p < 0.05). (C) Representative
Western blot for expression of p62 and actin from peritoneal PMNs of VitC sufficient and deficient Gulo−/−
mice. Densitometry of normalized p62 expression from peritoneal PMNs of VitC sufficient and deficient
Gulo−/− mice (N = 6 for each group, ns p = 0.3).

2.3.4 Endoplasmic Reticulum Stress Associated Gene Expression Is Up-Regulated in
Vitamin C Deficient Neutrophils
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Signaling initiated by the ER stress response (unfolded protein response, UPR) actively
participates in autophagy and ultimately contributes to the cell fate decision.(69) Since
autophagy signaling was induced in the VitC deficient PMNs, we next examined ER
stress gene expression in the PMNs. As seen in Figure 11, all the UPR genes examined
except for CHOP were significantly up-regulated in PMNs from VitC deficient mice (p <
0.05).

Figure 11 Endoplasmic reticulum stress associated gene expression in up-regulated in vitamin C deficient
neutrophils. Real time QPCR for activating transcription factor 4 (ATF4), glucose-regulated protein 78 (Grp78,
BiP), C/EBP homologous protein (CHOP), ER degradation-enhancing α-mannosidase-like protein (EDEM), Xbox binding protein-1 spliced (XBP-1s), and unspliced (XBP-1un) mRNA from peritoneal PMNs of VitC
sufficient and deficient Gulo−/− mice, (N = 6 for each group, * p < 0.05).

2.3.5 Vitamin C Deficient Neutrophils Undergo Attenuated Apoptosis
To determine the extent of apoptosis in peritoneal PMNs from VitC sufficient and VitC
deficient mice, we examined a well characterized marker of apoptosis, cleaved
caspase-3, by immunoblotting of PMN cell lysates. As seen in Figure 12, caspase-3
activation was significantly lower in VitC deficient PMNs (p < 0.05).
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Figure 12 Vitamin C deficient neutrophils undergo attenuated apoptosis. Representative Western blot for
expression of caspase-3 and cleaved caspase-3 from peritoneal PMNs of VitC sufficient and deficient
Gulo−/− mice. Densitometry of cleaved caspase-3/caspase-3 from peritoneal PMNs of VitC sufficient and
deficient Gulo−/− mice (N = 6 for each group, * p < 0.05).

2.3.6 Vitamin C Deficient Neutrophils Exhibit Increased NFκB Activation
The transcription factor NFκB modulates the expression of many immuno-regulatory
mediators in the acute inflammatory response in sepsis. Yang et al. found that
diminished nuclear translocation of NFκB in peripheral PMNs was associated with less
time on the ventilator and improved survival in critically ill patients.(70) NFκB activation
is also associated with increased ROS production and endoplasmic reticulum stress
signaling.(71) Therefore, we examined nuclear translocation of NFκB in peritoneal
PMNs isolated from VitC sufficient and deficient mice. As seen in Figure 13A,
significantly increased NFκB translocation was observed in nuclei of VitC deficient
PMNs (p < 0.05). Increased nuclear NFκB translocation was associated with induction
of the NFκB dependent pro-inflammatory genes for TNFα and IL-1β (Figure 13B, p <
0.05).
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Figure 13 Vitamin C deficient neutrophils exhibit increased NFκB activation. (A) Representative Western blot
for nuclear expression of NFκBp65 and Lamin B from peritoneal PMNs of VitC sufficient and deficient
Gulo−/− mice. Densitometry of NFκBp65/Lamin B from peritoneal PMNs of VitC sufficient and deficient
Gulo−/− mice (N = 4 for each group, * p < 0.05). (B) Real time QPCR for TNFα and IL-1β mRNA from peritoneal
PMNs of VitC sufficient and deficient Gulo−/− mice, (N = 6 for each group, * p < 0.05).

2.3.7 Vitamin C Attenuates NET Formation in Activated Human Neutrophils
Freshly isolated human PMNs formed NETs following activation by PMA (50 nM) for
three hours as seen by immunofluorescence staining (Figure 14B, E). Loading the cells
with VitC (3 mM) prior to PMA stimulation greatly reduced NET formation by human
PMN (Figure 14C, F). Further, quantification of cf-DNA from the supernatants showed
VitC (3 mM) loading significantly reduced NETs release from activated PMN (Figure
14G, p < 0.05).
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Figure 14 Vitamin C attenuates NET formation in activated human neutrophils. Representative image of
immunofluorescent staining for NETs in human neutrophils: DNA (blue); myeloperoxidase (green). Upper
Panels: Control PMNs (A, 20×); PMNs exposed to PMA (50 nM) for 3 h (B, 20×); PMNs loaded with VitC (3 mM)
for 1 h and then exposed to PMA (50 nM) for 3 h (C, 20×). Lower Panels: Control PMNs (D, 60×); PMNs
exposed to PMA (50 nM) for 3 h (E, 60×); PMNs loaded with VitC (3 mM) for 1 h and then exposed to PMA (50
nM) for 3 h (F, 60×). (N = 3 for each group, Magnification: upper panel 20×, lower panel 60×). (G)
Quantification of cf-DNA in the supernatants above (N = 3 for each group, p < 0.05).
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2.4 Discussion
In this study we show that VitC could play a critical role in regulating the ultimate
fate of PMNs in sepsis. Activated PMNs undergo extensive NETosis in septic mice
lungs, resulting in potential damage to lung alveolar and endothelial cells. This effect
was predominant in PMNs from VitC deficient mice and could be rescued by VitC
infusion after the onset of sepsis. In contradistinction, PMNs from VitC sufficient mice
underwent attenuated NETosis. Importantly, at a molecular level, VitC deficient
peritoneal PMNs were likely to be more pro-inflammatory, to resist apoptosis, and to
preferentially undergo NETosis.
Although several signaling mechanisms responsible for NET formation have been
reported, critical regulatory elements remain unidentified. This study advances our
understanding of PMN function and NET biology by identifying a novel regulatory
mechanism for NET formation in both murine and human PMNs. Using our previously
well-characterized model of abdominal peritonitis induced sepsis we show that sepsis
promotes NET formation in lungs of VitC deficient mice (Figure 8). NETosis in this
model was accompanied by increased circulating cf-DNA (Figure 8F). VitC sufficiency
or infusion of VitC after initiation of sepsis significantly decreased NETosis in lungs and
circulating cf-DNA content (Figure 8). NET formation in VitC deficient peritoneal PMNs
required activation of well characterized signaling pathways including ROS generation
(data not shown), activation of the peptidylargininedeiminase PAD4 (Figure 9),
autophagy (Figure 10), endoplasmic reticulum stress (Figure 11), and inhibition of
apoptosis (Figure 12). NFκB, a pro-inflammatory, pro-survival transcription factor was
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activated in the VitC deficient peritoneal PMNs (Figure 13). VitC sufficiency or treatment
with VitC attenuated these signaling pathways in PMNs.
Intracellular chromatin decondensation is essential for NET formation. Chromatin
decondensation is brought about by peptidylargininedeiminase 4 (PAD4), a nuclear
enzyme that deiminates arginine residues on histone tails thereby converting positively
charged arginines to uncharged citrullines.(56, 57) The importance of PAD4 is that
many NET forming stimuli including PMA, LPS, and IL-8 as well as various bacterial and
fungal species converge to its activation. While PAD4 is expressed in PMNs and is
localized to the nucleus (64, 65), little is known about its mechanism of action or its
transcriptional regulation. Ying et al. have shown that PAD1, which belongs to the same
family of enzymes as PAD4, is transcriptionally regulated by NFκB.(72) We have
previously shown that VitC blocks NFκB activation in septic mouse lungs.(29) Cárcamo
et al. also demonstrated that VitC blocks IκB kinase activity and NFκB activation.(73) In
this study we observed that nuclear NFκB levels were higher in the VitC deficient PMNs
(Figure 13A). Further, PAD4 mRNA expression was also significantly higher in PMNs
from VitC deficient mice (Figure 9). Therefore, we hypothesize that VitC decreases
PAD4 expression by suppressing NFκB activation in PMNs. Further, by decreasing
PAD4 expression VitC could decrease histone citrullination activity and therefore
chromatin decondensation in VitC sufficient PMNs.
Autophagy has been identified as a well-conserved, homeostatic mechanism that clears
damaged organelles or proteins and plays an essential role in cell survival during
periods of nutrient depletion.(74) Despite the view that it might not occur in neutrophils,
autophagy was recently shown to occur both in murine and human PMNs.(75, 76) While
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Mitroulis et al. reported that autophagy occurs in human PMNs in response to PMA
activation.(77) Remijsen et al. have shown that autophagy is necessary for the induction
of intracellular chromatin decondensation during PMA-induced NETosis.(56) In our
study, we found increased expression of autophagy genes (Figure 3A) as well as
significantly enhanced LC3B-I to LC3B-II conversion in VitC deficient PMNs (Figure 3B)
indicative of the presence of more autophagosomes in VitC deficient PMNs. However,
LC3B-I to LC3B-II conversion is a static measure of autophagosome number, and does
not measure the actual activity of the pathway. The increased LC3B-II could be
interpreted as either high autophagic activity or a downstream block in the system that
results in an accumulation of LC3B-II protein, even though autophagic degradation itself
is

diminished.

To

supplement

our

observations

we

examined

levels

of

p62/sequestosome I, a cytosolic chaperone protein with an LC3B binding domain.(78)
The normal function of p62 protein is to carry polyubiquitinated proteins to the
autphagolysosome where it binds to LC3B before getting degraded. Thus, the loss of
p62 protein is a measure of the flux of autophagy and indicative of increased
autophagy.(78) In our studies we found a trend towards decreased p62 levels in the
VitC deficient PMNs (Figure 10C). While this decline did not reach statistical
significance, in combination with the increased autophagy gene expression and
increased LC3B conversion, our data imply increased autophagy in VitC deficient
PMNs. The unfolded protein response (UPR) and autophagic machinery have been
shown to be critically linked to each other. It is well established that activation of the
UPR genes transcriptionally up-regulates several autophagy related genes required for
induction and construction of the autophagy machinery.(79) However, it is not known
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whether activation of the UPR drives autophagy and eventually leads to NET formation
in PMNs. Our study shows that most of the UPR genes examined except for CHOP
were significantly up-regulated in PMNs from VitC deficient mice (Figure 11). This
implies that VitC deficient PMNs could be actively undergoing ER stress, which in turn
could drive autophagy genes and increase their susceptibility to undergo NETosis.
The transcription factor NFκB is central to pro-inflammatory/pro-survival responses in
sepsis. It is normally sequestered to IκB in the cytosol. Upon appropriate stimulation,
IκB is degraded allowing NFκB to migrate to the nucleus and drives transcription of
numerous genes that regulate the immune response in sepsis. Moine et al. have
demonstrated increased NFκB translocation in the lungs of patients with ALI.(80) Yang
et al. found that increased nuclear levels of NFκB in unstimulated neutrophils were
associated with a worse clinical outcome.(70) As discussed above, NFκB likely drives
expression of PAD4 in PMNs. NFκB activation also drives expression of pro-survival
genes.(81) In this study we found that nuclear NFκB translocation was higher in VitC
deficient PMNs (Figure 13A). Further, NFκB translocation in these VitC deficient PMNs
increased expression of the pro-inflammatory genes TNFα and IL-1β (Figure 13). NFκB
activation also inhibited apoptosis as seen by the reduced activation of caspase 3 in
VitC deficient PMNs (Figure 12). These results suggest that NFκB may play a critical
role in modulating cell signaling pathways that eventually regulate the fate of PMNs. By
activating PAD4 (chromatin decondensation), inducing ER stress and subsequent
autophagy, and inhibiting apoptosis, NFκB may drive the cellular machinery of VitC
deficient PMNs towards NET formation (Figure 15). VitC sufficiency or infusion of VitC
allows PMNs to increase intracellular levels of VitC and attenuate NFκB activation. This
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could dampen the pathways required for NETosis and may allow PMNs to undergo
apoptosis instead. While the decreased apoptosis rate in VitC deficient PMNs may
benefit the host by giving more time for PMNs to perform their innate immune functions,
studies show that it could also be detrimental in sepsis due to the PMN-dependent
inflammation and tissue damage that could be heightened by a prolonged lifespan.
Recent reports in the literature have implicated NETs in transfusion-related acute lung
injury (TRALI), the leading cause of death after transfusion therapy.(82, 83) NETs were
shown to be present during TRALI both in mice and humans and so it was suggested
that targeting NET formation may be a new approach for the treatment of acute lung
injury. While we did not examine TRALI in our studies, it is conceivable that VitC
infusion could be a useful adjunct for the prevention/treatment of TRALI or other
disease states involving exuberant formation of NETs particularly in the lungs.
Our study has several limitations: (1) It is possible that the PMNs isolated within the
peritoneal cavity by thioglycollate could be partially activated; (2) We examined PMN
function ex vivo. Further in vivo studies are needed to characterize the fate of PMNs; (3)
others have performed studies with PMNs isolated from bone marrow instead of
thioglycollate elicitation. These PMNs would be less “activated” when compared to
thioglycollate elicited PMNs, but would also have a large component of immature PMNs
which have been shown to behave somewhat differently from mature PMNs.(84)
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Figure 15 Schematic hypothesis of regulation of signaling pathways that leads to NETosis by VitC. Septic
stimuli activate NFκB in PMNs with increased activation observed in VitC deficient PMNs. NFκB nuclear
translocation drives expression of PAD4, ER stress and autophagy signaling genes while inhibiting caspase
3 in activated PMNs. This drives the fate of activated PMN away from apoptosis and enhances NETosis. VitC
likely blocks up-regulation of PAD4, ER stress and autophagy signaling genes by decreasing NFκB
activation. Activated PMNs now undergo apoptosis while NETosis is attenuated.

2.5 Conclusion
In the past few years circulating cf-DNA has been identified as a prognostic marker
in severe sepsis.(52, 85, 86) Indeed cf-DNA was shown to have better discriminatory
power than IL-6, thrombin or protein C to predict ICU mortality in sepsis.(52) The
cellular origin of cf-DNA from host cells was shown by Dwivedi et al. (52) who confirmed
that the release of cf-DNA was independent of the infecting organism and was likely
mediated by inflammatory mediators generated during the exacerbated host immune
response. Our study showed attenuated NET formation and reduced cf-DNA in the
serum of septic VitC sufficient mice and in VitC deficient mice treated with ascorbic acid
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(Figure 1). Our study did not examine the origin of cf-DNA in the serum of these mice. It
is possible that some of this DNA could be non-neutrophilic in origin since mast cells,
eosinophils, and basophils have also been shown to expel their DNA in a manner
similar to PMNs.(87) However, a detailed examination of the origin of cf-DNA in these
septic mice is beyond the scope of this study. Nevertheless, data from our study implies
that attenuation of NETs maybe crucial for resolution of sepsis in mice.
Overall, our in vitro and in vivo findings identify a novel regulatory mechanism that limits
NET formation in sepsis. These findings implicate VitC as a previously unrecognized
layer of regulation that prevents generation of excessive NETs.
2.6 Supplementary Material
Vitamin C (VitC) deficient neutrophils are susceptible to NETosis. In order to determine
whether peritoneal neutrophils from VitC sufficient or VitC deficient mice produced
NETs without further stimulation, thioglycollate-elicited peritoneal PMNs were seeded
onto 8-well IbiTreat µ-slides (Ibidi #80826) and allowed to adhere for 16 h. As described
in the Methods section of the manuscript, PMNs were fixed with 4% paraformaldehyde,
permeabilized with 0.15% Triton X-100 in PBS, and blocked with 5% normal chicken
serum (Sigma) in PBS. To stain NETs, slides were incubated with a mouse monoclonal
anti-myeloperoxidase (MPO) antibody and a secondary Alexa Fluor ® 488-conjugated
chicken anti-mouse IgG antibody. After staining of DNA with DAPI, PMNs were
visualized by immunofluorescence microscopy. As seen below (Figure 16a), PMNs from
VitC sufficient mice retained their lobulated structure with no significant co-localization
of DNA and MPO signals (no inter-mixing of nuclear and cytosolic contents). In contrast,
PMNs from VitC deficient mice demonstrated some degree of co-localization of DNA
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and MPO signals (Figure 16b). Importantly, nuclei from some of these PMNs (arrows)
were delobulated and had released their DNA content into the cytosol. However, full
NET structures are not evident in these images. This suggests that thioglycollate
stimulation of PMNs is insufficient to induce NETs in murine PMNs from VitC sufficient
mice. Conversely, some PMNs from VitC deficient mice were sufficiently activated and
had commenced the process of NET formation by intermixing nuclear and cytosolic
contents.

Figure 16 Vitamin C deficient neutrophils are susceptible to NETosis. Representative image of
immunofluorescent staining of Thioglycollate elicited peritoneal PMNs (DNA (blue); myeloperoxidase
(green)) obtained from: (a) VitC sufficient mice; nuclei from VitC sufficient mice retained their lobulated
structure, and (b) VitC deficient mice; PMNs from VitC deficient mice demonstrated some degree of colocalization of DNA and MPO signals. Nuclei from some of these PMNs (arrows) were delobulated and had
released their DNA content into the cytosol.

Detection of reactive oxygen species in peritoneal neutrophils by flow cytometry. The
generation of ROS and superoxide radicals in peritoneal PMNs was measured by using
the cell permeable dye 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate
(carboxy-H2DCFDA, Invitrogen) as described by Chatterjee et al.(88) Briefly, peritoneal
PMNs from VitC sufficient and deficient Gulo-/- mice were re-suspended in cold PBS/
1% BSA (4˚C) and incubated in the dark for 15 min with 10µM carboxy-H2DCFDA.
Samples were acquired on a BD Accuri® C6 Flow Cytometer (BD Accuri Cytometers,
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MI, USA) and mean fluorescence intensity recorded for at least 10,000 neutrophils.
Data was analyzed using FlowJo software (Tree Star, Ashland, OR). Results were
compared using Student-Newman-Keuls test and the post hoc Mann-Whitney U test to
identify specific differences between the groups. There was no significant difference
(Figure 17) in the amount of ROS produced by peritoneal PMNs isolated from VitC
deficient/sufficient Gulo-/- mice (N=8/group).

Figure 17 Vitamin C status (sufficient/deficient) does not alter neutrophils’
reactive oxygen species production that is essential for its normal
immunological function. Deficient neutrophils trended lower but there was
no statistically significant difference (n= 8/group).
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Chapter 3: Resolution of Sterile Inflammation: Role for Vitamin C
3.1 Introduction
Resolution of inflammation typically follows an ordered series of events
orchestrated by different cell types.(89) During the early stages of inflammation,
leukocytes such as polymorphonuclear neutrophils (PMN) are the first immune cells to
arrive at the site of inflammation. PMNs are recruited by gradients of proinflammatory
signals and usually reach peak numbers within 24–48 hrs. PMNs have short half-lives
and are normally cleared from sites of inflammation by undergoing apoptosis.(90)
Mobilized monocyte-derived macrophages extravasate to inflammatory tissue sites and
clear apoptotic PMN in a non-phlogistic fashion by the process of efferocytosis.
Apoptotic PMN release

“find-me” signals

that

are

sensed

by extravasated

macrophages.(91) Following phagocytosis, apoptotic PMN provides resolution cues to
macrophages by evoking distinct signaling events that block release of proinflammatory
mediators thus allowing further engulfment of apoptotic cells. Mantovani et al. and
Fleming and Mosser note that mobilized macrophages are divided into three groups
based upon their activation states.(92, 93) These include the M1, M2, and the recently
described regulatory macrophages (Mres). M1 macrophages, classically referred to as
activated macrophages, secrete proinflammatory factors that mediate host defense
against invading pathogens. M2 macrophages,

termed alternatively activated

macrophages, are considered to be anti-inflammatory.(94, 95) Finally, Mres
macrophages secrete considerable amounts of anti-inflammatory cytokines that prevent
inflammatory and autoimmune pathology.(96, 97) Mres macrophages also secrete
various lipid mediators that play critical roles in resolution of inflammation (see below).
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Extensive new research has identified expression markers or phenotypic signatures for
the various macrophage activation states in mice. They include gene expression
changes in IL- 1𝛽, TNF𝛼, and iNOS for classical activation and arginase-1 (Arg1),
chitinase 3-like 3 (YM-1), and TGF𝛽 for the alternatively activated macrophages.(95)
Resolution of inflammation and restoration of normal tissue function prevent the
development of “complications” of excessive inflammation, a process referred to as
catabasis.(98) Catabasis is driven by synthesis and release of proresolution lipid
mediators such as resolvins, protectins, and lipoxins.(99) Lipoxins and protectins are
synthesized by lipoxygenase enzymes (such as 15-lipoxygenase (15-Lox)).(100, 101)
Resolvins

are

derived

from

omega-3

polyunsaturated

fatty

acids

such

as

docosahexaenoic acid and eicosapentaenoic acid.(102) They are products of
metabolism involving 15-Lox and cyclooxygenase. Russell and Schwarze have
reviewed the proresolution effects of proresolution mediators in a variety of
inflammatory states.(103) However, their regulation by vitamin C (VitC, ascorbic acid,
AscA) has yet to be examined.
VitC readily functions as one or two electron-reducing agents for many oxidants
and serves as a primary chemical antioxidant in most cell types. It modulates complex
biochemical pathways that form an essential part of normal metabolism of immune
cells.(104) Intracellular levels of VitC in cells differ significantly from circulating plasma
levels. In particular, VitC accumulates in millimolar quantities in immune cells such as
PMN and macrophages in which intracellular VitC concentrations are typically 40–60
fold higher than that present in circulation.(27, 105) In PMN, Vissers and Wilkie showed
that intracellular VitC levels regulate neutrophil apoptosis.(54) Further, VitC contributes
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to the antioxidant defenses as well as normal PMN and macrophage function. Oberritter
and colleagues showed that intracellular concentrations of VitC in macrophages are in
the low millimolar range in freshly prepared peritoneal macrophages and in vivo or in
vitro activation of peritoneal macrophages results in a significant decline in their VitC
content.(106) Li et al. found that VitC deficiency worsens the inflammatory response
following infection with the influenza virus.(107) Moreover, mice deficient in VitC
generate excessive proinflammatory responses upon infection with the virulent
bacterium Klebsiella pneumonia.(108) In humans, VitC levels are significantly reduced
in critically ill patients and specifically in patients with poorly resolving proinflammatory
states (e.g., sepsis, systemic inflammatory response syndrome).(22, 109) Several
studies performed in septic patients have found that plasma VitC levels correlate
inversely with the incidence of organ failure and directly with survival.(110, 111) We
recently showed that VitC attenuates inflammation and normalizes PMN function in
septic

mice.(31,

112)

We

further

showed

that

parenteral

VitC

attenuates

proinflammatory biomarkers and reduces mortality in human sepsis.(32) However
information is limited regarding the mechanism by which VitC regulates the progression
and eventual resolution of inflammatory states.
In the current study we examined the progression and resolution of inflammation
using a murine thioglycollate (TG)-elicited peritonitis model in VitC sufficient and
deficient mice. While humans lack L-gulono-𝛾-lactone oxidase (Gulo), the final enzyme
in the biosynthesis pathway of VitC,(55) mice express functional Gulo, resulting in cells
and tissues generally maintaining high levels of VitC thereby complicating the
translatability of VitC studies in mice, to humans. In order to establish the studies more
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relevant to humans, TG-induced peritonitis was performed in transgenic mice lacking
Gulo (Gulo−/−). Our studies reveal that progression and resolution of TG-induced
inflammation is significantly delayed in VitC deficient mice. In particular, the
spatiotemporal profile of pro- and anti-inflammatory mediator production by TG-elicited
macrophages was significantly different between the VitC sufficient and deficient mice.
Further, macrophage function and phenotype, as well as the antioxidant capacity of VitC
deficient macrophages, was significantly impaired by the decline in intracellular VitC
levels. Infusion of parenteral VitC as ascorbic acid (AscA) partly restored macrophage
phenotype and function in VitC deficient mice.
3.2 Materials and Methods
3.2.1 Animals.
Gulo−/− mice were bred in-house from an established homozygous colony as
previously described.(31) In order to maintain their plasma VitC levels similar to that
observed in humans, VitC sufficient mice were fed ad libitum with regular chow and
water supplemented with vitamin C (0.33 g/L) renewed twice per week. Gulo−/− mice
were made VitC deficient by reducing VitC supplementation (0.033 g/L) for 1 week,
followed by complete removal of dietary VitC for additional 2 weeks. We and others
have shown that this reduced supplementation significantly decreases the concentration
of VitC in immune cells, plasma, and organs.(31, 58, 59)
3.2.2 Thioglycollate

Induced

Peritonitis

and

Isolation

of

Mouse

Peritoneal

Macrophages.
Thioglycollate-mediated peritonitis was established by intraperitoneal (i.p.) injection of
1mL aged, sterile 3% TG solution to 9–11-week old Gulo−/− mice. Thirty minutes
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following i.p. challenge, some VitC deficient mice were randomized to receive daily i.p.
injection of VitC as AscA (200mg/kg in saline) for a further 3 or 5 days. Untreated mice
received i.p. saline instead of VitC. Mice were euthanized on day 3 or day 5, and the
peritoneal cavity lavaged with 7mL of Hanks’ balanced salt solution (HBSS) containing
1% bovine serum albumin (BSA). The lavage was centrifuged and the resulting
leukocyte pellet was washed with HBSS and resuspended in RPMI-1640 medium. Cell
counts of the peritoneal lavage were performed using a Hemocytometer. Cytochemical
staining of peritoneal cells was performed using HARLECO Hemacolor solution
(EMDMillipore).(112) PMNs were then separated from macrophages by adherence to a
plastic dish as described previously.(60, 112) Peritoneal macrophages were plated at a
density of 2 × 106 cells in 35mm dishes in growth media (DMEM, 10% FBS). Media
were changed after 2 h to remove floating cells prior to experimentation.
3.2.3 Cell Culture.
Human acute monocytic leukemia suspension cell line (THP-1) was obtained from
ATCC (Manassas, VA). THP-1 cells were maintained in RPMI-1640 medium containing
10% FBS according to the instructions supplied. For induction of macrophages, PMA
(100 nM) was added to the medium and cells were seeded at a density of 0.1 × 106
cells/cm2 into tissue culture dishes and maintained in a humidified atmosphere of 95%
air and 5% CO2. Media containing PMA were replaced every 2 days, and experiments
started after 5 days in culture, when the cells were phenotypically macrophage.(113)
3.2.4 Vitamin C Analysis.
Plasma and intracellular VitC levels of peritoneal macrophages seeded onto 35mm
dishes were measured using a fluorescence end-point assay adopted from Vislisel et
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al..(114) Plasma was deproteinized as described previously.(32) Briefly, 0.2mL of cold
20% trichloroacetic acid (TCA) and 0.2mL of cold 0.2% dithiothreitol (DTT) were added
to 0.1mL of plasma, vortexed for 2min, and centrifuged (10,000 g, 10 min, 4∘C).
Supernatants were aliquoted and frozen at −70∘C for batch analysis. Peritoneal
macrophages were similarly extracted with TCA and DTT and frozen at −70∘C for batch
analysis. Supernatant or AscA standards were transferred in triplicate to a 96-well plate.
Assay buffer containing 1M sodium acetate, pH 5.5, and 1mM TEMPOL was added to
each well and the plate was incubated for 10 minutes at room temperature. Freshly
prepared o-phenylenediamine (OPDA) solution (5.5mMOPDA in acetate buffer of pH
5.5) was then added. After further 30min incubation in the dark, fluorescence was
measured at an emission wavelength of 425 nm following excitation at 345 nmand
values determined after comparison to a standard curve. Intracellular AscA levels were
estimated spectrophotometrically from the standard curve and the intracellular
concentrations derived from the measured amount of AscA and the knownmacrophage
cell volume.(115)
3.2.5 RNA Isolation and Real-Time Quantitative PCR (QPCR) Analysis.
Isolation of total RNA and real-time QPCR analyses were performed as described
previously.(30) Briefly total RNA was extracted and purified using QIAshredders and
RNeasy columns according to the manufacturer’s specifications (Qiagen). Total RNA
(1𝜇g) was reverse-transcribed into cDNA using the High Capacity cDNA Reverse
Transcription kit. Complimentary DNA (cDNA) was diluted (1 : 500) and real time QPCR
performed using POWER SYBR Green QPCR Master Mix. Primers were designed to
anneal to sequences on separate exons or to span two exons. Primers used for QPCR
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are listed in Table 1. Cycling parameters were 950C, 10min, 40 cycles of 950C, 15 sec,
and 600C, 1min. A dissociation profile was generated after each run to verify specificity
of amplification. All PCR assays were performed in triplicate. No template controls and
no reverse transcriptase controls were included. The mRNA expression in macrophages
from a “sufficient” mouse or a media well was set to “1.” The mRNA expression of all
other samples was compared relative to this sample which was used as the baseline.
18S rRNA was used as housekeeping gene against which all the samples were
normalized for differences in the amount of total RNA added to each cDNA reaction and
for variation in the reverse transcriptase efficiency among the different cDNA reactions.
Automated gene expression analysis was performed using the Comparative
Quantitation module of MxPro QPCR Software (Agilent).
Table 1 Primer sequences for Real Time Quantitative PCR.

Name

Sequence 5’ to 3’

Murine IL-1β forward

CTGAACTCAACTGTGAAATGCC

Murine IL-1 β reverse

CAGGTCAAAGGTTTGGAAGC

Murine TNF-α forward

GATGAGAAGTTCCCAAATGGC

Murine TNF- α reverse

TTGGTGGTTTGCTACGACG

Murine MCP-1 forward

TTCTGGGCCTGCTGTTCACAG

Murine MCP-1 reverse

CCAGCCTACTCATTGGGATCATCTTGC

Murine YM1 forward

CAAGACTTGCGTGACTATGAAGC

Murine YM1 reverse

AGGTCCAAACTTCCATCCTCC

Murine Arg1 forward

AGGAAAGCTGGTCTGCTGG

Murine Arg1 reverse

TTGAAAGGAGCTGTCATTAGGG

Murine IL-10 forward

CAAGGAGCATTTGAATTCCC

Murine IL-10 reverse

ATTCATGGCCTTGTAGACACC
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Murine Gal1 forward

CAGCAACCTGAATCTCAAACC

Murine Gal1 reverse

AGTGTAGGCACAGGTTGTTGC

Murine 15-Lox forward

TGGTGGCTGAGGTCTTTGC

Murine 15-Lox reverse

TCTCTGAGATCAGGTCGCTCC

Human IL-6 forward

GGATTCAATGAGGAGACTTGCC

Human IL-6 reverse

TCTGCAGGAACTGGATCAGG

Human IL-8 forward

GTGTGAAGGTGCAGTTTTGC

Human IL-8 reverse

GAGCTCTCTTCCATCAGAAAGC

Human TNF-α forward

CCTCTTCTCCTTCCTGATCG

Human TNF- α reverse

CGAGAAGATGATCTGACTGCC

3.2.6 Western Blot Analysis.
Mouse macrophage and THPI whole-cell extracts were isolated for western blot
analysis as described previously.(30) Proteins were resolved by SDS polyacrylamide
gel electrophoresis (4–20%) and electrophoretically transferred to polyvinylidene
fluoride membranes (0.2 𝜇m pore size). Immunodetection was performed using
chemiluminescent detection with the Renaissance Western Blot Chemiluminescence
Reagent Plus (Perkin Elmer Life Sciences Inc., Boston, MA). Blots were stripped using
the Restore Western Blot Stripping Buffer (Pierce Biotechnology Inc., Rockford, IL) as
described by the manufacturer. Purified rabbit polyclonal antibodies to phospho-NF𝜅B
p65 (Ser276, Cell Signaling), NF𝜅B p65 (sc-109, Santa Cruz Biotechnology), iNOS (sc650, Santa Cruz Biotechnology), and actin (sc-1616, Santa Cruz Biotechnology) were
used.Optical densities of antibody-specific bands were determined using Quantity One
acquisition and analysis software (Bio-Rad, Hercules, CA).
3.2.7 Flow Cytometry.
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Mouse peritoneal lavage obtained on day 3 and day 5 from VitC sufficient or deficient
mice following induction of TG-induced peritonitis was pelleted by centrifugation at 4 0C.
Cells were resuspended in FACS buffer containing Fc receptor block (CD16/CD32
eBioscience) for 10min at 40C. Aliquots of the suspension were incubated at 40C for
30min (in the dark) with fluorescein isothiocyanate (FITC-) conjugated anti-mouse CD45
(eBioscience)

and

allophycocyanin

(APC-)

conjugated

anti-mouse

CD11b

(eBioscience). Unstained and single color controls were employed for each experiment.
Samples were then fixed with 1% formaldehyde for 20min at room temperature. All runs
were performed on a BD Accuri C6 Flow Cytometer (BD Accuri Cytometers, MI, USA)
and analyzed using FlowJo software (Tree Star, Ashland, OR).
3.2.8 Fluorescence Microscopy.
Fluorescence microscopy for evaluation of mitochondrial reactive oxygen species
(ROS) in macrophages was performed using the cell-permeant probe MitoTracker Red
CMXRos as described by the manufacturer. Briefly, macrophages from VitC sufficient or
deficient mice were grown on Ibidi 6-channel IbiTreat 𝜇-slide VI. Following treatments
(H2O2, 18 hours) culture media were aspirated and cells were fixed in 3.7%
paraformaldehyde in PBS for 10 minutes at 4 0C. Fluorescence imaging was performed
using an Olympus model IX70 inverted phase microscope (Olympus America, Melville,
NY) outfitted with an IX-FLA fluorescence observation system equipped with a TRITC
filter cube (530–560nmexcitationand590–650nmemission, Chroma Technology Corp.
Brattleboro, VT) through an Uplan FI objective (40x). Fluorescence images were
digitized and captured by a MagnaFire digital camera (Optronics, Goleta, CA).
3.2.9 Lipid Extraction and Analysis.
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Quantitative analysis of eicosanoids was performed as previously described by us with
minor modifications.(116-121) Briefly, peritoneal lavage was clarified by centrifugation
and 0.05% BHT and 10 ng of each internal standard added. The internal standards
used were (𝑑4) 8-iso PGF2𝛼, (𝑑11) 5-iso PGF2𝛼-VI, (𝑑4) 6k PGF1𝛼, (𝑑4) PGF2𝛼, (𝑑4)
PGE2, (𝑑4) PGD2, (𝑑4) LTB4, (𝑑5) Lipoxin A4, (𝑑5) Resolvin D2, (𝑑4) TXB2, (𝑑4) LTC4,
(𝑑5) LTD4, (𝑑5) LTE4, (𝑑8) 5-hydroxyeicosatetranoic acid (5HETE), (𝑑8) 15hydroxyeicosatetranoic acid (15HETE), (𝑑8) 14,15 epoxyeicosatrienoic acid, (𝑑8)
arachidonic acid, and (𝑑5) eicosapentaenoic acid. The samples were mixed by
vortexing and subjected to purification via solid phase extraction (SPE) using a 24 port
vacuum manifold (Sigma-Aldrich). Strata-X SPE columns (Phenomenex) were washed
with methanol (2 mL) and then dH2O (2mL). The samples were applied to the column.
Thereafter the sample vials were rinsed with 5% MeOH (2mL), which was then used to
wash the columns. Finally, the eicosanoids were eluted with isopropanol (2 mL). The
eluents were then dried under vacuum and reconstituted in LCMS grade 50 : 50 EtOH:
dH2O (100𝜇L) for eicosanoid quantitation via UPLC ESI-MS/MS analysis. A 14-minute
reversed-phase LC method utilizing a Kinetex C18 column (100 × 2.1 mm, 1.7 𝜇m) and
a Shimadzu UPLC was used to separate the eicosanoids at a flow rate of 500 𝜇L/min at
50 0C. The column was first equilibrated with 100% Solvent A (acetonitrile : water :
formic acid (20 : 80 : 0.02, v/v/v)) for two minutes and then 10 𝜇L of sample was
injected. 100% Solvent A was used for the first two minutes of elution. Solvent B
(acetonitrile : isopropanol (20 : 80, v/v)) was increased in a linear gradient to 25%
Solvent B to 3 minutes, to 30% by 6 minutes, to 55% by 6.1 minutes, to 70% by 10
minutes, and to 100% by 10.1 minutes. 100% Solvent B was held until 13 minutes and
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then was decreased to 0% by 13.1 minutes and held at 0% until 14 minutes. The eluting
eicosanoids were analyzed using a hybrid triple quadrapole linear ion trap mass
analyzer (ABSciex 6500 QTRAP) via multiple-reaction monitoring in negative-ion mode.
Eicosanoids were monitored using species specific precursor → product MRM pairs.
The mass spectrometer parameters used were curtain gas: 30; CAD: High; ion spray
voltage: −3500V; temperature: 300∘C; Gas 1: 40; and Gas 2: 60; declustering potential,
collision energy, and cell exit potential were optimized per transition.
3.2.10 Statistical Analysis.
Statistical analysis was performed using SAS 9.3 and GraphPad Prism 6.0 (GraphPad
Software, San Diego, CA, USA). Data are expressed as mean ± SE. Results were
compared using one-way ANOVA and the post-hoc Tukey test. Statistical significance
was confirmed at a p-value of <0.05.
3.3 Results
3.3.1 VitC Deficiency Alters the Progression of TG-Induced Peritoneal Inflammation.
In order to make the Gulo−/− mice VitC deficient, supplementation of water with AscA
was withdrawn as described in the Methods section. Within 3 weeks of removal of VitC
supplementation, plasma VitC levels of Gulo−/− mice declined significantly (Figure 1).
This decline was not associated with deleterious changes in weight or health status in
the VitC deficient mice (data not shown).
To determine whether VitC deficiency impacts the progression of peritoneal
inflammation, VitC sufficient or deficient mice were injected with TG and the progression
of inflammation was monitored on days 3 and 5 (as described in Section 2). Some VitC
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deficient mice were injected i.p. with
AscA (200mg/kg) prior to harvest of
peritoneal lavage (see Section 2).
Daily i.p. administration of ascorbate
for 3 days restored circulating plasma
VitC concentrations in these mice to
levels observed in the VitC sufficient
mice (Figure 18). In all 3 groups, the
infiltration of inflammatory cells on
day 1 was similar to that observed in
wild type mice and was in agreement
with our previous observations (Table

Figure 18 Vitamin C deficiency alters the progression of TGinduced peritoneal inflammation. Plasma VitC levels were
measured in VitC sufficient and deficient Gulo -/− mice as
well as in deficient mice treated daily with i.p. AscA for 3
days (𝑁= 3–6 mice/group, ns = not significant).

2).(112, 122) As seen in Table 2,
there was also no difference in the total number of cells elicited from the peritoneal
exudation of day 3 and day 5. However, significant differences in the cellular
composition of the lavage were evident on day 3 and day 5 between the 3 groups. In
the VitC sufficient mice group, mononuclear cells were the predominant cell type on
days 3 and 5 (Table 2). PMN numbers, which peaked on day 1,(112) returned to
baseline by days 3 and 5. In contrast, significantly elevated numbers of PMNs persisted
in the peritoneal exudates of VitC deficient mice on days 3 and 5 (Table 2). Infusion of
AscA reduced PMN numbers by day 3 with a significant decline in PMN numbers to
baseline similar to the VitC sufficient mice by day 5 Table 2.
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Table 2: Differential cell counts from peritoneal exudates following thioglycollateinduced peritonitis (𝑁 = 6–8 mice/group, n.d. = not determined).

Day 1

Day 3

Day 5

Sufficient

Deficient

Deficient + AscA

PMN (x106)

20.02 ± 3.4

23.2 ± 2.6

n.d.

M0 (x106)

5.0 ± 0.8

3.9 ± 0.6

n.d.

PMN (x106)

1.8 ± 0.4

8.1 ± 1.9a

3.8 ± 0.4

M0 (x10 )

18.4 ± 3.2

13.1 ± 3.1

14.5 ± 3.2

PMN (x106)

1.0 ± 0.6

4.4 ± 1.1b

0.4 ± 0.2c

M0 (x106)

18.8 ± 5.6

22.1 ± 4.2

14.3 ± 4.1

6

Sufficient versus deficient, 𝑃 = 0.006.
Sufficient versus deficient, 𝑃 = 0.02.
c
Deficient versus deficient + AscA, 𝑃 = 0.02.
a
b

3.3.2 Spatiotemporal Profiling of Inflammatory Mediators following TG-Induced
Peritoneal Inflammation.
We previously observed that TG-elicited PMN from VitC deficient mice (on day 1)
demonstrated increased expression of the proinflammatory genes TNF𝛼 and IL1𝛽.(112) Here we examined the expression of multiple pro- and anti-inflammatory
mediators originating from macrophages, the predominant cell type recruited to the
inflamed peritoneum on days 3 and 5. As seen in Figure 19, significant differences were
evident in the magnitude of pro- and anti-inflammatory mediator expression on days 3
and 5. On day 3, increased expression of the pro-inflammatory mediators (IL-1𝛽, TNF𝛼,
and MCP-1) was observed in macrophages from VitC deficient mice when compared to

61

macrophages

from

VitC

sufficient

mice

(Figure

19(a),

(A),

(C),

and

(E)).

Figure 19 Spatiotemporal profiling of inflammatory mediators following TG-induced peritoneal inflammation.
Real time QPCR for IL-1𝛽, TNF𝛼,MCP-1, YM1, Arg1, and IL-10mRNA from peritoneal macrophages elicited on
day 3 (a) and day 5 (b) following TG-induced peritonitis from VitC sufficient and deficient Gulo−/− mice.
Following TG challenge, some VitC deficient mice were randomized to receive daily i.p. injection of VitC as
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AscA (200mg/kg in saline) for a further 3 days (day 3, deficient + AscA) or 5 days (day 5, deficient + AscA) (𝑁
= 6 mice/group, ns = not significant)

Pro-inflammatory gene expression was significantly attenuated by i.p. infusion of AscA
in the VitC deficient mice (Figure 19(a), (A), (C), and (E)). In contrast, anti-inflammatory
gene expression (YM1 and Arg1, but not IL-10) was elevated in macrophages from VitC
sufficient mice (Figure 19(a), (B), (D), and (F)). Daily AscA infusion induced YM1
expression in VitC deficient macrophages but failed to restore Arg1 expression. IL-10
expression on the other hand was significantly lowered by AscA infusion on day 3
(Figure 19(a), (B), (D), and (F)). On day 5 (Figure 19(b)), pro-inflammatory gene
expression remained persistently elevated in macrophages from VitC deficient mice (IL1𝛽 andMCP-1) but was attenuated by AscA infusion. In contrast, anti-inflammatory gene
expression in VitC deficient macrophages was significantly higher when compared to
macrophages from VitC sufficient mice (Arg1, IL-10). AscA infusion did not alter antiinflammatory gene expression on day 5 although Arg1 levels were now similar to that
observed in VitC sufficient mice (Figure 19(b), (B), (D), and (F)).
3.3.3 Ex Vivo Bacterial Lipopolysaccharide Differentially Activate Pro-inflammatory
Gene Expression in Macrophages from VitC Sufficient and Deficient Mice.
Canali et al. recently showed that in contrast with baseline physiological activation,
exposure to a second “hit” such as an inflammatory stimulus results in a markedly
different modulation of gene expression in human peripheral blood mononuclear cells in
the presence or absence of VitC supplementation.(123) To examine whether peritoneal
macrophages would exhibit an altered modulation of gene expression, we exposed day
3 peritoneal macrophages from VitC sufficient and deficient mice to bacterial
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lipopolysaccharide (LPS, 50 ng/mL). Some macrophages were incubated with AscA (3
mM, 16 hours) prior to LPS exposure. As seen in Figures 20(a) and 20(b), LPS
exposure

Figure 20 LPS differentially activates pro-inflammatory gene expression in macrophages from vitamin C
sufficient and deficient mice. Peritoneal macrophages elicited on day 3 following TG-induced peritonitis from
VitC sufficient and deficient Gulo−/− mice were exposed to LPS (50 ng/mL) for 4 hours. Macrophages from
some VitC deficient mice were incubated with AscA (3 mM, 16 hours) prior to LPS exposure (deficient +
AscA). Real time QPCR was performed for IL-1𝛽 (a) and TNF𝛼 (b) (𝑁 = 6/group). (c) Upper panel:
representative western blot for expression of phospho-NF𝜅B andNF𝜅B from VitC deficient macrophages
exposed to media alone (M), AscA (3 mM, 16 hours (AscA)), LPS (50 ng/mL) for 1 hour (LPS), or AscA for 16
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hours followed by LPS for 1 hour (LPS + AscA). Lower panel: densitometry for normalized expression of
phospho-NF𝜅B from macrophages (𝑁 = 3/group). (d) Upper panel: representative western blot for expression
of iNOS and actin from macrophages groups described in (c) and exposure to LPS (50 ng/mL) for 4 hour.
Lower panel: densitometry for normalized expression of iNOS from macrophages (𝑁 = 3/group).

resulted in a robust increase in expression of pro-inflammatory markers (IL-1𝛽, TNF𝛼) in
macrophages from VitC sufficient mice. Pro-inflammatory gene expression was also
induced in macrophages from VitC deficient mice, but the magnitude of induction was
significantly greater than that observed in the VitC sufficient macrophages (Figures
20(a) and 20(b)). Importantly, exposure of VitC deficient macrophages to AscA prior to
LPS significantly attenuated IL-1𝛽 and TNF𝛼 expression. Increased NF𝜅B activation
(Figure 20(c)) and iNOS protein expression (Figure 20(d)) was observed upon exposure
of VitC deficient macrophages to LPS (𝑃 < 0.05). AscA pretreatment attenuated NF𝜅B
activation and iNOS expression in VitC deficient macrophages.
3.3.4 VitC Regulates Macrophage Function during the Resolution of Inflammation.
Macrophages undergo reprogramming to adopt a variety of functional phenotypes upon
receiving differentiation cues from their surrounding environment.(124) It was recently
shown that macrophage reprogramming is vital for the resolution of acute
inflammation.(125) We examined whether macrophage VitC sufficiency or deficiency
could influence macrophage function during resolution of acute inflammation.
Macrophages were isolated on day 3 following TG-mediated peritonitis from VitC
sufficient or deficient mice and intracellular concentrations of VitC measured (as
described in Section 2). Some VitC deficient mice were injected daily with i.p. AscA
(200mg/kg) prior to harvest of peritoneal lavage (see Section 2).
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Figure 21 Vitamin C regulates macrophage function during the resolution of inflammation. (a)Macrophages
were isolated on day 3 following TG-mediated peritonitis from VitC sufficient or deficient mice as well as in
deficient mice treated daily with i.p. AscA for 3 days and intracellular concentrations of VitC measured (𝑁 =
3–10 mice/group, ns = not significant). (b) Real time QPCR for Gal1 and 15-Lox from peritoneal macrophages
elicited on day 3 following TG-induced peritonitis from VitC sufficient and deficient Gulo−/− mice. Thirty
minutes following TG challenge, some VitC deficient mice were randomized to receive i.p. injection of VitC as
AscA (200mg/kg in saline) for a further 3 days (deficient + AscA). (𝑁 = 6 mice/group, ns = not significant). (c)
Real time QPCR for Gal1 and 15-Lox from peritoneal macrophages elicited on day 5 following TG-induced
peritonitis from VitC sufficient and deficient Gulo−/− mice. Thirty minutes following TG challenge, some VitC
deficient mice were randomized to receive i.p. injection of VitC as AscA (200mg/kg in saline) for a further 5
days (Deficient + AscA) (𝑁 = 6 mice/group, ns = not significant). (d) UPLC ESI-MS/MS quantification of
resolvin D1 (RvD1) and E1 (RvE1) in peritoneal lavage on day 5 following TG-induced peritonitis from VitC
sufficient and deficient Gulo−/− mice (𝑁= 3-4 mice/group, ns = not significant).

As seen in Figure 21(a), macrophages from VitC sufficient mice have high intracellular
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VitC concentrations. In contrast, intracellular ascorbate levels were significantly
depleted in macrophages from VitC deficient mice. Daily i.p. administration of AscA for 3
days also restored macrophage intracellular concentrations to levels observed in the
VitC sufficient mice (Figure 21(a)). Gal-1 and 15-Lox expression is induced in
macrophages during peritonitis. Their expression is associated with generation of proresolving lipid mediators and successful resolution of inflammation.(99, 126) Therefore
we examined Gal-1 and 15-Lox expression in day 3 and day 5 macrophages from VitC
sufficient or deficient mice. As seen in Figure 21(b), Gal-1 and 15-Lox expression was
significantly induced in macrophages from VitC sufficient mice on day 3 when compared
to macrophages from VitC deficient mice. AscA infusion restored Gal-1 expression in
VitC deficient macrophages but did not affect 15-Lox expression on day 3 (Figure
21(b)). In contrast, Gal-1 expression in VitC deficient macrophages was delayed and
observed to be higher on day 5 following TG-induced peritonitis (Figure 21(c)). 15-Lox
expression was induced by AscA infusion on day 5 and was higher than that observed
in macrophages from VitC sufficient or deficient mice. In agreement with the expression
data seen above, resolvin (Figure 21(d)) production was higher on day 5 in VitC
deficient mice indicating delayed resolution of inflammation.
3.3.5 VitC Influences Macrophage Phenotype during Resolution of Inflammation.
Rostoker et al. recently showed that Gal-1 was selectively expressed in CD11b-high
macrophages, and its expression declined significantly once these cells converted
toward a CD11b-low phenotype.(127) Moreover, CD11blow macrophages are the
predominant subtype to depart the peritoneum.(127) To determine whether VitC
regulated reprogramming of peritoneal macrophages to pro-resolution CD11b-low
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phenotype we used flow cytometry to examine the distribution of CD11b-high and
CD11b-low population on macrophages isolated on day 3 and day 5 following TGinduced peritonitis in VitC sufficient or deficient mice. As seen in Figure 22, there was a
significant transition from CD11b-high to a CD11b-low phenotype observed from day 3
to day 5 in the VitC sufficient macrophages. This was not evident in the macrophages
from VitC deficient mice indicative of a delay in the resolution of TG-induced peritonitis
in these mice.

Figure 22
Vitamin C influences macrophage phenotype during resolution of
inflammation. Flow cytometry for distribution of CD11bhigh and CD11blow population
from macrophages isolated on day 3 and day 5 following TG-induced peritonitis in
VitC sufficient or deficient mice (𝑁 = 5mice/group, 𝑃 < 0.05, CD11blow day 3 versus
day 5, ns = not significant).

3.3.6 Macrophages Deficient in VitC Have Reduced Antioxidant Capacity.
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Activated macrophages potentially generate

mitochondria-damaging deleterious

reactive oxygen species (ROS).

Figure 23 Macrophages deficient in Vitamin C have reduced antioxidant capacity. Peritoneal macrophages
elicited on day 3 following TG-induced peritonitis fromVitC sufficient ((a)–(d)) and deficient Gulo−/− ((e)–(h))
mice were exposed to 12.5, 25, and 50 𝜇MH2O2 for 18 hours and probed with MitoTracker Red CMXRos.
Macrophages from some VitC deficient mice were incubated with AscA (3 mM, 16 hours) prior to exposure to
H2O2 followed by staining with MitoTracker Red CMXRos (Deficient + AscA, ((i)–(l))).

Release of large amounts of ROS during activation exposes macrophages themselves
to oxidant stresses not encountered by most other cell types.(128) To test whether VitC
deficiency affected mitochondrial function in macrophages, we exposed peritoneal
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macrophages (day 3) from VitC sufficient or deficient mice to varying concentrations of
H2O2 for 18 hours and stained the cells with Mito- Tracker Red CMXRos as described in
Section 2. This probe is selectively retained by mitochondria, where it is oxidized to its
fluorescent form. As seen in Figures 23(a) and 23(e), control macrophages from VitC
sufficient or deficient mice were stained brightly with the probe. Oxidative stress from
exposure to H2O2 decreased fluorescent staining in macrophages from both VitC
sufficient and VitC deficient mice. However, the magnitude of decrease was significantly
greater in macrophages from VitC deficient mice (Figures 23(f) – 23(h)). This decrease
was partially reversed by pretreatment of VitC deficient macrophages with AscA
(Figures 23(j) and 23(k)). These studies indicate that VitC deficient macrophages
sustain greater mitochondrial dysfunction when challenged with ROS.
3.3.7 VitC

Attenuates

Proinflammatory

Gene

Expression

in

Human

Monocyte/Macrophages.
To address whether the modulatory activities of VitC are effective in human monocyte/
macrophages, we exposed THP-1 cells to bacterial LPS and examined the mRNA
expression of the pro-inflammatory genes IL-6, IL-8, and TNF𝛼. Since the culture
medium in which THP-1 cells are grown contains no VitC, we increased intracellular
concentrations of VitC by loading cells with AscA prior exposure to LPS. As seen in
Figure 24(a), exposure of THP-1 cells to LPS resulted in a robust activation of mRNA
for IL-6, IL-8, and TNF𝛼. Loading cells with AscA did not affect baseline proinflammatory gene expression. However LPS exposure of AscA loaded cells resulted in
significant attenuation of mRNA expression of these proinflammatory genes.
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Attenuation of mRNA expression was likely achieved by reduction in activation of the
transcription factor NF𝜅B following LPS exposure (Figure 24(b)).

Figure 24 Vitamin C attenuates proinflammatory gene expression in human THP-1 monocyte/macrophages.
THP-1 macrophages were exposed to media alone (Media), AscA (3mM, 16 hours (AscA)), and LPS (50 ng/mL)
for 4 hour (LPS) or AscA for 16 hours followed by LPS for 4 hour (LPS + AscA). (a) Real time QPCR for IL-6, IL8, and TNF𝛼 was performed as described in Section 2 (𝑁 = 4/group; 𝑃 < 0.05, Media versus LPS and LPS
versus LPS + AscA). (b) Left panel: representative western blot for expression of phospho-NF𝜅B andNF𝜅B
from THP-1 groups described above following exposure to LPS (50 ng/mL) for 0, 15, 30, and 60 minutes. Right
panel: densitometry for normalized expression of phospho-NF𝜅B fromTHP-1 (𝑁 = 4/group, 𝑃 < 0.05, LPS
versus LPS + AscA).
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3.4 Discussion
In this study, we examined the mechanism by which VitC regulates the resolution of
sterile inflammation. Using mice lacking the ability to synthesize VitC, we showed that
subnormal cellular VitC levels negatively impact the progression and resolution of sterile
inflammation. In particular, our results demonstrate that low circulating VitC levels are
associated with significant delays in the timing of resolution of inflammation. This
apparent VitC-dependent process primarily occurs due to failure of macrophages to
transition from a pro-inflammatory to a pro-resolving phenotype. The initial response to
sterile inflammation was identical in VitC sufficient and deficient mice. During the early
pro-inflammatory phase no differences in the cell numbers or cell types were observed.
However, by days 3 and 5, VitC deficient mice exhibited significant numbers of PMN in
peritoneal exudates (Table 2). Spatiotemporal mRNA profiling of macrophage-derived
inflammatory mediators revealed dramatic differences in the magnitude of pro and antiinflammatory mediator gene expression (Figure 19). Macrophages from VitC sufficient
mice

displayed

prominent

anti-inflammatory phenotypes,

while

VitC

deficient

macrophages persistently expressed mRNA for IL-1𝛽, TNF𝛼, and MCP-1, findings
characteristic of a pro-inflammatory phenotype. LPS activation of day 3 macrophages
from VitC deficient mice led to pro-inflammatory gene expression that was significantly
greater in magnitude than that observed in VitC loaded macrophages (Figure 20). LPS
stimulation was characterized by enhanced NF𝜅B activation and iNOS induction in VitC
deficient macrophages (Figure 20). Importantly, on day 3, VitC sufficient macrophages
demonstrated cues for reprogramming into resolution type macrophages, a vital step
required for resolution of inflammation. In day 3 macrophages from VitC sufficient mice,
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expression of Gal-1 and 15-Lox mRNA was robust (Figure 21). In contradistinction,
enhanced Gal-1 and 15-LoxmRNA expression was delayed to day 5 in VitC deficient
macrophages. The delays in resolution we observed in VitC deficient mice were
confirmed by quantification of resolvins in peritoneal exudates; increases of which were
present only on day 5 (Figure 21). Further confirmation of altered spatiotemporal
relationships was achieved by studying macrophage phenotypic changes by examining
the distribution of CD11b on macrophages from VitC sufficient or deficient mice on day
3 and day 5 following TG-induced peritonitis (Figure 22). Phenotypic changes in
macrophages

were

accompanied

by

alterations

in

macrophage

function

as

demonstrated by the increased susceptibility of VitC deficient macrophages to
mitochondrial dysfunction when exposed to reactive oxygen species (Figure 23). In final
studies, we employed the human monocyte/macrophage cell line THP-1, which lacks
VitC in culture medium when cultured under standard conditions. We demonstrated
increased pro-inflammatory gene expression in THP-1 when exposed to LPS under
VitC-deprived conditions. Loading THP-1 cells with AscA significantly

attenuated

mRNA expression of pro-inflammatory genes via a mechanism likely involving reduced
activation of the transcription factor NF𝜅B. VitC loading was effective both in vitro and in
vivo since daily AscA infusion following induction of peritonitis significantly restored
macrophage phenotype and function in the VitC deficient mice. Few studies have
examined the role of VitC in resolution of sterile inflammation. Ganguly et al. initially
reported that VitC deficiency affected migration of guinea pig macrophages under in
vitro conditions.(129) They further showed that addition of exogenous VitC partially
restored the migratory response. May et al. showed that activated macrophages use
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ascorbate to lessen self-generated oxidant stress.(105) They later showed that
ascorbate deficient peritoneal macrophages were more susceptible to H2O2-induced
mitochondrial dysfunction and apoptosis.(130) However, no studies to date have
examined macrophage function during resolution of inflammation in mice lacking the
ability to synthesize their own VitC. Our observation of persistence of PMN at the site of
inflammation in VitC deficient mice is in agreement with our previous results and those
of Vissers and Wilkie who used a similar TG model of peritonitis to show impairment in
PMN apoptosis and clearance.(54, 112) It has been suggested that the engulfment of
apoptotic cells is generally anti-inflammatory or immunologically silent due to the fact
that it sequesters dying cells thus preventing release of potentially toxic cell contents
into the local environment.(131) Based on the observations that PMN persists for up to
5 days in the peritoneum of VitC deficient mice (Table 2), it is therefore possible that the
apoptosis-resistant PMN can cause strong pro-inflammatory responses from the
macrophages that extravasate to sites of inflammation. Indeed strong and persistent
pro-inflammatory responses were evident in VitC deficient macrophages elicited on day
3 and even day 5 (Figure 19). Efferocytosis, a process by which dead and/or dying cells
are being engulfed and removed by other cells, has been reported to induce production
of anti-inflammatory mediators from macrophages that suppress inflammation thereby
silently clearing apoptotic cells and thus dampening pro-inflammatory responses.(132)
VitC sufficient mice exhibited anti-inflammatory mediator expression in macrophages
early (day 3) in the post TG-induced inflammatory process, a phenomenon indicative of
functional efferocytosis. In contrast, VitC deficient macrophages failed to upregulate
anti-inflammatory mediator production until day 5 (Figure 19). Gal-1 and 12/15-Lox play

74

vital roles in resolution of inflammation. Rostoker et al. have shown that Gal-1 promotes
the generation of M2-like macrophages, which then favors tissue repair during early
resolution of inflammation.(127) Ariel and Timor demonstrated that Gal-1 promotes
generation of Mres from M2 macrophages, which generates pro-resolving lipid
mediators. This phenotype change promotes macrophage departure from peritoneal
cavities with resolving inflammation, thus allowing return of tissue to homeostasis.(133)
Moreover, Gal-1 expression, which is enhanced inCD11bhigh macrophages, declines
sharply as cells revert to the CD11blow phenotype. CD11blow macrophage
phenotypes, as noted previously, promote departure from peritoneal cavities with
resolving inflammation.(127) Our findings (Figures 21 and 22) which agree with the
above studies implicate VitC as a critical regulator of macrophage transition during
resolution of inflammation. Expression and function of 12/15-Lox produce key mediators
(e.g., lipoxins, resolvins, protectins, and maresins) that promote resolution of proinflammatory

pathologies.(134)

In

particular,

human

and

murine

monocytes/macrophages expression of 15-Lox is upregulated by efferocytosis with
production of mediators such as RvD1, a mediator shown to promote the resolution of
murine peritonitis.(125, 135) Further, Gal-1 directly promotes 15-lipoxygenase
expression and activity in macrophages during the inflammatory and resolving phases
of peritonitis.(127) The earlier increases in Gal-1 and 15-Lox mRNA expression in VitC
sufficient macrophages (Figures 21(b) and 21(c)) and the delayed resolvin production in
the VitC deficient macrophages (Figure 21(d)) indicate for the first time that VitC
influences multiple processes leading to the resolution of inflammation.
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3.5 Conclusion

The findings in this mouse model have significant human relevance since VitC levels
are subnormal in multiple human inflammatory disease states including sepsis, systemic
inflammatory response syndrome (SIRS), trauma, and cancer, among others. In a
recently completed Phase I trial (ClinicalTrials.gov identifier NCT01434121) of
intravenous AscA in critically ill patients with severe sepsis, we showed that septic
patients exhibited abnormally low VitC plasma levels and that intravenous AscA infusion
could significantly increase circulating VitC levels.(32) Further, AscA infusion
significantly reduced

the

pro-inflammatory biomarkers C-reactive

protein

and

procalcitonin as well as multiple organ dysfunction.(32) Our findings here add a
previously unrecognized element to our understanding of the machinery that governs
the resolution of inflammation.
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Chapter 4: VITAMIN C IN WOUND HEALING: A NEW PERSPECTIVE

4.1 Intoduction:
Wound healing is a normal physiologic process aimed at restoring the anatomical
structure and function of injured skin.(136) Many factors have been identified that affect
wound healing like age, wound location, wound size, nutritional status, immune system
status, and underlying co-morbidities such as diabetes and obesity.(137, 138) Delayed
wound healing can result in a number of complications such as increased hospital
length of stay, amputations, and even death.(138) There is a 2 % prevalence of chronic,
non-healing wounds in the general population that is associated with an annual
estimated cost of > $50 billion and this expenditure is expected to rise in the coming
years.(139) Hence there is an unmet need to better identify the mechanisms that delay
normal wound healing.
The ultimate goal of wound repair is achieving an adequate restoration of
epidermal barrier (wound closure) without a loss of function within a reasonable time
frame. Re-establishing the integrity of injured skin necessitates a delicate balance
between four sequential yet overlapping stages: hemostasis, inflammation, proliferation
and remodeling (maturation).(140) This process involves a highly ordered series of
cellular events: platelet activation and fibrin clot formation at the wound site
(hemostasis); polymorphonuclear neutrophil (PMN) infiltration to contain invading microorganisms and clear damaged matrix and tissue debris, followed by macrophage
infiltration to engulf and clear apoptotic sated PMNs (inflammation); and fibroblast
migration and proliferation (proliferation) to lay down the new matrix collagen that
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progressively matures, cross-links, and organizes (remodeling/maturation).(140) These
cellular events are orchestrated by chemokines and cytokines such as platelet derived
growth factor (PDGF), transforming growth factor beta (TGF-α), vascular endothelial
growth factor (VEGF), connective tissue growth factor (CTGF), interlukin-6 (IL-6),
interleukin-1β (IL-1β), and tumor necrosis factor alpha (TNF-α)(141, 142) whose
expression ultimately determine the course and fate of wound healing.
Wounds create an environment of higher catabolic state.(143) Following injury,
the rate at which micronutrients are metabolized increases significantly often leading to
critical deficiencies.(143) Indeed, levels of vitamin C (VitC), a small, organic, water
soluble micronutrient, with strong anti-oxidant properties, (2, 144) fall rapidly during
inflammation. Moreover, scorbutic individuals experience delayed healing and
decreased rates of collagen synthesis and maturation.(145) Along with its strong antioxidant properties, VitC is an essential co-factor for multiple enzymatic reactions and
has recently been shown to suppress pro-inflammatory processes by pleiotropic
mechanisms

while

promoting

anti-inflammatory

and

pro-resolution

effects

in

macrophages.(29, 31, 112, 146) VitC is also intimately involved in collagen metabolism
and regulation and therefore many studies have focused on this particular role in wound
healing.(147-150) Humans lack functional L-gulono- -lactone oxidase (Gulo), the final
enzyme for VitC biosynthesis, and hence are dependent upon an external supply (in
diet) of VitC.(2, 144) In contrast, wild type mice express functional Gulo and maintain
high levels of VitC in their tissues. In order to better understand the role of VitC in
wound healing we used humanized knock-out mice lacking Gulo (Gulo−/−) in our studies.
In these studies, we went beyond the known effects of VitC on collagen synthesis to
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explore the role of VitC on the spatiotemporal changes in the inflammatory, proliferative
and maturation stages of wound healing.
4.2 Methods
4.2.1 Animals: All animal studies were performed in accordance to the Virginia
Commonwealth University Animal Care and Use Committee’s approved protocols. Gulo /-

mice were bred in-house from an established homozygous colony maintained on a

C57BL/6J background as previously described.(31) Mice were fed ad libitum with
regular chow and had free access to water supplemented with AscA (330 mg/L)
renewed twice a week to yield sufficient mice. Supplements were given in de-ionized
water with 20 µL of 0.5 M EDTA/L to increase the stability of the AscA in solution. At
week 10 of age, some mice were rendered VitC deficient by reducing VitC
supplementation for one week (33 mg/L), followed by complete removal of VitC
supplementation for an additional week. This reduced supplementation was shown to
result in very low plasma VitC concentration, yet insufficient to result in scurvy.(58, 59)
In this study, mice were divided into three groups: VitC sufficient, VitC deficient and VitC
deficient+AscA mice. The third group was given daily parenteral AscA (200 mg/kg
intraperitoneal injection) and AscA supplemented drinking water (330 mg/L) for up to 14
days following wounding.
4.2.2 Surgical Procedure: Animals were maintained under isoflurane anesthesia. In
addition, they were also injected subcutaneously with the analgesic buprenorphine
(4µg/ml) for pain management. Wounds were created using the methods described by
Galiano et al.(151) Briefly, the mouse hair on the dorsum of the mice thoracic curvature
was shaved with an electric clipper followed by an additional treatment with a depilatory
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cream (Nair), for 3 minutes, to remove any remaining fur. The surgical area was then
neutralized with betadine followed by another disinfection step with alcohol swaps. Two
full thickness excisional wounds were created on the back of VitC sufficient/deficient
Gulo-/- mice using a sterile 6-mm biopsy punch. Wounds were covered with nonadherent dressing (Telfa™, Covidien); and animals were housed individually with ad
libitum water and food access as discussed earlier. At day 7 and day 14 post-wounding,
mice were anesthetized, blood was collected via cardiac puncture (anti-coagulated with
sodium citrate 1:10) and kept on ice to be processed for VitC analysis. Mice were then
sacrificed and the wound tissue was collected using forceps and scissors. Per mouse,
the tissue from one wound was fixed in formalin for 48hr and processed for histology.
The tissue from the second wound was excised, bisected, and stored in liquid nitrogen
followed by long term storage at -800C for subsequent RNA and protein extraction.
Human Neonatal Dermal Fibroblast (HnDF) Culture: Primary HnDF cells were
obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were
maintained in high glucose, Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, penicillin (100µg/mL), and streptomycin (100µg/mL) under
a 5% CO2 atmosphere at 37°C. All experiments were performed using cells at passages
3 to 5.
4.2.3 VitC Analysis: Blood samples obtained from mice on day 7 and 14 post
wounding were kept on ice, centrifuged and the resultant plasma was deproteinized as
previously described.(146) Briefly, 100µL of plasma was deproteinized with 200µL of
cold 20% trichloroacetic acid (TCA), and treated with 200µL of cold 0.2% dithiothreitol
(DTT) to prevent oxidation. The mixture was vortexed intermittently for 2 min and
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centrifuged (10,000g, 4 0C, 10 min). Supernatants were stored at -80 0C for batch
analysis using a fluorescence end-point assay.(130)
4.2.4 Histological Staining and Wound Assessment: Formalin fixed paraffin
embedded wound sections (3-4 μm) were cleared in xylene washes, rehydrated in a
series of decreasing alcohol concentrations and brought to water. Prepared specimens
were stained with Masson’s Trichrome according to manufacturer’s protocol (Richard
Allan Scientific, Catalogue # KTRA87019, Kalamazoo, MI).
4.2.5 RNA Isolation and Real-Time Quantitative PCR (QPCR) analysis: Total RNA
isolation and real-time QPCR were performed as described previously.(146) Assays
were run in triplicate with no template controls and no reverse transcriptase controls.
The mRNA expression from a “sufficient” mice or a media well was set to “1.0” and
mRNA expression of all other samples was compared relative to this sample and
represented as a fold change. To normalize for differences in the amount of total RNA
added to each cDNA reaction and possible variation in the reverse transcriptase
efficiency among the different cDNA reactions, the housekeeping gene 18S rRNA was
used. Automated gene expression analysis was performed using the Comparative
Quantitation module of MxPro QPCR Software (Agilent). Both the forward and reverse
primers for each target are listed in table (1) below.
Table 1. Murine and Human Primers used for qPCR
Name
Sequence 5’ to 3’
CTGAACTCAACTGTGAAATGCC
Murine IL-1 forward
CAGGTCAAAGGTTTGGAAGC
Murine IL-1 reverse
GATGAGAAGTTCCCAAATGGC
Murine TNF forward
TTGGTGGTTTGCTACGACG
Murine TNF reverse
Murine KC forward
CAATGAGCTGCGCTGTCAGTGCCTGCAG
Murine KC reverse
CTGAACCAAGGGAGCTTCAGGGTC
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Table 1. Murine and Human Primers used for qPCR
Murine Mpo forward
CTGGATCATGACATCACCTTGACTCC
Murine Mpo reverse
GATCTGGTTGCGAATGGTGATGTTGTTCC
Murine HO-1 forward
GGTACACATCCAAGCCGAGAATGCTGAG
Murine HO-1 reverse
CGGTGCAGCTCCTCAGGGAAGTAGAG
Murine VEGF forward
GAGACCCTGGTGGACATC
Murine VEGF reverse
CTTTCTTTGGTCTGCATTCAC
Murine CTGF forward
CCCAACTATGATGCGAGCC
Murine CTGF reverse
ACAGGCTTGGCGATTTTAGG
TGACGTCACTGGAGTTGTACGG
Murine TGF- forward
CCACGTGGAGTTTGTTATCTTTGC
Murine TGF- reverse
Murine Gal1 forward
CAGCAACCTGAATCTCAAACC
Murine Gal1 reverse
AGTGTAGGCACAGGTTGTTGC
Human IL-6 forward
GGATTCAATGAGGAGACTTGCC
Human IL-6 reverse
TCTGCAGGAACTGGATCAGG
Human Nanog forward
AATGTCTTCTGCTGAGATGCC
Human Nanog reverse
GCTGTCCTGAATAAGCAGATCC
Human OCT4 forward
CTTGCTGCAGAAGTGGG
Human OCT4 reverse
CACTCGGTTCTCGATACTGG
Human p21 forward
CTGTCTTGTACCCTTGTGCC
Human p21 reverse
CCTCTTGGAGAAGATCAGCC
Human p27 forward
TGGACCCAAAGACTGATCC
Human p27 reverse
CATTTTCTTCTGTTCTGTTGGC

4.2.6 Western Blot Analysis: Wound tissues whole cell extract and HnDF whole-cell
and nuclear extracts were isolated and used for Western Blot analysis as described
previously.(29) Nuclear extracts were isolated using the NE-PER kit (Pierce
Biotechnology, Rockford, IL, USA). Antibodies to hemoxygenase-1 (HO-1) (ADI-SPA896-D, Enzo life sciences, Farmingdale, NY, USA), Oct-3/4 (sc-5279, Santa Cruz
Biotechnology, Santa Cruz, CA), lamin B (sc-6216, Santa Cruz Biotechnology), and
actin (sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA) were used in this study.
Optical densities of antibody-specific bands were determined using Quantity One
acquisition and analysis software (BioRad, Hercules, CA).
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VitC Uptake by HnDF:

HnDF were grown under normal culture conditions to confluence in

12-well plates. Cells were then exposed to media alone or AscA (0.5mM and 1mM) for 3
hours. Media was removed and cells were washed twice with PBS. Fifty µl of tissue
culture grade water was added to each well. Cells were lysed by repeated freeze-thaw
cycles (x3). Lysates were treated with TCA and DTT and intracellular VitC content was
determined as described above.
4.2.7 HnDF Proliferation Assay: HnDF were seeded into 96-well plates at an initial
cell density of 3K cells per well. Cells were allowed to rest for a day and then exposed
to media only, media + 0.5mM AscA, or media + 1mM AscA for 24 hours. Media was
then aspirated and proliferation determined using the CyQUANT® cell proliferation
assay kit (Invitrogen, Carlsbad, CA, USA) as per manufacturer instructions.
4.2.8 Healed skin tensile testing: For these set of experiments, mice were sacrificed
at day 14 post-wounding and 20mm X 4mm skin specimens were harvested along the
mouse central axis. Specimens were wrapped in PBS-moistened gauze and stored at
40C overnight prior to testing. Dimensions of each specimen were taken 3 times using a
digital caliper and the average was used to calculate the cross-sectional area. Two
samples were harvested per animal with the healed wound area located mid-substance.
Mechanical testing was performed at room temperature using MTS tensile testing
machine and Testworks 4.06A software (MTS Systems, Eden Prairie, MN). The starting
conditions were a preload of 0.01 Newtons (N), and tensile grip moving rate of 10
mm/min. Only samples that failed mid-substance were included in the analysis,
otherwise samples were excluded (due to failure at the clamp or samples slipped from
the clamp).
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4.2.9 Statistical Analysis: Statistical analysis was performed using GraphPad Prism
6.0 (GraphPad Software, San Diego, CA, USA). Data are expressed as mean ± SE.
Results were compared using one-way ANOVA. Post hoc Tukey test was used to carry
out multi-comparisons between groups. The level of significance for all statistical tests
was p < 0.05.
4.3 Results
4.3.1 VitC levels affect the progression of wound healing: To examine the effect of
VitC on wound progression, three groups of Gulo-/- were generated and subject to the
wounding procedure described in the Methods section. We then measured plasma VitC
levels on day 7 and 14 post-wounding. As seen in Figure 25A, at day 7 post-wounding,
VitC “sufficient” mice had significantly higher circulating plasma VitC when compared to
the other groups. The VitC levels in the “deficient +AscA” group were also significantly
higher than the deficient group by day 7. By day 14 (Figure 25B), circulating plasma
VitC levels in the “sufficient” and “deficient + AscA” became comparable and
significantly higher than the “deficient” group. Masson’s trichrome stained wound
sections on day 7 demonstrated dense granulation tissue and higher collagen
deposition (blue color) from “sufficient” and “deficient + AscA” mice when compared to
the wound sections from “deficient” mice (Figure 26 A-C). In both the VitC groups, the
dermis and epidermis were better connected to one another. Moreover, the basal
lamina and keratin layer were also well developed and presented as distinct layers. In
contrast, day 7 sections from “deficient” mice demonstrate loose granulation tissue with
reduced collagen deposition. Additionally, in deficient mice, the dermis was more
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cellular (and reticular) and the lamina was not yet fully distinct (Figure 26 B). Most of
these striking differences were also evident on day 14 post-wounding (Figure 26 D-E).
4.3.2 VitC attenuates mediators of inflammation in wound healing: Next we
examined the mRNA expression of the pro-inflammatory genes (IL-1, KC, TNF-, and
MPO) in healing tissue 7 and 14 days post-wounding. VitC “sufficiency” or treatment of
“deficient” mice with AscA significantly attenuated transcript levels of these proinflammatory genes when compared to wound tissue from VitC “deficient” mice at day 7
(Figure 27). The transcript levels of the pro-inflammatory signaling cytokines (IL-1 and
KC) remained elevated on day 14 in the “deficient” mice compared to the “sufficient”
and “deficient + AscA” mice (Figure 28). MPO transcripts however were not detectable
in all 3 groups on day 14 (data not shown). TNF- transcript expression on day 14
showed the same trend as IL-1 and KC but these differences in expression did not
achieve statistical significance. In light of the elevated and persistent expression of proinflammatory mediator transcripts in VitC deficient animals, we examined whether
markers of inflammation resolution might be altered. Galectin-1 (Gal-1) expression is
associated with generation of pro-resolving lipid mediators and successful resolution of
inflammation.(152) Therefore, we examined Gal-1 expression in day 7 wounds. Gal1
transcript levels were significantly higher in VitC “sufficient” mice compared with the
“deficient” mice (Figure 29). Although Gal1 gene expression trended higher in the
“deficient + AscA” group, it did not reach statistical significance.
4.3.3 VitC induces genes that promote wound healing: We also examined the
expression of transcripts levels of several other known modulators of wound healing
including

hemoxygenase-1(HO-1),

vascular
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endothelial

growth

factor

(VEGF),

connective tissue growth factor (CTGF), and transforming growth factor beta (TGF-).
On day 7 post-wounding, both VitC “sufficient” and “deficient + AscA” Gulo-/- mice
showed significantly higher mRNA expression of HO-1, VEGF, and CTGF (Figure 30 AC) in comparison to the “deficient” mice. TGF- expression was significantly elevated in
“sufficient” mice compared to “deficient” mice. TGF- expression following AscA infusion
trended higher in the “deficient + AscA” group but did not reach statistical significance
(Figure 30D). Induction at the protein level was confirmed by Western blot analysis for
total HO-1 (Figure 31).
4.3.4 VitC and tensile strength of healed wound: Using the excisional wound model,
samples collected at day 14 post-wounding were used to carry out skin tension studies
as described in Methods. Stress at the healing section was measured using the midspecimen cross sectional area (in KiloPascals). The healed skin samples from the
“sufficient” mice demonstrated a significantly higher stiffness compared to the other
groups (Figure 32). However, there were no statistically significant differences between
the “deficient” and “deficient + AscA” groups. In addition, we also measured the Peak
load, a measure of the tensile strength a material can withstand before breaking.
However, no significant differences were observed between the different mice groups
(data not shown).
4.3.5 VitC promotes HnDF proliferation: Confluent HnDF cells were incubated for 3
hours with two concentrations of AscA (0.5 mM and 1mM). In the absence of
exogenous AscA, intracellular VitC concentrations in HnDF were extremely low. There
was a dose and time dependent increase in intracellular VitC concentrations following
AscA loading (Figure 33) suggesting that these cells have the ability to transport VitC
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intracellularly. Additionally, incubating sub-confluent HnDF cells with the same AscA
concentrations (0.5 mM and 1mM) for 24 hours resulted in significant dose dependent
increases in HnDF proliferation (24% and 40%, respectively) as seen in Figure 34.
VitC induces the expression of self-renewal, cell-cycle progression and fibroblast
motility genes in HnDF: To further investigate the increased proliferative capacity
brought by AscA, HnDF cells were incubated with AscA (0.5 mM and 1mM) for 3 hours
and mRNA expression of the self-renewal genes Nanog and octamer-binding factor 4
(OCT4) determined by QPCR. Both Nanog and OCT4 gene expression increased in a
dose dependent fashion following HnDF incubation with AscA (Figure 35). The
increased expression was not statistically significant with low level AscA (0.5 mM) but
was significant with the higher AscA concentration (p<0.05). The mRNA expression
levels of the cyclin-dependent kinase inhibitors and regulators of cell cycle, p21 and p27
were also determined (Figure 35). Transcript levels of p27 were significantly decreased
in a dose dependent fashion by AscA exposure. However p21 expression levels were
unchanged. Western Blot analysis confirmed the increased nuclear expression of OCT4
seen with QPCR at 24 hours post incubation with AscA (Figure 36). The pleiotropic
cytokine IL-6 has been shown to favorably promote cell motility and matrix remodeling
during the inflammatory phase of wound healing.(153, 154) In addition, IL-6 is a
resolution promoting cytokine by virtue of its inhibitory effects on pro-inflammatory
signaling via activation of IL-10 and IL-13, and by its ability to enhance polarization of
macrophages at wound healing sites towards an anti-inflammatory/alternatively
activated phenotype.(155) Therefore we examined IL-6 mRNA expression following
exposure of HnDF cells to AscA. As seen in Figure 9F, exposure of HnDF to AscA
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produced a dose dependent increase in IL-6 mRNA expression levels; 2.5 fold and 4
fold increase with 0.5mM and 1mM AscA, respectively.
4.4 Discussion
Wounds and more generally injuries are associated with rapid micronutrient
deficiencies.(143) Levels of one critical micronutrient, VitC, have been shown to drop
significantly (60-70%) at the wound site and not recover completely even after 14 days
post-wounding.(156, 157) These observations may reflect VitC depletion by the plethora
of free oxidant radicals generated in the wound microenvironment, and in part by the
increased consumption of VitC in different biological processes (e.g. collagen synthesis)
that are activated during the repair process. While higher oral intake is achievable,
attaining significant plasma levels are limited by gastric intolerance and also by limited
absorption and renal excretion thresholds.(19) We and others have shown that
parenteral VitC is advantageous in bypassing these limitations to produce and sustain
adequate plasma levels.(19, 158)
In our present study, we were able to show improved wound healing characteristics with
VitC sufficiency and also with i.p. VitC repletion of Gulo(-/-) mice. Day 7 wounds from
VitC “deficient” mice showed a spatiotemporal gene expression characterized by
persistent inflammation combined with delayed resolution and proliferation. The proinflammatory state persisted throughout day 14 post-wounds in the “deficient” mice but
not in the “sufficient” or “deficient + AscA” groups. In contrast, VitC “sufficient” and
supplemented Gulo(-/-) mice showed attenuated expression of pro-inflammatory
cytokines, increased expression of favorable biomarkers of wound healing, and better
expression of the pro-resolution markers of wound healing. However, tangible effects on
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the skin tensile strength properties at day 14 post-wounding were evident only in the
VitC “sufficient” mice. These improvements in wound healing in the VitC “sufficient” and
supplemented mice were corroborated by in vitro cultures of HnDF which showed that
VitC supplementation led to robust uptake and fibroblast proliferation, induction of selfrenewal genes and up-regulation of a pro-resolution cytokine that also plays a role in
fibroblast mobility.
Histological examination of day 7 and day 14 Masson’s Trichrome stained sections
showed that wounds from VitC “sufficient” and supplemented mice had better matrix
organization with clear distinction of all skin layers and significant extracellular matrix
deposition. In contrast, wounds from VitC “deficient” mice were characterized by a loose
dermis that was highly cellular and accompanied by limited collagen deposition. At a
molecular level, wounds from “deficient” mice actively expressed the pro-inflammatory
cytokines IL-1 and TNF-. Additionally, wounds from “deficient” mice demonstrated
significantly higher MPO expression compared to wounds from VitC “sufficient” and
AscA infused mice. MPO is an enzyme almost exclusively produced by PMNs (5% of
total neutrophil protein) and to some extent in monocytes and is often used as a marker
of PMN infiltration.(159) High MPO levels have been found to be associated with poor
healing wounds.(160) A similar pattern was observed with the gene expression of the
PMN chemoattractant factor, KC. Murine KC is analogous to human CXCL-1 (a
functional homologue of IL-8). We interpret the presence of these pro-inflammatory
markers as ongoing/sustained pro-inflammatory cellular infiltration into the wound site
and an extended pro-inflammatory phase in wounds from “deficient’ mice. In contrast,
the attenuated expression of these pro-inflammatory mediators in VitC “sufficient” and
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AscA infused mice is indicative of termination of pro-inflammatory cell infiltration to the
wound site and perhaps the end of the pro-inflammatory phase. The expression pattern
on day 14 further supports this assumption.
The proliferation stage of wound healing is typically characterized by increased
expression of the pro-reparative growth factor cytokines such as TGF-, CTGF, and
VEGF.(141) TGF- plays an important role at all stages of wound healing. In the initial
stages, it serves as a chemotactic factor for pro-inflammatory cells as well as
fibroblasts. In later stages, TGF- provides a strong mitogenic signal for fibroblasts.
Braiman-Wiksman et al have shown that high levels of TGF- are most beneficial after
epidermal closure is complete.(161) In our present work, TGF- expression levels were
significantly higher in day 7 wounds from “sufficient” mice. Wounds from mice receiving
daily AscA infusion showed TGF- levels that trended higher compared to “deficient”
mice but did not reach statistical significance. Another growth factor in the wound milieu
is CTGF whose transcription is regulated mainly by TGF-. It is believed that it is a
downstream mediator of some of the actions of TGF-.(162)

However, TGF-

independent regulation of CTGF has also been reported.(163) Recently, Alfaro et al
(2013) reported that CTGF levels at wound sites increase during the proliferation
phase.(164) CTGF functions in promoting granulation tissue formation (fibroblast cell
division and migration and fibroblast matrix deposition e.g. collagen type I and
fibronectin) and wound remodeling.(165) In our study, VitC “sufficiency” and AscA
supplementation were associated with significantly higher CTGF expression compared
to the “deficient” mice at day-7 post-wounding (p<0.05). Combined with histological
evidence, these results indicate an active cellular and molecular proliferation in the VitC
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“sufficient” and AscA supplemented mice versus an attenuated/lagging proliferation
response in “deficient” mice. Several studies have shown that VEGF significantly
promotes angiogenesis and neovascularization in healing wounds.(140) Multiple factors
such as pH, reduced oxygen tension, increased lactate as well as pro-inflammatory
cytokines have been reported to induce VEGF production at the wound site.(140, 142)
In our study, we observed higher VEGF expression in the VitC “sufficient” and AscA
infused mice indicating increased angiogenesis and neovascularization in the wounds of
“sufficient” and AscA supplemented mice. A role for HO-1 in wound healing has only
been recently described.(166) Grochot-Przeczek et al showed that HO-1 inhibition
adversely affects wound healing in diabetic mice while HO-1 over-expression promoted
healing.(166) Earlier, the same research group showed that HO-1 upregulated VEGF
production and therefore could indirectly promote neovascularization. In our study, HO1 expression levels were significantly higher in VitC “sufficient” and AscA supplemented
mice. In sum, the expression pattern of these growth promoting factors can be
interpreted as a robust biological response to wounds in VitC “sufficient” mice when
compared to the “deficient” mice. In addition, daily i.p. VitC supplementation seems to
restore the growth promoting response in wounds of VitC “deficient” mice.
Physiologic wound healing involves a regulated fibroblast differentiation into
myofibroblasts that play an active role in reconstruction of damaged tissue following
injury.(167) A critical mediator of this process is Gal-1, a lectin produced by various
tissues. Recently, Lin et al (2015) showed that Gal-1 induced myofibroblast activation
and proliferation. Moreover Gal-1(-/-) knockout mice experienced reduced myofibroblast
migration, which was corrected with topical Gal-1 administration in excisional wound
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models.(168) Elsewhere, Perzelova et al showed that exposure of dermal fibroblasts to
Gal-1 stimulated extracellular matrix production that subsequently supported endothelial
cell growth.(169) In our studies, only VitC “sufficient” mice had significantly higher Gal-1
expression levels as compared to other groups. We have previously shown that both
VitC “sufficiency” and VitC supplementation were able to induce early Gal-1 expression
in peritoneal macrophages, which correlated with markers of resolution.(146) This
suggests that VitC may be required to sustain Gal-1 expression in healing wounds and
that the level of supplementation provided to the “deficient” mice is probably insufficient
to adequately restore Gal-1 expression in healing wounds.
Much to our surprise, only VitC “sufficient” mice demonstrated significantly higher
healed-skin stiffness compared to the other groups despite the observed increased
collagen deposition evident by histological analysis in the “sufficient” and “deficient +
AscA” mice. Although by day 14, we had achieved plasma VitC levels in the “deficient +
AscA” group that were comparable to the VitC “sufficient” mice, it is possible that the
VitC levels in the healing wound may not have reached the same level as the sufficient
mice. While humans have evolved over millennia to up regulate the VitC transporter
SVCT2 at times of deficiency (170) it is unknown whether SVCT2 is up regulated to the
same extent in the healing wounds of these knockout mice. Indeed it has been shown
that the knockdown of SVCT2 in bone marrow derived stromal cells decreased wound
healing, and that supplementing with VitC failed to rescue these cells.(171) Therefore,
we interpret these results as insufficient uptake of VitC in the healing wound and that
perhaps, an additional topical application of VitC at the wound site or a higher dose of
i.p. VitC could prove beneficial.
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Using HnDF cells, we showed that AscA exposure resulted in a dose dependent and
significant increase in intracellular AscA uptake and fibroblast proliferation. This was
associated with a dose dependent inhibition of p27 expression. The inhibitors p21 and
p27 suppress cell cycle progression by inhibiting cyclin-dependent kinases as well as by
down regulating expression of other genes involved with cell cycle progression.(172)
Conversely, AscA treatment was associated with a dose dependent increase in the
expression of pluripotent and self-renewal genes Nanog and OCT4.(173) These
findings suggest a crucial role for VitC in regulating fibroblast proliferation. Although this
is a novel finding in fibroblasts, there is precedence for these actions of VitC in stem
cells, and in particular the adipose derived stem cells wherein VitC has been used to
increase the yield and regenerative potential of adipose derived stem cells.(174)
IL-6 is a cytokine with pleotropic functions that is produced by several cell types in the
wound microenvironment including fibroblasts.(153, 175) It plays an important role in
development of Th17 cells and is known to contribute to the inflammatory component of
autoimmune diseases.(176) However, recent studies suggest a pro-resolution and antiinflammatory role for IL-6 in wound healing environments.(155) Kuhn et al showed that
inhibition of IL-6 resulted in impaired wound healing due to decreased epithelial
proliferation.(177) IL-6 knockout mice exhibit delayed wound healing (delayed reepithelialization, granulation tissue formation, and sub-optimal inflammatory response)
compared to wild type mice; this could be reverted with recombinant IL-6.(178, 179)
Further, Gallucci et al reported IL-6 signaling to promote dermal fibroblast differentiation
into myofibroblasts, increase their motility and also promote matrix remodeling.(153,
180) We found that exposure of HnDF cells to AscA promoted a dose dependent
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increase in IL-6 mRNA levels. These findings suggest a novel mechanism by which VitC
could promote fibroblast motility and matrix remodeling. Presumably, insufficient
fibroblast VitC levels could impair IL-6 expression and delay the resolution of wound
healing.
Thus, on the basis of these in vitro studies, we speculate that in the absence of
adequate VitC supplementation, the proliferation and maturation phases of wound
healing would be delayed or would remain incomplete, thereby resulting in non-healing
wounds.
4.5 Conclusion:
Wound repair is a complex process that requires the co-ordination of various
local cellular and biochemical events. To date, the majority of studies have used oral
supplementation to augment plasma/tissue levels of VitC. However, recent studies by
Padayatty et al and others have shown that oral supplementation does not provide the
requisite VitC levels for restoration of plasma VitC levels.(19, 59) We have recently
shown that parenteral routes of VitC administration are safe and effective in critical care
situations in both mice and humans.(158) Moreover, these doses of VitC, when
administered parenterally, were sufficient to restore circulating plasma VitC levels. The
current study presents new evidence that beyond its well characterized role in collagen
metabolism, vitamin C status plays a crucial role in orchestrating multiple wound healing
processes. Vitamin C repletion by parenteral infusion has the potential to be a safe and
inexpensive therapy for enhancing tissue repair and shortening healing time.
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Figure 25: Plasma VitC levels from VitC “sufficient”, “deficient” and “deficient + AscA” Gulo mice at day 7
(a) and day 14 (b) post wounding. Daily supplementation of deficient mice with i.p. AscA post-wounding
resulted in significantly higher plasma VitC levels in the “deficient + AscA” mice compared to “deficient”
mice by day 7 post wounding. These levels further rises and became comparable to sufficient mice plasma
VitC levels at day 14 (n= 3–6 mice/group, ns= not significant).

Figure 26: Representative Masson’s trichrome stained sections from VitC “sufficient”, “deficient”, and
−/−
“deficient + AscA” Gulo mice at day 7 (A-C) and day 14 (D-F) post wounding. VitC “sufficient” (A) and
“deficient + AscA” (C) sections were showing more dense granulation tissue with significant collagen
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disposition and distinct lamina. In contrast, sections from the “deficient” mice demonstrated a more cellular
loose granulation tissue with little collagen disposition (B). Also the lamina was not yet distinct. Day 14
sections were more mature. However, sections from the VitC “deficient” mice were still showing a less
compact collagen disposition.

Figure 27: Real time QPCR for IL-1β, KC, TNFα, and Mpo mRNA from day 7 wounds of VitC “sufficient”
−/−
“deficient”, and “deficient + AscA” Gulo mice. Wounds from Vitamin C “sufficienct” and “deficient +
AscA” mice demonstrated an attenuated pro-inflammatory gene expression profile compared to “deficient”
mice. (n = 3-6 for each group).
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Figure 28: Real time qPCR for IL-1β, KC, and TNF-α mRNA from day 14 wounds of VitC “sufficient”
−/−
“deficient”, and “deficient + AscA” Gulo mice. Wounds from Vitamin C “deficient” was still experience a
heightened pro-inflammatory gene expression response compared to VitC sufficient/supplemented mice. (n =
3-6 for each group).
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Figure 29: Real time qPCR for Gal1 and Ym1 from day 7 wounds. VitC sufficiency is associated with
significantly higher Gal1 expression. VitC “sufficient”, but not “deficient + AscA”, showed significantly
higher Gal1 expression compared to “deficient” wounds at day 7.
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Figure 30: Spatiotemporal profiling of growth factors and HO-1 genes expressions in day 7 wounds. Real
time QPCR for (TFG-B, CTGF, and VEGF) , and HO-1 mRNA from day 7 wounds from VitC “sufficient”,
−/−
“deficient”, and “deficient + AscA” Gulo mice. (n = 3-6 mice/group, ns = not significant).
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Figure 31: Wound Healing is delayed in Vitamin C deficient wounds. Representative Western blot for
expression of HO-1 and actin from day 7 wounds of VitC “sufficient”, “deficient”, and “deficient + AscA”
−/−
Gulo mice. The bar chart is a quantitative representation of the western blot results using densitometry (n
= 3 - 6 for each group).

Figure 32: Stiffness in KiloPascal recorded from skin tension studies performed on wounds collected on day
7 post incisional wounding. VitC sufficient mice demonstrated a significantly higher stiffness (calculated at
mid specimen) compared to the other groups. There was no statistically significant difference in the wound
stiffness between the “deficient” and “deficient + AscA” groups. (n = 6-12; ns = non-significant).
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Figure 33: VitC levels measured in HnDF cells after being loaded with AscA under normal culture conditions
for 3 hrs at 37°C. AscA concentrations were determined as described in Methods (n = 3 for each group).

Figure 34: HnDF loading with AscA resulted in dose dependent increase in proliferation (n= 3 for each
group).
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Figure 35: Real-time qPCR for interleukin-6 (IL-6), Nanog, Oct4, p21, and p27 from HnDF cells loaded with AscA
0.5mM and 1mM for 3 hrs (ns: not significant; n = 3 for each group).
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Figure 36: : Representative Western blot for nuclear expression of Oct4 and lamin B from HnDF cells
loaded with AscA 0.5mM and 1mM for 3 hrs. The bar chart below is a quantitative representation of the
Oct4 western blot results using densitometry (N = 3 - 6 for each group).
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Chapter 5: Impact of High Dose Ascorbic Acid on Inflammatory markers and
Atrial Fibrillation among Cardiac Surgery Patients

Future Direction - Study Protocol - Work in Progress

5.1 Abstract
Ischemia-perfusion injury is an inevitable event taking place during open heart
surgery involving cardiopulmonary bypass (CPB). Reactive oxidant species (ROS) and
the resultant oxidative burst have been demonstrated to be the main pathway for
inducing injury during this event. Both the inflammatory and coagulation systems play a
role in injury during CPB and are well estab-lished contributors to the oxidative burst.
Previous work in this area has shown a significant de-crease in the body’s anti-oxidant
capacity as the oxidative stress builds. Interestingly, Vitamin C levels, an important
dietary anti-oxidant, are reported to decrease after surgery in a similar fash-ion
corresponding to the increased oxidant species. Often a decreased systemic antioxidant capacity is seen and the body does not revert to normal levels until several days
after surgery. The role of Vitamin C has also been emphasized after reports of its use in
preventing atrial fibrillation (AF), which is known to occur following CPB surgery with the
highest incidence occurring by the third day after surgery. The pathogenesis of AF is
suspected to be multifactorial, with ev-idence to support an inflammatory mediated
response with a prominent ROS mechanistic com-ponent. The results associated with
the use of Vitamin C have been significant when given in-travenously in high doses. On
the other hand, studies employing oral administration have demonstrated some
controversy in establishing efficacy. Administration of Vitamin C via oral route result in
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plasma concentration tightly maintained around 150-250uM. At this level, the Vit-amin
concentration may not be enough to replenish tissues and cells and attaining mM
concen-tration is needed to compete for the oxidant species. Parenteral administration
opens the door for mM concentration to be readily achieved with minor inconveniences.
Based on this evidence, the main hypothesis is: “Parenteral administration of high dose
Vitamin C will decrease the ROS-mediated inflammatory/coagulopathies among
patients undergoing open heart surgery involving CPB”.

5.2 Public Health Impact (Project Narrator)
Cardiac surgery is a leading consumer of health care resources. In 2010, data
collected from 1,001 hospitals representing nearly 80% of all sites in the United States
that perform coronary artery bypass grafting (CABG), demonstrated that over 150,000
major procedures involved CABG; 18,008 involved both aortic valve replacement and
CABG; 2,378 involved mitral valve replacement and CABG; and 4,635 involved mitral
valve repair and CABG. The mean hospital charges for CABG and valve procedures
were $124,404 and $171,270 with a mean length of hospital stay of 9.1 and 11 days
and an in hospital death rate of 1.75% and 3.90%, respectively.(181-183) AF, a known
complication of cardiac procedures, is the most common type of arrhythmia experienced
following cardiac surgeries with the risk being highest by third post-operative day. AF
occurs in up to 40% of the patients and has been associated with poorer prognosis.(26,
184) It ac-counts for increased length of hospital stay, as well as increased morbidity
(e.g. stroke) and mortality.(25) It is now supported that the high levels of ROS achieved
in the myocardium can lead to both electrical and structure remodeling of the cardiac
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muscle leading to the development of AF.(26) Therefore, the administration of safe,
inexpensive Vitamin C using the parenteral route is a reasonable novel method to
decrease the ROS for patients undergoing CABG and CPB.
5.3 Specific Aims
Cardio-pulmonary bypass (CPB) is considered to be a major contributor of inflammatory
injury during cardiac surgery. Recently, the role of reactive oxidant species as a
prominent media-tor/stimulant has been defined, recognizing the inevitable oxidative
burst which occurs during surgery. Several trials have examined interventions aimed at
controlling and attenuating this oxidative burst. Other trials have investigated Vitamin
C’s ability to halt the oxidant species fueled processes. Unfortunately, the dual routes of
administration employed, more oral than in-travenous, have made the results of these
studies controversial. With oral dosing, the
fasting

plasma

concentrations

are

tightly

controlled to below 150-200μM.(19) In contrast,
with intravenous administration of high doses,
significantly higher plasma concentrations in the
milliMolar (mM) order were achievable.(19)
These facts agree with the principle that the
efficacy of an anti-oxidant is dependent upon its
concentration in the medium where the oxidant
species are generated and the damage is
anticipated.(185)

The

mM

concentrations

Figure 37:
Parenteral Vitamin C (200mg/kg)
reduced multiple organ dysfunction (SOFA) score
in septic patients.

attainable with parenteral administration provide potential for wider therapeutic
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applications of Vitamin C. A number of trials utilizing comparable and higher doses than
proposed in our work have demonstrated improvement in clinical outcomes and
decreased overall morbidity and mortality in different patient population having some
common

pathology.

A

recent

study

by

our

team

demonstrated

that

parenterally administered high dose Vitamin C attenuated sepsis-induced inflammation
and coagulopathies in animals, and showed favorable trends in a safety trial of the dose
in humans (Figures 1 and 2).(186) Therefore, we hypothesize that administering VitC in

Figure 38: Parenteral Vitamin C (200mg/kg) reduced inflammatory biomarkers in septic patients

a dose of 200mg/kg/day divided into 4 doses per day, as used in our previous work, at
the time of cardiac surgery (prior to CPB, during bypass and through post-op day 3) will
reduce inflammatory and coagulatory mediators and biomarkers by attenuating the
oxidative burst developing during CPB.
5.3.1 Specific Aim 1: Establishing the effects of high dose parenteral Vitamin C on the
inflammatory and coagulatory system.
a. Determine how the levels of circulating pro-inflammatory biomarkers profiles are
affected.
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b. Examine the effects of high dose parenteral Vitamin C on coagulation biomarkers
and platelets function.
c. Investigate the effects of high dose parenteral Vitamin C on the cardiac enzymes
profiles.
d. Measure vitamin C levels in both groups to draw correlation with blood
biomarkers.
It is expected that Vitamin C intervention will result in a significant decrease in the
plasma peak levels of inflammatory and coagulatory markers over time as compared to
a control group.
5.3.2 Specific Aim 2: Determine the effects of high dose parenteral Vitamin C on
patient clinical outcomes: Incidence of AF, ICU length of stay, overall Hospital
length of stay, length of time on mechanical ventilation, chest tube volume output
and time to wound healing.
Note: This pilot study will not be fully powered to answer specific aim #2 but preliminary
data will be collected on outcomes to support larger studies to follow.
5.4 Research Strategy
5.4.1 Background and Significance Cardiac surgery represents a high complexity
technical medical intervention. Patients presenting for cardiac surgery have changed
over the last 10 years, with clear trends towards treating elderly patients with complex
disease states such as congestive heart failure (CHF), worsening secondary diseases,
increasing numbers of mechani-cal support device placements and associated
complicated medical treatments. Still, the majori-ties of surgeries are coronary bypass
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and valve repair cases, which involve CPB. The body and heart are subjected to
inflammatory insults through varied causes: surgical trauma, blood contact with the
artificial surface of the CPB machine, changing of blood flow type, heparin anticoagulation, micro-embolism, endothelial thrombin release, free iron and hemoglobin
generation, blood transfusion and myocardium ischemia-reperfusion injury.(36) Indeed,
there is a plethora of literature describing the inflammatory and coagulopathy response
induced by CPB.(187) The ischemia-perfusion injury: Following cardioplegia and during
CPB, the heart is subjected to is-chemia of varying lengths dependent upon the nature
of the operation. The cardiac tissue at that point is electrically resting and its metabolic
demands are accordingly low. There is also a severely diminished supply of oxygen and
nutrients. Accordingly, ROS generation is low and together with the reduced metabolism
result in a slow and direct myocardium cellular damage which extends as the duration of
the ischemia increases.(36, 185) However, an actual peak of the oxi-dative stress
occurs shortly after reperfusion with oxygenated blood because of the already accumulated oxidative substrates and cellular depletion of reductive counterparts.(185)
While the for-mer is the major contributor to cardiac damage related to oxidative burst, it
is worth noting that ischemia-reperfusion is not the only contributor to oxidative stress
experienced during surgery in this particular patient population, which often has many
other co-morbidities. Most significantly of these co-morbidities are diabetes and
Coronary Artery Disease (CAD) whose pathologies have a significant ROS injury
component. In addition, insults from the operative procedure result in activating the
inflammatory and coagulation systems which contribute significantly to oxidative stress
through a number of self-perpetuating feedback loops and are further up-regulated

109

by oxidative stress. McColl A. J. et al. (1998) demonstrated that the total plasma
antioxidant status was significantly lower at 1.5hr, 6hr, 24hr, and 72hr after CPB. They
further reported that the larger drop was between the 0hr and 1.5hr time points when
the elevation in the lipid peroxide level was at the lowest level. The study also evaluated
the cardiac troponin T which was elevated at all-time points postoperatively with a
significant correlation between the lipid peroxide elevation at 1.5hr and troponin T
elevation.(188) In another study, involving 79 patients undergoing CABG involving CPB,
showed a significant increase in both total peroxide and oxidative stress index. The
stress index continued to be elevated for 48 hours post operatively with a
significant decrease in total antioxidant capacity.(189) Furthermore, as reviewed by
Larmann, J, & Theilmeier, G. (2004), the endothelium, platelets and leukocytes are
activated during CPB.(36) This activation is caused in part by ROS as well as proinflammatory mediators, an activated complement system and endotoxins released from
the gut which have an ROS component as well.(36) More recent, the role of ROSmediated inflammatory responses in the development of AF has been established. AF is
the most common type of arrhythmia experienced following cardiac surgeries with
highest risk on the third day of surgery. It occurs in up to 40% of the patients despite
several new therapies.(26) The development of AF post operatively has been
associated with poorer prognosis.(26, 184) It accounts for increased length of hospital
stay, as well as increased morbidity (e.g. stroke) and mortality.(25) High levels of ROS
achieved in the myocardium cause both electrical and structural remodeling of the
cardiac muscle leading to AF.(26) An association of more AF with increased
transfusions among CPB patients was also reported, thus recognizing the
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deleterious effects of the increased plasma load of inflammatory markers and mediators
from the transfused red cells.(25)
Interestingly, the concentration of Vitamin C decreases significantly during
surgery, sepsis, burns, postoperatively and with postoperative complications.(25)
Indeed, Vitamin C levels during and after cardiac surgery are low. Vitamin C serves as a
one or two electron-reducing agent ca-pable of seeking out several types of reactive
oxidant species.(30, 184) A number of randomized con-trolled trials involving trauma
patients, major burns, critically ill cardiac patients as well as patients with subarachnoid
hemorrhage employed intravenous (IV) vitamin C supplementation. Doses used were
between 1gm every 8hours to 66mg/kg/hr (110gm/24hours for a 70kg patient).
A significant improvement in patient outcomes was observed. There was a decrease in
patients’ ICU length of stay, hospital length of stay, duration on mechanical ventilation,
the inflammation marker C-reactive protein (CRP), wound edema, time to wound
healing and an overall decrease in morbidity and mortality.(25) Recent research in
cardiac surgery has suggested that the use of Vitamin C decreases AF. Although, the
incidence of AF in one study was as low as 16.3% compared to 34.9% in the control
group(25), the results from other cardiac studies regarding AF demonstrated increased
variability. Many of these studies employed Vitamin C orally in a relatively low dose,
which is thought to be less effective. Vitamin C plasma concentration is usually
maintained and controlled below 150 - 250uM with oral supplementation.(19) Oral
doses in excess of 200 mg are associated with no further increases in circulating
Vitamin C levels.(19) In contrast, when administered intravenously higher plasma
concentrations (many folds higher-milliMolar concentrations) are achievable.(19) This is
111

significant when considering factors such as hemodilution and the associated decrease
in the plasma antioxidant capacity. The parenteral route is then considered most
effective, and serves making Vitamin C a “new (emerging) drug” to be used in
conjunction

with

current

therapies

for

patients

undergoing

CABG.

Finally,

concerns regarding high doses Vitamin C have been raised before. Fortunately, the
safety of this dose has been verified in our preliminary human data and the safety of
higher doses has previously been verified in cancer trials.(190) The only known
reported toxicity of Vitamin C originates after continuous (days to weeks) of infusions or
intake and is limited to oxalate renal calculi.(36) Another potential concern was the
hypothesized pro-oxidant property of high dose Vitamin C. However, evidence
supporting this claim in literature is weak and the antioxidant property at even
higher doses was demonstrated to be predominant.(40) Therefore, overall it is a very
safe and low risk of toxicity intervention over a wide range of doses including the
suggested dose in this proposed work.
5.4.2 Innovation The proposed work is able to combine critical review of literature and
innovation for the following reasons: 1) Using high dose Vitamin C, 200mg/Kg/day,
intravenously will allow for the achievement of effective high plasma concentrations, 2)
First time to employ the novel intervention among the patient population undergoing
cardiac surgery involving CPB. With the first dose administered before the onset of
CPB, the body tissues will have the opportunity, most importantly cardiac tissues, to
replenish their storage of this natural anti-oxidant as well as in-crease the plasma antioxidant capacity, and 3) The interventions as described aim to interfere with the
inflammatory and ROS perpetuated mechanisms involved in developing atrial
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fibrillation as well as the associated increase in coagulopathies among this patient
population during the peri operative period. This pilot study will allow us to detect
favorable trends through monitoring of key markers of these interacting systems.
5.4.3 Approach
Specific Aim 1: Establishing the effects of high dose parenteral Vitamin C on the
inflammatory and coagulatory system.
a) Determine how the levels of circulating pro-inflammatory biomarkers profiles (CRP,
IL6 and TNF-α) are affected. CRP: is a known general marker of inflammatory
processes, as well as, an acute phase reactant. It is produced in the liver and is thought
to bind phosphotidylcho-line which is in cell membranes. Cell membrane breakdown
occurs with ensuing endothelial cell death. It is thought that vitamin C, as an antioxidant could/should protect endothelial cells form oxidative stress and early cell death
after ischemia and reperfusion injury and hence reduce the level of this biomarker. IL-6,
and TNF-α: are interleukins, or cell signaling proteins that white cells release to
attract/up regulate other leukocytes. A wide range of inflammatory processes will turn
on leukocytes to release these proteins and again it is thought that if vitamin C acts by
decreasing the body’s response to inflammation form CPB that these biomarkers of
inflammation should be lessened.
b) Determine the effects of high dose parenteral Vitamin C on coagulation biomarkers
and platelets function. Fibrinogen: is the most important circulating coagulation protein
in that it is the building block for solid clot. Fibrinogen is, like CRP, a liver produced
acute phase re-actant. Fibrinogen rises as a result of inflammation. Soluble
thrombomodulin: is released from intact endothelial cells in response to thrombin
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production or active coagulation espe-cially as a way to curb run away pro-coagulant
responses. Platelet and WBC counts: change as a response to inflammatory mediators.
On the other hand, Rotem is a whole blood clot analysis technology that is particularly
sensitive to the interactions of fibrinogen and platelets. As such it is predictive of which
patients will bleed after CPB Therefore if vitamin C manages to decrease overall
inflammation; we expect Rotem analysis of clot dynamics to demonstrate a better
preservation (homeostasis/buffering).
c) Determining the effects of high dose parenteral Vitamin C on cardiac enzyme profile.
CPB procedure results in ischemia mimicking myocardial infarction and more profound
is the combination of ischemia-reperfusion injury leading to myocardial cell injury, which
causes the release of several cardiac tissue markers. Cardiac Troponin I (cTn-1) is
considered one of the best predictors of myocardial cellular injury because it is specific
to the heart and it lacks cross reactivity with isoforms derived from skeletal muscles.
Elevated cTn-I is usually associated with poor clinical outcomes. It is our hypothesis that
Vitamin C, by attenuating the ischemia-perfusion injury, may lower peak cTn-I levels
and thus indicating lower levels of tissue injury.(191, 192) A limitation of this assay is
that the surgery itself and handling the heart could give rise to this marker regardless of
the ROS induced injury.

However, this marker will be nearly constant among the

patients as each patient will experience the same surgery procedure by a limited team.
d) Vitamin C levels will be measured in both groups to draw correlation with the
previously de-scribed markers.
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Specific Aim 2: Determine the effects of Vitamin C on patient clinical outcomes:
incidence of AF, ICU length of stay, overall Hospital length of stay, length of time on
mechanical ventilation, chest tube volume output and time to wound healing. The
incidence of post-op AF is known to be highest by the third day of surgery. Evidence
from the literature supports the inflammatory and ROS mechanistic components of AF
development and perpetuation. It is expected that high dose Vitamin C should be able
to attenuate considerably the inflammatory and ROS insults. Patients will be followed up
through discharge to record the incidence of AF by reviewing clinical notes for any
change in heart rhythm or treatment for AF. The rest of outcomes, described in this aim,
will be gathered after patient discharge from medical records and will be used to evaluate the clinical significance of the intervention.
Experimental Design: This is a pilot, single dose prospective, double-blind, placebocontrolled, randomized study among a placebo group and a Vitamin C 200mg/kg/day
group (divided into four doses throughout the day). The dose was chosen based on
preliminary data in sepsis patients. Patients will receive their first dose at the beginning
of surgery prior to CPB so the myocardial tissue has uptake time prior to ischemia and
reperfusion. The remaining three doses will be infused 6 hours apart. All patients will be
operated-on by a limited surgical team.

Inclusion criteria

Exclusion criteria

1. Age ≥18

1. Low ejection fraction patients (<35%)

2. Patients undergoing non-emergent
elective valve replacement or
valve/CABG

2. Patients with autoimmune disease and those
on immunosuppressant therapy

3. No known coagulopathy prior to
surgery

3. Emergency

4. Patients with relatively well preserved

4. History of renal calculi, low urine output, renal
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Inclusion criteria

Exclusion criteria

myocardial function (Ejection fraction
>35%)

dysfunction (creatinine clearance < 40 ml/min
or serum creatinine greater than 1.8mg/dl
preoperatively)
5. Patients with known bleeding diathesis
6. Active infection or Active tumor
7. History of A-Fib
8. Glucose-6-phosphate deficiency
9. CABG only

Study Procedures: All patients will be approached prior to their surgery with the
potential to participate in the study, and a formal Institutional Review Board (IRB)
approved Informed Con-sent will be discussed, and all questions answered prior to
obtaining their informed consent in writing. Their informed consent will be documented
in the patient medical record, the clinical re-search office and all patients will receive
copies of their signed consent forms. Once consented, patients will be randomized
(computer generated) to receive either placebo, Normal Saline (NS) or Vitamin C.
Experimental pharmacy will make up the infusion bags containing NS or sterile water for
injection plus Vitamin C. The IV bags will be sent to the operating room and since
Vitamin C has no color, the labeling of the bags would maintain this as a double blind
study. Neither the clinicians caring for the patient nor the research (coagulation and
inflammation) laboratory personnel would know the identity of the placebo vs. Vitamin C
grouping of the patient. If a severe adverse event were to occur the clinicians could
break the code by calling the experimental pharmacy. Anesthesia, perfusion (CPB) and
surgery will be techniques in standard clinical usage by the anesthesia and surgery
team. Enrollment in this study will not affect the standard care of the patients.
Blood samples will be obtained prior to treatment (base-line- after anesthesia induction
but prior to drug administration) and then throughout the 96 hour study (60 minutes on
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CPB, 20 minutes after protamine, in ICU at 12, 48 and 96 hours, respectively). The total
amount of blood drawn at each of the above time points will be approximately 15cc.
With the 6 time points outlined that means an excess of 90cc of blood drawn above the
usual clinical blood draws/loss of surgery. Other clinical data will be obtained from the
patient’s chart under direct supervision of the PI by a research coordinator and a
graduate student.
5.4.4 Sample size calculation and statistical Analysis Data from this pilot human
trial will be used for future development of a larger efficacy outcome trial. The effect of
Vitamin C on in-flammation during cardiac surgery is a novel idea and often must start
small due to cost and feasibility concerns.(193) Our study will enroll 24 to 50 patients
with 12 patients in each arm of this safety and efficacy study in this new patient
population. Descriptive statistics will be used to report patient demographics, medical
histories which will allow for population description, identification of potential
confounding factors and further hypothesis generation. Categorical variables will be
reported as absolute and percent values. Continuous variables (such as number of
vessels bypassed) will be expressed as median and interquartile ranges. Chi-square
and Mann-Whitney tests will be used to compare categorical and continuous variables
among the different groups using the JMPpro 10.0 Software for Windows. All tests will
be two-sided using α=0.05 level of significance. Distributions of all measures will be
examined to identify possible outliers; outliers will be thoroughly checked for collection
or data entry errors before being used in the analysis.
5.4.5 Ethical Aspects of Proposed Research This research will involve the use of
fresh blood drawn from patients. The blood draws will be done, when possible from in117

dwelling arterial line and central line catheters and at the time of their routine blood
draws. It is anticipated therefore that the only extra needle sticks a patient may have to
endure would be at the 48 and 96 hours, which is most likely after removal of the arterial
and central line catheters. The toxicity of Vitamin C is very low (discussed earlier),
therefore the research team feels that the potential benefit far outweighs known risks.
Patients will not be paid for participation and there will be no penalties imposed for
either refusing to participate or withdrawing consent once enrolled.
5.4.6 Future research direction Data from this study will be used to power a larger
clinical trial with a more inclusive test panel. If the hypothesis holds, Vitamin C effects
as an anti-sludging agent to protect against blood stasis observed in the CPB machine
will be explored.
5.4.7 Limitations of proposed research A small number of patients will be involved
in this pilot, but this is usually encountered in feasibility studies to standardize the
protocols as well as esti-mating the effects for sample size calculation. Only few
biomarkers will be employed which may not capture the whole effects of the
intervention, however this was compromised by just choos-ing those of highest relevant
to cardiovascular conditions and for which association with clinical outcomes has been
demonstrated.

118

References

1. Carpenter KJ. The discovery of vitamin C. Ann Nutr Metab. 2012;61(3):259-64.
2. Naidu KA. Vitamin C in human health and disease is still a mystery? an overview.
Nutr J. 2003 Aug 21;2:7.
3. De Tullio MC. The mystery of vitamin c<br />. Nature Education. 2010;3(9):48.
4. Aboul-Enein H, Al-Duraibi I, STEFAN R, Radoi C, Avramescu A. Analysis of L-and Dascorbic acid in fruits and fruit drinks by HPLC. In: Seminars in food analysis ;
1999Aspen Publishers; 1999. p. 31-7.
5. Wang YH, Dhariwal KR, Levine M. Ascorbic acid bioavailability in humans. ascorbic
acid in plasma, serum, and urine. Ann N Y Acad Sci. 1992 Sep 30;669:383-6.
6. De Tullio MC. Beyond the antioxidant: The double life of vitamin C. Subcell Biochem.
2012;56:49-65.
7. Stone I. Hypoascorbemia, the genetic disease causing the human requirement for
exogenous ascorbic acid. ; 1966. 133 p.
8. Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W,
Lawson TC, Sauberlich HE. Ascorbic acid dynamics in the seriously ill and injured. J
Surg Res. 2003 Feb;109(2):144-8.
9. PubChem Compund. Ascorbic Acid, CID 54670067 [Internet].
10. Baker EM, Hodges RE, Hood J, Sauberlich HE, March SC, Canham JE. Metabolism
of 14C- and 3H-labeled L-ascorbic acid in human scurvy. Am J Clin Nutr. 1971
Apr;24(4):444-54.
11. Harrison FE, May JM. Vitamin C function in the brain: Vital role of the ascorbate
transporter SVCT2. Free Radic Biol Med. 2009 Mar 15;46(6):719-30.
12. Lindblad M, Tveden-Nyborg P, Lykkesfeldt J. Regulation of vitamin C homeostasis
during deficiency. Nutrients. 2013 Jul 25;5(8):2860-79.
13. Corti A, Casini AF, Pompella A. Cellular pathways for transport and efflux of
ascorbate and dehydroascorbate. Arch Biochem Biophys. 2010;500(2):107-15.

119

14. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park
JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in
healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci
U S A. 1996 Apr 16;93(8):3704-9.
15. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance
of vitamin C for healthy young women. Proceedings of the National Academy of
Sciences. 2001 August 14;98(17):9842-6.
16. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan
NH. Pharmacokinetics of vitamin C: Insights into the oral and intravenous administration
of ascorbate. P R Health Sci J. 2008 Mar;27(1):7-19.
17. Blanchard J, Tozer TN, Rowland M. Pharmacokinetic perspectives on megadoses
of ascorbic acid. Am J Clin Nutr. 1997 Nov;66(5):1165-71.
18. Hornig D. Metabolism and requirements of ascorbic acid in man. S Afr Med J. 1981
Nov 21;60(21):818-23.
19. Levine M, Padayatty SJ, Espey MG. Vitamin C: A concentration-function approach
yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 Mar;2(2):78-88.
20. Vitamin C - Fact Sheet for Health Professionals [Internet]. Online: National Institutes
of Health, Office of Dietary Supplements June 05, 2013. Available from:
http://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ English.
21. Ge M, O’Reilly A, Baillie N, Twentyman G, Sturt J, Fitzpatrick M, Taylor T. Vitamin
C: Evidence, application and commentary. nzfp. 2008;35(5):312-8.
22. Schorah CJ, Downing C, Piripitsi A, Gallivan L, Al-Hazaa AH, Sanderson MJ,
Bodenham A. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations
in plasma of critically ill patients. Am J Clin Nutr. 1996 May;63(5):760-5.
23. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F,
Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in
critically ill surgical patients. ; 2002. 814 p.
24. Berger MM. Vitamin C requirements in parenteral nutrition. Gastroenterology.
2009;137(5):S70-8.
25. Fukushima R, Yamazaki E. Vitamin C requirement in surgical patients. Curr Opin
Clin Nutr Metab Care. 2010 Nov;13(6):669-76.
26. Rodrigo R. Prevention of postoperative atrial fibrillation: Novel and safe strategy
based on the modulation of the antioxidant system. Front Physiol. 2012;3:93.

120

27. Bergsten P, Amitai G, Kehrl J, Dhariwal KR, Klein HG, Levine M. Millimolar
concentrations of ascorbic acid in purified human mononuclear leukocytes. depletion
and reaccumulation. J Biol Chem. 1990 Feb 15;265(5):2584-7.
28. Evans RM, Currie L, Campbell A. The distribution of ascorbic acid between various
cellular components of blood, in normal individuals, and its relation to the plasma
concentration. Br J Nutr. 1982;47(03):473-82.
29. Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Fowler AA,3rd,
Natarajan R. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit
Care Med. 2011 Jun;39(6):1454-60.
30. Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Wegelin JA, Brophy D, Ward KR,
Voelkel NF, Fowler AA,3rd, Natarajan R. Mechanisms of attenuation of abdominal
sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol.
2012 Jul 1;303(1):L20-32.
31. Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Puri P, Massey HD, Idowu MO,
Brophy DF, Voelkel NF, Fowler AA,3rd, Natarajan R. Attenuation of sepsis-induced
organ injury in mice by vitamin C. JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):82539.
32. Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S. Phase I safety trial of
intravenous ascorbic acid in patients with severe sepsis. . 2014
33. Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper
Reference Levels of Nutrients and Interpretation, Uses of DRIs, Standing Committee on
the Scientific Evaluation of Dietary Reference Intakes,Food, Nutrition Board, I. Dietary
Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. The National
Academies Press; 2000.
34. Jacob RA, Sotoudeh G. Vitamin C function and status in chronic disease. Nutr Clin
Care. 2002 Mar-Apr;5(2):66-74.
35. Abbasy MA. The diuretic action of vitamin C. Biochem J. 1937 Feb;31(2):339-42.
36. Larmann J, Theilmeier G. Inflammatory response to cardiac surgery:
Cardiopulmonary bypass versus non-cardiopulmonary bypass surgery. Best Pract Res
Clin Anaesthesiol. 2004 Sep;18(3):425-38.
37. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and
recommendations for vitamin C intake. JAMA. 1999 Apr 21;281(15):1415-23.
38. Mallory MA, Sthapanachai C, Kowdley KV. Iron overload related to excessive
vitamin C intake. Ann Intern Med. 2003 Sep 16;139(6):532-3.

121

39. Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic
acid in glucose-6-phosphate dehydrogenase deficiency. BMJ. 1993 Mar
27;306(6881):841-2.
40. Lehr H, Germann G, McGregor G, Migeod F, Roesen P, Tanaka H, Uhlig C,
Biesalski H. CONSENSUS MEETING ON “RELEVANCE OF PARENTERAL VITAMIN
cin ACUTE ENDOTHELIAL DEPENDENT PATHOPHYSIOLOGICAL CONDITIONS
(EDPC)”. Eur J Med Res. 2006;11:516-26.
41. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K,
Rousseau C, Robitaille L, Miller WH,Jr. Phase I clinical trial of i.v. ascorbic acid in
advanced malignancy. Ann Oncol. 2008 Nov;19(11):1969-74.
42. Winterbourn CC, Kettle AJ. Redox reactions and microbial killing in the neutrophil
phagosome. Antioxidants & redox signaling. 2013;18(6):642-60.
43. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33(5):657-70.
44. Takei H, Araki A, Watanabe H, Ichinose A, Sendo F. Rapid killing of human
neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied
by changes different from typical apoptosis or necrosis. J Leukoc Biol. 1996
Feb;59(2):229-40.
45. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS,
Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004
Mar 5;303(5663):1532-5.
46. Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew A, Phoon MC, van Rooijen
N, Chow VT. Excessive neutrophils and neutrophil extracellular traps contribute to acute
lung injury of influenza pneumonitis. The American journal of pathology.
2011;179(1):199-210.
47. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med.
2011 Mar-Apr;17(3-4):293-307.
48. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP,
Lohmeyer J, Preissner KT. Neutrophil extracellular traps directly induce epithelial and
endothelial cell death: A predominant role of histones. PloS one. 2012;7(2):e32366.
49. Douda DN, Jackson R, Grasemann H, Palaniyar N. Innate immune collectin
surfactant protein D simultaneously binds both neutrophil extracellular traps and
carbohydrate ligands and promotes bacterial trapping. J Immunol. 2011 Aug
15;187(4):1856-65.

122

50. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil
extracellular DNA lattices by placental microparticles and IL-8 and their presence in
preeclampsia. Hum Immunol. 2005;66(11):1146-54.
51. Papayannopoulos V, Zychlinsky A. NETs: A new strategy for using old weapons.
Trends Immunol. 2009;30(11):513-21.
52. Dwivedi DJ, Toltl LJ, Swystun L, Pogue J, Liaw K, Weitz JI, Cook DJ, FoxRobichaud AE, Liaw PC, Canadian Critical Care Translational Biology Group.
Prognostic utility and characterization of cell-free DNA in patients with severe sepsis.
Crit Care. 2012;16(4):R151.
53. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee J, Chen S, Corpe C, Dutta A,
Dutta SK. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J Am
Coll Nutr. 2003;22(1):18-35.
54. Vissers MC, Wilkie RP. Ascorbate deficiency results in impaired neutrophil
apoptosis and clearance and is associated with up-regulation of hypoxia-inducible factor
1alpha. J Leukoc Biol. 2007 May;81(5):1236-44.
55. Nishikimi M, Fukuyama R, Minoshima S, Shimizu N, Yagi K. Cloning and
chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone
oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. J Biol Chem.
1994 May 6;269(18):13685-8.
56. Remijsen Q, Berghe TV, Wirawan E, Asselbergh B, Parthoens E, De Rycke R,
Noppen S, Delforge M, Willems J, Vandenabeele P. Neutrophil extracellular trap cell
death requires both autophagy and superoxide generation. Cell Res. 2010;21(2):290304.
57. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H,
Grigoryev SA, Allis CD, Coonrod SA. Histone hypercitrullination mediates chromatin
decondensation and neutrophil extracellular trap formation. J Cell Biol. 2009 Jan
26;184(2):205-13.
58. Kim H, Bae S, Yu Y, Kim Y, Kim H, Hwang Y, Kang JS, Lee WJ. The analysis of
vitamin C concentration in organs of gulo-/-mice upon vitamin C withdrawal. Immune
network. 2012;12(1):18-26.
59. Vissers MC, Bozonet SM, Pearson JF, Braithwaite LJ. Dietary ascorbate intake
affects steady state tissue concentrations in vitamin C-deficient mice: Tissue deficiency
after suboptimal intake and superior bioavailability from a food source (kiwifruit). Am J
Clin Nutr. 2011 Feb;93(2):292-301.

123

60. Tsurubuchi T, Aratani Y, Maeda N, Koyama H. Retardation of early-onset PMAinduced apoptosis in mouse neutrophils deficient in myeloperoxidase. J Leukoc Biol.
2001 Jul;70(1):52-8.
61. Fowler AA, Fisher BJ, Centor RM, Carchman RA. Development of the adult
respiratory distress syndrome: Progressive alteration of neutrophil chemotactic and
secretory processes. Am J Pathol. 1984 Sep;116(3):427-35.
62. Meng W, Paunel-Görgülü A, Flohé S, Witte I, Schädel-Höpfner M, Windolf J,
Lögters TT. Deoxyribonuclease is a potential counter regulator of aberrant neutrophil
extracellular traps formation after major trauma. Mediators Inflamm. 2012;2012
63. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y,
Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular
traps. J Cell Biol. 2007 Jan 15;176(2):231-41.
64. Asaga H, Nakashima K, Senshu T, Ishigami A, Yamada M. Immunocytochemical
localization of peptidylarginine deiminase in human eosinophils and neutrophils. J
Leukoc Biol. 2001 Jul;70(1):46-51.
65. Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L,
Casaccia-Bonnefil P, Moscarello MA. Increased citrullination of histone H3 in multiple
sclerosis brain and animal models of demyelination: A role for tumor necrosis factorinduced peptidylarginine deiminase 4 translocation. J Neurosci. 2006 Nov
1;26(44):11387-96.
66. Cheng OZ, Palaniyar N. NET balancing: A problem in inflammatory lung diseases.
Frontiers in immunology. 2013;4
67. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K,
Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA. Guidelines for the use and
interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445-544.
68. Bjørkøy G, Lamark T, Pankiv S, Øvervatn A, Brech A, Johansen T. Monitoring
autophagic degradation of p62/SQSTM1. Meth Enzymol. 2009;452:181-97.
69. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism:
On the regulation of autophagy by endoplasmic reticulum stress. Cellular and Molecular
Life Sciences. 2013;70(14):2425-41.
70. Yang K, Arcaroli JJ, Abraham E. Early alterations in neutrophil activation are
associated with outcome in acute lung injury. American journal of respiratory and critical
care medicine. 2003;167(11):1567-74.
71. Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, Baumann WT,
Tyson JJ, Xuan J, Wang Y. Endoplasmic reticulum stress, the unfolded protein
124

response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer
Res. 2012;72(6):1321-31.
72. Ying S, Kojima T, Kawada A, Nachat R, Serre G, Simon M, Takahara H. An intronic
enhancer driven by NF-κB contributes to transcriptional regulation of peptidylarginine
deiminase type I gene in human keratinocytes. J Invest Dermatol. 2010;130(11):254352.
73. Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Golde DW. Vitamin C suppresses
TNFα-induced NFκB activation by inhibiting IκBα phosphorylation. Biochemistry (N Y ).
2002;41(43):12995-3002.
74. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation.
Science. 2000 Dec 1;290(5497):1717-21.
75. Beertsen W, Willenborg M, Everts V, Zirogianni A, Podschun R, Schroder B,
Eskelinen EL, Saftig P. Impaired phagosomal maturation in neutrophils leads to
periodontitis in lysosomal-associated membrane protein-2 knockout mice. J Immunol.
2008 Jan 1;180(1):475-82.
76. Huang J, Canadien V, Lam GY, Steinberg BE, Dinauer MC, Magalhaes MA,
Glogauer M, Grinstein S, Brumell JH. Activation of antibacterial autophagy by NADPH
oxidases. Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6226-31.
77. Mitroulis I, Kourtzelis I, Kambas K, Rafail S, Chrysanthopoulou A, Speletas M, Ritis
K. Regulation of the autophagic machinery in human neutrophils. Eur J Immunol.
2010;40(5):1461-72.
78. Patel AS, Morse D, Choi AM. Regulation and functional significance of autophagy in
respiratory cell biology and disease. American journal of respiratory cell and molecular
biology. 2013;48(1):1-9.
79. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K,
Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky
M, Wouters BG. The unfolded protein response protects human tumor cells during
hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin
Invest. 2010 Jan;120(1):127-41.
80. Moine P, McIntyre R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y, Moore EE,
Abraham E. NF-kappaB regulatory mechanisms in alveolar macrophages from patients
with acute respiratory distress syndrome. Shock. 2000 Feb;13(2):85-91.
81. Burstein E, Duckett CS. Dying for NF-κB? control of cell death by transcriptional
regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003;15(6):732-7.

125

82. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M,
Toy P, Werb Z, Looney MR. Platelets induce neutrophil extracellular traps in
transfusion-related acute lung injury. J Clin Invest. 2012 Jul 2;122(7):2661-71.
83. Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, Cifuni SM,
Fuchs TA, von Andrian UH, Hartwig JH, Aster RH, Wagner DD. Extracellular DNA traps
are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012 Jun
28;119(26):6335-43.
84. Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of immature
neutrophils in patients with sepsis and severe systemic inflammatory response
syndrome. Crit Care Med. 2013 Mar;41(3):820-32.
85. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA
concentration as a predictor of mortality and sepsis in critically ill patients. Critical Care.
2006;10(2):R60.
86. Saukkonen K, Lakkisto P, Pettila V, Varpula M, Karlsson S, Ruokonen E, Pulkki K,
Finnsepsis Study Group. Cell-free plasma DNA as a predictor of outcome in severe
sepsis and septic shock. Clin Chem. 2008 Jun;54(6):1000-7.
87. Guimarães-Costa AB, Nascimento MT, Wardini AB, Pinto-da-Silva LH, Saraiva EM.
ETosis: A microbicidal mechanism beyond cell death. Journal of parasitology research.
2012;2012
88. Chatterjee M, Saluja R, Kumar V, Jyoti A, Kumar Jain G, Kumar Barthwal M, Dikshit
M. Ascorbate sustains neutrophil NOS expression, catalysis, and oxidative burst. Free
Radical Biology and Medicine. 2008;45(8):1084-93.
89. Laurin LP, Brissette MJ, Lepage S, Cailhier JF. Regulation of experimental
peritonitis: A complex orchestration. Nephron Exp Nephrol. 2012;120(1):e41-6.
90. McGrath EE, Marriott HM, Lawrie A, Francis SE, Sabroe I, Renshaw SA, Dockrell
DH, Whyte MK. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory
neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol. 2011
Nov;90(5):855-65.
91. Elliott MR, Ravichandran KS. Clearance of apoptotic cells: Implications in health and
disease. J Cell Biol. 2010 Jun 28;189(7):1059-70.
92. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization:
Tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol. 2002;23(11):549-55.
93. Fleming BD, Mosser DM. Regulatory macrophages: Setting the threshold for
therapy. Eur J Immunol. 2011;41(9):2498-502.
126

94. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and
polarization. Front Biosci. 2008 Jan 1;13:453-61.
95. Gordon S, Martinez FO. Alternative activation of macrophages: Mechanism and
functions. Immunity. 2010 5/28;32(5):593-604.
96. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets.
Nature Reviews Immunology. 2011;11(11):723-37.
97. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits
cytokine production by activated macrophages. The Journal of Immunology. 1991
December 01;147(11):3815-22.
98. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S,
Serhan CN. Molecular circuits of resolution: Formation and actions of resolvins and
protectins. J Immunol. 2005 Apr 1;174(7):4345-55.
99. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate
inflammation-resolution programmes. Nature. 2007;447(7146):869-74.
100. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid
mediators of endogenous anti-inflammation and resolution. Prostaglandins, leukotrienes
and essential fatty acids. 2005;73(3):141-62.
101. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP,
Petasis NA. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural
stereoisomers: Assignments of dihydroxy-containing docosatrienes. J Immunol. 2006
Feb 1;176(3):1848-59.
102. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac
RL. Resolvins: A family of bioactive products of omega-3 fatty acid transformation
circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med.
2002 Oct 21;196(8):1025-37.
103. Russell CD, Schwarze J. The role of pro‐resolution lipid mediators in infectious
disease. Immunology. 2014;141(2):166-73.
104. Bail S, Weindruch R, Walford R. Free radicals, ageing and degenerative diseases.
Antioxidants and the Immune Response. 1996:427-756.
105. May JM, Li L, Qu Z, Huang J. Ascorbate uptake and antioxidant function in
peritoneal macrophages. Arch Biochem Biophys. 2005;440(2):165-72.
106. Oberritter H, Glatthaar B, Moser U, Schmidt K. Effect of functional stimulation on
ascorbate content in phagocytes under physiological and pathological conditions. Int
Arch Allergy Immunol. 1986;81(1):46-50.
127

107. Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of
influenza virus-infected gulo-/- mice. J Nutr. 2006 Oct;136(10):2611-6.
108. Gaut JP, Belaaouaj A, Byun J, Roberts II LJ, Maeda N, Frei B, Heinecke JW.
Vitamin C fails to protect amino acids and lipids from oxidation during acute
inflammation. Free Radical Biology and Medicine. 2006;40(9):1494-501.
109. Long C, Maull K, Krishnan R, Laws H, Geiger J, Borghesi L, Franks W, Lawson T,
Sauberlich H. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res.
2003;109(2):144-8.
110. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, Suter PM.
Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins
can predict the development of multiple organ failure in patients at risk. Crit Care Med.
1996;24(3):392-7.
111. Galley HF, Davies MJ, Webster NR. Ascorbyl radical formation in patients with
sepsis: Effect of ascorbate loading. Free Radical Biology and Medicine. 1996;20(1):13943.
112. Mohammed BM, Fisher BJ, Kraskauskas D, Farkas D, Brophy DF, Natarajan R.
Vitamin C: A novel regulator of neutrophil extracellular trap formation. Nutrients.
2013;5(8):3131-50.
113. Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage: Cloning,
sequencing, and expression of full-length cDNA. Physiol Genomics. 2000 Jan 24;2(1):18.
114. Vislisel JM, Schafer FQ, Buettner GR. A simple and sensitive assay for ascorbate
using a plate reader. Anal Biochem. 2007;365(1):31-9.
115. Melmed RN, Karanian PJ, Berlin RD. Control of cell volume in the J774
macrophage by microtubule disassembly and cyclic AMP. J Cell Biol. 1981
Sep;90(3):761-8.
116. Wijesinghe DS, Brentnall M, Mietla JA, Hoeferlin LA, Diegelmann RF, Boise LH,
Chalfant CE. Ceramide kinase is required for a normal eicosanoid response and the
subsequent orderly migration of fibroblasts. J Lipid Res. 2014 May 13;55(7):1298-309.
117. Mietla JA, Wijesinghe DS, Hoeferlin LA, Shultz MD, Natarajan R, Fowler AA,3rd,
Chalfant CE. Characterization of eicosanoid synthesis in a genetic ablation model of
ceramide kinase. J Lipid Res. 2013 Jul;54(7):1834-47.
118. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S, Chalfant C,
Conrad DH, Kepley CL. Epoxyeicosatrienoic acids are involved in the C< sub> 70

128

fullerene derivative–induced control of allergic asthma. J Allergy Clin Immunol.
2012;130(3):761,769. e2.
119. Khanna S, Rink C, Ghoorkhanian R, Gnyawali S, Heigel M, Wijesinghe DS,
Chalfant CE, Chan YC, Banerjee J, Huang Y. Loss of miR-29b following acute ischemic
stroke contributes to neural cell death and infarct size. Journal of Cerebral Blood Flow &
Metabolism. 2013;33(8):1197-206.
120. Simanshu DK, Kamlekar RK, Wijesinghe DS, Zou X, Zhai X, Mishra SK,
Molotkovsky JG, Malinina L, Hinchcliffe EH, Chalfant CE. Non-vesicular trafficking by a
ceramide-1-phosphate transfer protein regulates eicosanoids. Nature. 2013
121. Wijesinghe DS, Chalfant CE. Systems-level lipid analysis methodologies for
qualitative and quantitative investigation of lipid signaling events during wound healing.
Advances in Wound Care. 2013;2(9):538-48.
122. Qureshi R, Jakschik BA. The role of mast cells in thioglycollate-induced
inflammation. J Immunol. 1988 Sep 15;141(6):2090-6.
123. Canali R, Natarelli L, Leoni G, Azzini E, Comitato R, Sancak O, Barella L, Virgili F.
Vitamin C supplementation modulates gene expression in peripheral blood
mononuclear cells specifically upon an inflammatory stimulus: A pilot study in healthy
subjects. Genes & nutrition. 2014;9(3):1-13.
124. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An
immunologic functional perspective. Annu Rev Immunol. 2009;27:451-83.
125. Schif‐Zuck S, Gross N, Assi S, Rostoker R, Serhan CN, Ariel A. Saturated‐
efferocytosis generates pro‐resolving CD11blow macrophages: Modulation by resolvins
and glucocorticoids. Eur J Immunol. 2011;41(2):366-79.
126. Gil C, Cooper D, Rosignoli G, Perretti M, Oliani S. Inflammation-induced
modulation of cellular galectin-1 and-3 expression in a model of rat peritonitis.
Inflammation Res. 2006;55(3):99-107.
127. Rostoker R, Yaseen H, Schif-Zuck S, Lichtenstein RG, Rabinovich GA, Ariel A.
Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors
their conversion toward a pro-resolving phenotype. Prostaglandins Other Lipid Mediat.
2013;107:85-94.
128. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002
Mar 5;105(9):1135-43.
129. Ganguly R, Durieux MF, Waldman RH. Macrophage function in vitamin C-deficient
guinea pigs. Am J Clin Nutr. 1976 Jul;29(7):762-5.

129

130. Babaev VR, Whitesell RR, Li L, Linton MF, Fazio S, May JM. Selective
macrophage ascorbate deficiency suppresses early atherosclerosis. Free Radical
Biology and Medicine. 2011;50(1):27-36.
131. Henson PM. Dampening inflammation. Nat Immunol. 2005;6(12):1179-81.
132. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: Signals for a good
meal. Nature Reviews Immunology. 2007;7(12):964-74.
133. Ariel A, Timor O. Hanging in the balance: Endogenous anti‐inflammatory
mechanisms in tissue repair and fibrosis. J Pathol. 2013;229(2):250-63.
134. Serhan CN. Novel lipid mediators and resolution mechanisms in acute
inflammation: To resolve or not? The American journal of pathology. 2010;177(4):157691.
135. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human
alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest. 1993 Sep;92(3):1572-9.
136. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Percoraro RE, Rodeheaver
G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of
healing. Wound Repair and Regeneration. 1994;2(3):165-70.
137. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner
GC, Longaker MT. Human skin wounds: A major and snowballing threat to public health
and the economy. Wound Repair and Regeneration. 2009;17(6):763-71.
138. Rasik AM, Shukla A. Antioxidant status in delayed healing type of wounds. Int J
Exp Pathol. 2000;81(4):257-63.
139. Fife CE, Carter MJ, Walker D, Thomson B. Wound care outcomes and associated
cost among patients treated in US outpatient wound centers: Data from the US wound
registry. Wounds. 2012;24(1):10-7.
140. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and
delayed healing. Front Biosci. 2004;9(1):283-9.
141. Shah JMY, Omar E, Pai DR, Sood S. Cellular events and biomarkers of wound
healing. Indian journal of plastic surgery: official publication of the Association of Plastic
Surgeons of India. 2012;45(2):220.
142. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines.
Physiol Rev. 2003 Jul;83(3):835-70.

130

143. Demling RH. Nutrition, anabolism, and the wound healing process: An overview.
Eplasty. 2009;9:e9.
144. De Tullio M. The mystery of vitamin C. Nature Education. 2010;3(9):48.
145. Moores J. Vitamin C: A wound healing perspective. Br J Community Nurs.
2013;18(Sup12):S6-S11.
146. Mohammed BM, Fisher BJ, Huynh QK, Wijesinghe DS, Chalfant CE, Brophy DF,
Natarajan R. Resolution of sterile inflammation: Role for vitamin C. Mediators Inflamm.
2014;2014
147. Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA. Stimulation of collagen gene
expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation?
J Biol Chem. 1989 Oct 5;264(28):16957-62.
148. Peterkofsky B. The effect of ascorbic acid on collagen polypeptide synthesis and
proline hydroxylation during the growth of cultured fibroblasts. Arch Biochem Biophys.
1972;152(1):318-28.
149. Barnes M. Function of ascorbic acid in collagen metabolism. Ann N Y Acad Sci.
1975;258(1):264-77.
150. Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. Regulation
of collagen synthesis by ascorbic acid. Proc Natl Acad Sci U S A. 1981 May;78(5):287982.
151. Galiano RD, Michaels V, Dobryansky M, Levine JP, Gurtner GC. Quantitative and
reproducible murine model of excisional wound healing. Wound repair and
regeneration. 2004;12(4):485-92.
152. Rabinovich GA, Sotomayor CE, Riera CM, Bianco I, Correa SG. Evidence of a role
for galectin‐1 in acute inflammation. Eur J Immunol. 2000;30(5):1331-9.
153. Luckett L, Gallucci R. Interleukin‐6 (IL‐6) modulates migration and matrix
metalloproteinase function in dermal fibroblasts from IL‐6KO mice. Br J Dermatol.
2007;156(6):1163-71.
154. Duarte TL, Cooke MS, Jones GD. Gene expression profiling reveals new
protective roles for vitamin C in human skin cells. Free Radical Biology and Medicine.
2009;46(1):78-87.
155. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory
cytokine, interleukin-6, enhances the polarization of alternatively activated
macrophages. PloS one. 2014;9(4):e94188.

131

156. Kim M, Otsuka M, Yu R, Kurata T, Arakawa N. The distribution of ascorbic acid
and dehydroascorbic acid during tissue regeneration in wounded dorsal skin of guinea
pigs. Int J Vitam Nutr Res. 1994;64(1):56-9.
157. Shukla A, Rasik AM, Patnaik GK. Depletion of reduced glutathione, ascorbic acid,
vitamin E and antioxidant defence enzymes in a healing cutaneous wound. Free Radic
Res. 1997;26(2):93-101.
158. Fowler AA, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing
CA, Larus TL, Martin E, Brophy DF, Gupta S, Fisher BJ, Natarajan R. Phase I safety
trial of intravenous ascorbic acid in patients with severe sepsis. ; 2014. 32 p.
159. Yager DR, Kulina RA, Gilman LA. Wound fluids: A window into the wound
environment? Int J Low Extrem Wounds. 2007 Dec;6(4):262-72.
160. Moor AN, Vachon DJ, Gould LJ. Proteolytic activity in wound fluids and tissues
derived from chronic venous leg ulcers. Wound Repair and Regeneration.
2009;17(6):832-9.
161. Braiman-Wiksman L, Solomonik I, Spira R, Tennenbaum T. Novel insights into
wound healing sequence of events. Toxicol Pathol. 2007 Oct;35(6):767-79.
162. Leask A, Abraham DJ. The role of connective tissue growth factor, a
multifunctional matricellular protein, in fibroblast biology. Biochemistry and cell biology.
2003;81(6):355-63.
163. Moussad EEA, Brigstock DR. Connective tissue growth factor: What's in a name?
Mol Genet Metab. 2000;71(1):276-92.
164. Alfaro MP, Deskins DL, Wallus M, DasGupta J, Davidson JM, Nanney LB, Guney
MA, Gannon M, Young PP. A physiological role for connective tissue growth factor in
early wound healing. Laboratory Investigation. 2013;93(1):81-95.
165. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic‐Canic M. Growth factors
and cytokines in wound healing. Wound Repair and Regeneration. 2008;16(5):585-601.
166. Grochot-Przeczek A, Lach R, Mis J, Skrzypek K, Gozdecka M, Sroczynska P,
Dubiel M, Rutkowski A, Kozakowska M, Zagorska A. Heme oxygenase-1 accelerates
cutaneous wound healing in mice. PloS one. 2009;4(6):e5803.
167. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest
Dermatol. 2007;127(3):526-37.
168. Lin Y, Chen J, Wu M, Hsieh I, Liang C, Hsu C, Hong T, Chen Y. Galectin-1
accelerates wound healing by regulating the neuropilin-1/Smad3/NOX4 pathway and
ROS production in myofibroblasts. J Invest Dermatol. 2015;135(1):258-68.
132

169. Perzelova V, Varinska L, Dvorankova B, Szabo P, Spurny P, Valach J, Mojzis J,
Andre S, Gabius HJ, Smetana K,Jr, Gal P. Extracellular matrix of galectin-1-exposed
dermal and tumor-associated fibroblasts favors growth of human umbilical vein
endothelial cells in vitro: A short report. Anticancer Res. 2014 Aug;34(8):3991-6.
170. Steiling H, Longet K, Moodycliffe A, Mansourian R, Bertschy E, Smola H, Mauch
C, Williamson G. Sodium-dependent vitamin C transporter isoforms in skin: Distribution,
kinetics, and effect of UVB-induced oxidative stress. Free Radical Biology and
Medicine. 2007;43(5):752-62.
171. Sangani R, Pandya CD, Bhattacharyya MH, Periyasamy-Thandavan S, Chutkan N,
Markand S, Hill WD, Hamrick M, Isales C, Fulzele S. Knockdown of SVCT2 impairs invitro cell attachment, migration and wound healing in bone marrow stromal cells. Stem
cell research. 2014;12(2):354-63.
172. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: A function for each
cell compartment? Trends Cell Biol. 2003;13(2):65-70.
173. Loh Y, Wu Q, Chew J, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong
B, Liu J. The Oct4 and nanog transcription network regulates pluripotency in mouse
embryonic stem cells. Nat Genet. 2006;38(4):431-40.
174. Kim JH, Kim W, Sung YK, Kwack MH, Song SY, Choi J, Park SG, Yi T, Lee H, Kim
D. The molecular mechanism underlying the proliferating and preconditioning effect of
vitamin C on adipose-derived stem cells. Stem cells and development.
2014;23(12):1364-76.
175. Goodman L, Stein GH. Basal and induced amounts of interleukin-6 mRNA decline
progressively with age in human fibroblasts. J Biol Chem. 1994 Jul 29;269(30):19250-5.
176. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: The interleukin-6
receptor. Rheumatology (Oxford). 2010 Jan;49(1):15-24.
177. Kuhn KA, Manieri NA, Liu T, Stappenbeck TS. IL-6 stimulates intestinal epithelial
proliferation and repair after injury. PloS one. 2014;9(12):e114195.
178. Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T,
Luster MI. Impaired cutaneous wound healing in interleukin-6-deficient and
immunosuppressed mice. FASEB J. 2000 Dec;14(15):2525-31.
179. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N. Essential involvement of IL-6
in the skin wound-healing process as evidenced by delayed wound healing in IL-6deficient mice. J Leukoc Biol. 2003 Jun;73(6):713-21.

133

180. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin
expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol.
2006;126(3):561-8.
181. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata
DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard
VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus
GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter
NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D,
Turner MB, American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Executive summary: Heart disease and stroke statistics--2012 update: A
report from the american heart association. Circulation. 2012 Jan 3;125(1):188-97.
182. Society of Thoracic Surgeons. STS Adult Cardiac Surgery Database: executive
summary: 10 years [Internet].
183. U.S. Department of Health & Human Services, Agency For Healthcare Research
and Quality. Healthcare Cost and Utilization Project [Internet].
184. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative
stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol.
2007;115(2):135-43.
185. Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of
reactive oxygen species generation during myocardial ischemia and reperfusion.
Pharmacol Ther. 2012;133(2):230-55.
186. Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S. Phase I safety trial of
intravenous ascorbic acid in patients with severe sepsis. . 2014
187. Biglioli P, Cannata A, Alamanni F, Naliato M, Porqueddu M, Zanobini M, Tremoli E,
Parolari A. Biological effects of off-pump vs. on-pump coronary artery surgery: Focus on
inflammation, hemostasis and oxidative stress. European journal of cardio-thoracic
surgery. 2003;24(2):260-9.
188. McColl AJ, Keeble T, Hadjinikolaou L, Cohen A, Aitkenhead H, Glenville B,
Richmond W. Plasma antioxidants: Evidence for a protective role against reactive
oxygen species following cardiac surgery. Annals of Clinical Biochemistry: An
international journal of biochemistry in medicine. 1998;35(5):616-23.
189. Kunt AS, Selek S, Celik H, Demir D, Erel O, Andac MH. Decrease of total
antioxidant capacity during coronary artery bypass surgery. Mt Sinai J Med. 2006
Sep;73(5):777-83.

134

190. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor
P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal
cancer patients. P R Health Sci J. 2009;24(4)
191. Nair S, Iqbal K, Phadke M, Jadhav UE, Khandekar J, Khandeparkar JM. Effect of
cardiopulmonary bypass on tissue injury markers and endothelial activation during
coronary artery bypass graft surgery. J Postgrad Med. 2012 Jan-Mar;58(1):8-13.
192. Wang ZJ, Hu WK, Liu YY, Shi DM, Cheng WJ, Guo YH, Yang Q, Zhao YX, Zhou
YJ. The effect of intravenous vitamin c infusion on periprocedural myocardial injury for
patients undergoing elective percutaneous coronary intervention. Can J Cardiol.
2014;30(1):96-101.
193. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to
perform innovative translational research. Sci Transl Med. 2011 Jun 15;3(87):87ps24.

135

